var title_f28_11_28848="Approach to acute optic neuropathy";
var content_f28_11_28848=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F63122&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F63122&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 598px\">",
"   <div class=\"ttl\">",
"    Approach to patient with acute optic neuropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 578px; height: 602px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CRP: C-reactive protein; CSF: cerebrospinal fluid; DM: diabetes mellitus; ESR: erythrocyte sedimentation rate; GCA: giant cell arteritis; HTN: hypertension; LP: lumbar puncture; MRI: magnetic resonance imaging; NAION: nonarteritic ischemic optic neuropathy.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_11_28848=[""].join("\n");
var outline_f28_11_28848=null;
var title_f28_11_28849="S prolificans microsopy";
var content_f28_11_28849=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F63775&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F63775&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    S prolificans microsopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 290px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Microscopic appearance of S. prolificans illustrating the flask-shaped, inflated conidiogenous cell (arrow) with conidium attached.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Barbara D. Alexander, MD, MHS and Sylvia F. Costa, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_11_28849=[""].join("\n");
var outline_f28_11_28849=null;
var title_f28_11_28850="Echo MR in MI apical long axis color Doppler echo";
var content_f28_11_28850=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/73594/aplacmrm_conv.mp4?title=Echo+MR+in+MI+apical+long+axis+color+Doppler+echo\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Echocardiogram apical long axis post MI mitral regurgitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 238px; height: 415px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Apical long axis view from a 2-D echocardiogram with color flow Doppler shows mitral regurgitation with a jet directed toward the posterior left atrial wall. The etiology is papillary muscle dysfunction from a prior inferior wall myocardial infarction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_11_28850=[""].join("\n");
var outline_f28_11_28850=null;
var title_f28_11_28851="Clindamycin and benzoyl peroxide: Pediatric drug information";
var content_f28_11_28851=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Clindamycin and benzoyl peroxide: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36371?source=see_link\">",
"    see \"Clindamycin and benzoyl peroxide: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?20/6/20580?source=see_link\">",
"    see \"Clindamycin and benzoyl peroxide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F152776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Acanya&reg;;",
"     </li>",
"     <li>",
"      BenzaClin&reg;;",
"     </li>",
"     <li>",
"      Duac&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F854892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      BenzaClin&reg;;",
"     </li>",
"     <li>",
"      Clindoxyl",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1046452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Acne Products",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Topical Skin Product",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1046446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36371?source=see_link\">",
"      see \"Clindamycin and benzoyl peroxide: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Children &ge;12 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Acanya&trade;: Apply pea-sized amount of gel once daily; use &gt;12 weeks has not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     BenzaClin&reg;: Apply twice daily (morning and evening)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duac&reg;: Apply once daily in the evening",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F152760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gel, topical: Clindamycin phosphate 1% and benzoyl peroxide 5% (50 g); Clindamycin phosphate 1.2% and benzoyl peroxide 5% (45 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acanya&reg;: Clindamycin phosphate 1.2% and benzoyl peroxide 2.5% (50 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     BenzaClin&reg;: Clindamycin phosphate 1% and benzoyl peroxide 5% (25 g, 35 g, 50 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duac&reg;: Clindamycin phosphate 1.2% and benzoyl peroxide 5% (45 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F152748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1046455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     FOR EXTERNAL USE ONLY. Not for oral, ophthalmic, or intravaginal use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical: Skin should be clean and dry before applying. Apply thin layer to affected areas avoiding contact with eyes, lips, inside of nose, mouth, and all mucous membranes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Acanya&trade;: Add clindamycin solution in the bottle to the benzoyl peroxide gel and stir 1",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     minutes with spatula until homogenous.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     BenzaClin&reg;: Add indicated amount of purified water to the mark on the vial; immediately  shake to dissolve clindamycin. Add clindamycin solution to the gel and stir 1",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     minutes until homogenous.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1046449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Acanya&reg;: Store at room temperature of 25&deg;C (77&deg;F); do not freeze. Prior to dispensing, add clindamycin solution to the benzoyl peroxide gel and stir (&ge;1.5 minutes) until homogenous. Discard unused portion after 2 months.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     BenzaClin&reg;: Store at room temperature of 25&deg;C (77&deg;F); do not freeze.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duac&reg;: Prior to dispensing, store in refrigerator, between 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Once dispensed, may be stored by patient at room temperature of up to 25&deg;C (77&deg;F) if used within 60 days. Do not freeze.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1046454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical treatment of acne vulgaris (FDA approved in ages &ge;12 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F152795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Burning, dry skin, erythema, itching, peeling, pruritus, scaling, stinging, sunburn",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Application site reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Allergic reactions, anaphylaxis,",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD), colitis, diarrhea, exfoliation, irritation, pain at application site, pseudomembranous colitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1046459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to benzoyl peroxide, clindamycin, lincomycin, or any component; history of regional enteritis, ulcerative colitis, pseudomembranous colitis, or antibiotic-associated colitis",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1046445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid contact with eyes and mucous membranes; use of antibiotic agents may be associated with the overgrowth of nonsusceptible organisms including fungi; if this occurs, discontinue use; concomitant topical acne therapy should be used with caution because a possible cumulative irritancy effect may occur, especially with the use of peeling, desquamating, or abrasive agents. Inform patients to use skin protection and minimize prolonged exposure to sun or tanning beds.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1046444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use of topical clindamycin results in absorption from the skin surface; diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical and systemic clindamycin; the colitis is usually characterized by severe persistent diarrhea and severe abdominal cramps and may be associated with the passage of blood and mucus; discontinue drug if significant diarrhea occurs. Antiperistaltic agents such as opiates or diphenoxylate with atropine may prolong and worsen the condition. May bleach hair or clothing. Concomitant use with topical or oral erythromycin-containing products is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F152755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F152757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F152767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted; use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1046443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clindamycin and benzoyl peroxide have activity against",
"     <i>",
"      Propionibacterium acnes in vitro",
"     </i>",
"     . This organism has been associated with acne vulgaris. Benzoyl peroxide releases free-radical oxygen which oxidizes bacterial proteins in the sebaceous follicles decreasing the number of anaerobic bacteria and decreasing irritating-type free fatty acids. Clindamycin reversibly binds to 50S ribosomal subunits preventing peptide bond formation thus inhibiting bacterial protein synthesis; bacteriostatic or bactericidal depending on the drug concentration, infection site, and organism.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1046457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1046458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1046451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/6/20580?source=see_link\">",
"      see \"Clindamycin and benzoyl peroxide: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid contact with eyes, inside of nose, mouth, and all mucous membranes; do not apply on cuts or open wounds; may bleach hair and clothing; notify physician if severe diarrhea, dryness, redness, peeling, or photosensitivity reaction occurs.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15].",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12548 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-C7EAEF3114-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_11_28851=[""].join("\n");
var outline_f28_11_28851=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152776\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854892\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046452\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046446\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152760\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152748\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046455\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046449\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046454\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152795\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046459\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046445\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046444\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299059\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152755\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152757\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152767\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046443\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046457\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046458\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046451\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12548\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12548|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36371?source=related_link\">",
"      Clindamycin and benzoyl peroxide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/6/20580?source=related_link\">",
"      Clindamycin and benzoyl peroxide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_11_28852="Chapter 11C: Effect of arterial pH on ventilation";
var content_f28_11_28852=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chapter 11C: Effect of arterial pH on ventilation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/11/28852/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/11/28852/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/11/28852/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/11/28852/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/11/28852/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/11/28852/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/11/28852/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/11/28852/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 15, 2000.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alveolar ventilation provides the oxygen necessary for oxidative metabolism and eliminates the CO2 produced by these metabolic processes. It is therefore appropriate that the main physiologic stimuli to respiration are an elevation in the PCO2 and a reduction in the PO2 (hypoxemia) (",
"    <a class=\"graphic graphic_figure graphicRef50198 \" href=\"UTD.htm?38/26/39341\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28852/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The CO2 stimulus to ventilation primarily occurs in chemosensitive areas in the respiratory center in the brainstem, which appear to respond to CO2-induced changes in the cerebral interstitial pH [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28852/abstract/3\">",
"     3",
"    </a>",
"    ]. This effect is extremely important in the maintenance of the acid-base balance, since roughly 15,000 mmol of CO2 is produced daily from endogenous metabolism, added to the capillary blood, and then eliminated via the lungs. In contrast, hypoxemia is primarily sensed by peripheral chemoreceptors in the carotid bodies, which are located near the bifurcation of the carotid arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28852/abstract/2,4\">",
"     2,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RESPIRATORY COMPENSATION TO METABOLIC AND RESPIRATORY ACIDOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alveolar ventilation also is affected by metabolic acid-base disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28852/abstract/5-11\">",
"     5-11",
"    </a>",
"    ]. In metabolic acidosis, for example, minute ventilation can increase from the normal of approximately 5",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    to greater than 30",
"    <span class=\"nowrap\">",
"     L/min,",
"    </span>",
"    as the arterial pH falls from 7.40 to 7.00 (",
"    <a class=\"graphic graphic_figure graphicRef50478 \" href=\"UTD.htm?25/29/26076\">",
"     figure 2",
"    </a>",
"    ). The initial rise in ventilation is mediated primarily by the peripheral chemoreceptors in the carotid bodies, which immediately sense the reduction in pH. However, the ensuing fall in PCO2 produces an acute elevation in CSF and cerebral interstitial pH, since CO2 but not HCO3- rapidly crosses the blood-brain barrier. As a result, the central chemoreceptors sense alkalemia and act to diminish ventilation, thereby limiting the ventilatory response [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28852/abstract/5\">",
"     5",
"    </a>",
"    ]. If the acidemia persists for hours to days, however, the cerebral pH will fall, due to ionic diffusion or to the formation of new cerebrospinal fluid that reflects the change in systemic pH [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28852/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. This cerebral adaptation allows the full degree of hyperventilation to be seen, usually within 12 to 24 h [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28852/abstract/5,7\">",
"     5,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increase in ventilation with metabolic acidosis is an appropriate compensatory response, since the concomitant reduction in PCO2 will return the extracellular pH toward normal [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28852/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Conversely, hypoventilation with a consequent elevation in PCO2 lowers the pH toward normal in metabolic alkalosis, where the plasma HCO3- concentration is increased [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28852/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential importance of these respiratory compensations to metabolic acidosis and alkalosis can be appreciated from the following hypothetical example. In diabetic ketoacidosis, the increased production of ketoacids is buffered in part in the extracellular fluid, resulting in a decline in the plasma HCO3- concentration. If the latter were reduced to 6",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    and the PCO2 remained at the normal 40 mmHg, then",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 6",
"    <br/>",
"    &nbsp; &nbsp;pH &nbsp; = &nbsp; &nbsp; 6.1 &nbsp;+ &nbsp;log &mdash;&mdash;&mdash;&mdash;&mdash; &nbsp; = &nbsp; 6.80",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0.03 &nbsp;x &nbsp;40",
"   </p>",
"   <p>",
"    However, if ventilation were stimulated by the acidemia and the PCO2 fell to 15 mmHg, then",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 6",
"    <br/>",
"    &nbsp; &nbsp;pH &nbsp; = &nbsp; 6.1 &nbsp;+ &nbsp;log &mdash;&mdash;&mdash;&mdash;&mdash; &nbsp; = &nbsp; 7.22",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0.03 &nbsp;x &nbsp;15",
"   </p>",
"   <p>",
"    Thus, the respiratory compensation has turned a life-threatening reduction in pH into one that is much less dangerous.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Limitation of respiratory compensation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the effectiveness of the respiratory compensation, the pH is protected for only a few days, since the initially beneficial change in PCO2 then alters renal HCO3- reabsorption. In metabolic acidosis, for example, the compensatory fall in PCO2 decreases HCO3- reabsorption (",
"    <a class=\"graphic graphic_figure graphicRef75228 \" href=\"UTD.htm?1/23/1405\">",
"     figure 3",
"    </a>",
"    ) and, therefore, the plasma HCO3- concentration. The net effect is that, after several days, the extracellular pH is the same as it would have been if no respiratory compensation had occurred, since the decline in PCO2 is balanced by a further reduction in the HCO3- concentration&dagger; [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28852/abstract/12\">",
"     12",
"    </a>",
"    ]. Fortunately, most forms of severe metabolic acidosis are acute (ketoacidosis, lactic acidosis, ingestions), so that the associated hyperventilation does protect the pH.",
"   </p>",
"   <p>",
"    Similar considerations apply to the compensatory hypoventilation seen with chronic metabolic alkalosis. The rise in PCO2 in this setting leads to increased H+ secretion, a further elevation in the plasma HCO3- concentration, and no net improvement in the alkalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28852/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is presumed that alterations in renal tubular cell pH are responsible for these changes in H+ secretion. In metabolic acidosis, for example, the fall in the plasma HCO3- concentration will produce a parallel reduction in the cell pH that is probably the signal to enhance H+ secretion. Returning the extracellular pH toward normal by increasing ventilation, however, will also raise the cell pH, since reducing the PCO2 will result in CO2 diffusion out the cell. This will lead to an initially lower level of net acid excretion and therefore a further reduction in the plasma HCO3- concentration.",
"   </p>",
"   <p>",
"    These observations once again illustrate the importance of the steady state. A patient with chronic metabolic acidosis who produces an extra 100 meq of acid per day will enter the steady state only when daily acid excretion increases by 100 meq. The signal to maintain this increment in H+ secretion is probably a reduction in the cell pH; furthermore, the required level of cellular acidification to enhance acid excretion by 100 meq will be the same whether or not the respiratory compensation has occurred. Thus, the extracellular pH will also be the same in both settings, since it is the primary determinant of changes in the cell pH [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28852/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;From the Henderson-Hasselbalch equation, the arterial pH is a function of the [HCO3-]",
"    <span class=\"nowrap\">",
"     /",
"    </span>",
"    0.03PCO2 ratio. Three processes are involved in the maintenance of the arterial pH: (1) the extracellular and intracellular buffers act to minimize changes in pH induced by an acid or base load; (2) the plasma HCO3- concentration is held within narrow limits by the regulation of renal H+ excretion; and (3) the PCO2 is controlled by variations in alveolar ventilation. How these processes interact to protect the pH can be appreciated from the response to a HCl load (",
"    <a class=\"graphic graphic_figure graphicRef80104 \" href=\"UTD.htm?2/41/2719\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Extracellular buffering of the excess H+ by HCO3- occurs almost immediately.",
"     </li>",
"     <li>",
"      Within several minutes, the respiratory compensation begins, resulting in hyperventilation, a decrease in the PCO2, and an increase in the pH toward normal.",
"     </li>",
"     <li>",
"      Within 2 to 4 h, the intracellular buffers (primarily proteins and organic phosphates) and bone provide further buffering, as H+ ions enter the cells in exchange for intracellular K+ and Na+. These responses act to prevent wide swings in the arterial pH until acid-base homeostasis can be restored by the renal excretion of the H+ load as NH4+ and titratable acidity.",
"     </li>",
"     <li>",
"      The corrective renal response begins on the first day and is complete within 5 to 6 days [",
"      <a class=\"abstract\" href=\"UTD.htm?28/11/28852/abstract/15-17\">",
"       15-17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This sequence tends to be reversed with a NaHCO3 load. The corrective renal response, however, tends to be more rapid as the excess HCO3- is quickly excreted in the urine. Both decreased reabsorption and HCO3- secretion in the cortical collecting tubule play a contributory role in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28852/abstract/18-21\">",
"     18-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alterations in pH induced by changes in the PCO2 produce a somewhat different response. There is virtually no extracellular buffering, since HCO3- cannot effectively buffer H2CO3. Similarly, there is no compensatory change in alveolar ventilation, since the primary disturbance is one of abnormal respiration. Thus the intracellular buffers (including hemoglobin) and changes in renal H+ excretion constitute the only protective mechanisms against respiratory acidosis or alkalosis.",
"   </p>",
"   <p>",
"    If, for example, the PCO2 is increased, the intracellular buffers will act to increase the plasma HCO3- concentration, thereby minimizing the degree of acidemia (",
"    <a class=\"graphic graphic_figure graphicRef78945 \" href=\"UTD.htm?34/5/34909\">",
"     figure 5",
"    </a>",
"    ). This process is complete within 10 to 30 min [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28852/abstract/22\">",
"     22",
"    </a>",
"    ]. These buffers increase the plasma HCO3- concentration by only 1",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    for each 10 mmHg rise in the PCO2 and are therefore relatively ineffective in protecting the pH. If the hypercapnia persists, however, there will be an appropriate increase in renal H+ excretion, resulting in a further elevation in the plasma HCO3- concentration.",
"   </p>",
"   <p>",
"    It is this renal compensation, which begins within several hours but is not complete for several days [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28852/abstract/23\">",
"     23",
"    </a>",
"    ], that constitutes the main defense against respiratory acidosis. Even if the PCO2 is chronically elevated at 80 mmHg, the pH usually is not much lower than 7.30 because of the effectiveness of the renal compensation.",
"   </p>",
"   <p>",
"    This sequence is reversed with respiratory alkalosis, as there is an appropriate reduction in the plasma HCO3- concentration, due to intracellular buffering and to decreased net acid excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28852/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. It should be noted that the renal responses to alterations in the PCO2 are compensatory but not corrective. Acid-base homeostasis will not be restored unless alveolar ventilation is normalized.",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/57/10136?source=see_link\">",
"     \"Chapter 12A: Distribution of potassium between the cells and ECF\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    (From Rose, BD, Post, TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York, 2001.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Lambertsen, CJ. Chemical control of respiration at rest. In Medical Physiology, 14th ed, Mountcastle, VB (Ed), Mosby, St. Louis 1980;.",
"    </li>",
"    <li>",
"     Berger, AJ, Mitchell, RA, Severinghaus, JW. Regulation of respiration. N Engl J Med 1977; 297:92, 138, 194.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28852/abstract/3\">",
"      Fencl V, Miller TB, Pappenheimer JR. Studies on the respiratory response to disturbances of acid-base balance, with deductions concerning the ionic composition of cerebral interstitial fluid. Am J Physiol 1966; 210:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28852/abstract/4\">",
"      Lugliani R, Whipp BJ, Seard C, Wasserman K. Effect of bilateral carotid-body resection on ventilatory control at rest and during exercise in man. N Engl J Med 1971; 285:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28852/abstract/5\">",
"      Mitchell RA, Singer MM. Respiration and cerebrospinal fluid pH in metabolic acidosis and alkalosis. J Appl Physiol 1965; 20:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28852/abstract/6\">",
"      Fencl V, Vale JR, Broch JA. Respiration and cerebral blood flow in metabolic acidosis and alkalosis in humans. J Appl Physiol 1969; 27:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28852/abstract/7\">",
"      Pierce NF, Fedson DS, Brigham KL, et al. The ventilatory response to acute base deficit in humans. Time course during development and correction of metabolic acidosis. Ann Intern Med 1970; 72:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28852/abstract/8\">",
"      Albert MS, Dell RB, Winters RW. Quantitative displacement of acid-base equilibrium in metabolic acidosis. Ann Intern Med 1967; 66:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28852/abstract/9\">",
"      Bushinsky DA, Coe FL, Katzenberg C, et al. Arterial PCO2 in chronic metabolic acidosis. Kidney Int 1982; 22:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28852/abstract/10\">",
"      Javaheri S, Shore NS, Rose B, Kazemi H. Compensatory hypoventilation in metabolic alkalosis. Chest 1982; 81:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28852/abstract/11\">",
"      Javaheri S, Kazemi H. Metabolic alkalosis and hypoventilation in humans. Am Rev Respir Dis 1987; 136:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28852/abstract/12\">",
"      Madias NE, Schwartz WB, Cohen JJ. The maladaptive renal response to secondary hypocapnia during chronic HCl acidosis in the dog. J Clin Invest 1977; 60:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28852/abstract/13\">",
"      Madias NE, Adrogu&eacute; HJ, Cohen JJ. Maladaptive renal response to secondary hypercapnia in chronic metabolic alkalosis. Am J Physiol 1980; 238:F283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28852/abstract/14\">",
"      Krapf R, Berry CA, Alpern RJ, Rector FC Jr. Regulation of cell pH by ambient bicarbonate, carbon dioxide tension, and pH in the rabbit proximal convoluted tubule. J Clin Invest 1988; 81:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28852/abstract/15\">",
"      Hamm LL, Simon EE. Roles and mechanisms of urinary buffer excretion. Am J Physiol 1987; 253:F595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28852/abstract/16\">",
"      Tizianello A, Deferrari G, Garibotto G, et al. Renal ammoniagenesis in an early stage of metabolic acidosis in man. J Clin Invest 1982; 69:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28852/abstract/17\">",
"      Kraut JA, Wish JB, Sweet SJ, et al. Failure of increased sodium avidity to facilitate renal acid excretion in dogs fed sulfuric acid. Kidney Int 1981; 20:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28852/abstract/18\">",
"      Levine DZ, Jacobson HR. The regulation of renal acid secretion: new observations from studies of distal nephron segments. Kidney Int 1986; 29:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28852/abstract/19\">",
"      Jacobson HR, Furuya H, Breyer MD. Mechanism and regulation of proton transport in the outer medullary collecting duct. Kidney Int Suppl 1991; 33:S51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28852/abstract/20\">",
"      Lombard WE, Kokko JP, Jacobson HR. Bicarbonate transport in cortical and outer medullary collecting tubules. Am J Physiol 1983; 244:F289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28852/abstract/21\">",
"      Star RA, Burg MB, Knepper MA. Bicarbonate secretion and chloride absorption by rabbit cortical collecting ducts. Role of chloride/bicarbonate exchange. J Clin Invest 1985; 76:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28852/abstract/22\">",
"      BRACKETT NC Jr, COHEN JJ, SCHWARTZ WB. CARBON DIOXIDE TITRATION CURVE OF NORMAL MAN. EFFECT OF INCREASING DEGREES OF ACUTE HYPERCAPNIA ON ACID-BASE EQUILIBRIUM. N Engl J Med 1965; 272:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28852/abstract/23\">",
"      POLAK A, HAYNIE GD, HAYS RM, SCHWARTZ WB. Effects of chronic hypercapnia on electrolyte and acid-base equilibrium. I. Adaptation. J Clin Invest 1961; 40:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28852/abstract/24\">",
"      Gennari FJ, Goldstein MB, Schwartz WB. The nature of the renal adaptation to chronic hypocapnia. J Clin Invest 1972; 51:1722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28852/abstract/25\">",
"      Gougoux A, Kaehny WD, Cohen JJ. Renal adaptation to chronic hypocapnia: dietary constraints in achieving H+ retention. Am J Physiol 1975; 229:1330.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7262 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-89768E4622-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_11_28852=[""].join("\n");
var outline_f28_11_28852=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RESPIRATORY COMPENSATION TO METABOLIC AND RESPIRATORY ACIDOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Limitation of respiratory compensation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7262\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7262|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/26/39341\" title=\"figure 1\">",
"      Regulation of ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/29/26076\" title=\"figure 2\">",
"      Ventilation in DKA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/23/1405\" title=\"figure 3\">",
"      PCO2 and HCO3 reabsorption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/41/2719\" title=\"figure 4\">",
"      Sequential response H load",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/5/34909\" title=\"figure 5\">",
"      Response PC02 increase",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/57/10136?source=related_link\">",
"      Chapter 12A: Distribution of potassium between the cells and ECF",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_11_28853="Wrist joints";
var content_f28_11_28853=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53465&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53465&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 556px\">",
"   <div class=\"ttl\">",
"    Joints of the wrist",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 536px; height: 433px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_11_28853=[""].join("\n");
var outline_f28_11_28853=null;
var title_f28_11_28854="Bexarotene (systemic): Drug information";
var content_f28_11_28854=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bexarotene (systemic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?35/14/36069?source=see_link\">",
"    see \"Bexarotene (systemic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F7995443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F12995356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Targretin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F7995834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Miscellaneous;",
"     </li>",
"     <li>",
"      Retinoic Acid Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F7995482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cutaneous T-cell lymphoma, refractory:",
"     </b>",
"     Oral: Initial: 300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day taken as a single daily dose; if well tolerated, but no response after 8 weeks of therapy, may increase to 400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day; continue as long as clinical benefit is demonstrated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cutaneous T-cell lymphomas, relapsed/refractory (unlabeled dose):",
"     </b>",
"     Oral: 150 mg daily (in combination with denileukin diftitox) (Foss, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Mycosis fungoides/Sezary syndrome, refractory/resistant (unlabeled dose):",
"     </b>",
"     Oral: 75-150 mg daily in combination with PUVA; maximum dose: 300 mg daily (Rupoli, 2010; Singh, 2004)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F7995523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F7995524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied); however, renal insufficiency may result in significant protein binding changes and alter pharmacokinetics of bexarotene.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F7995525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied); however, hepatic impairment would be expected to result in decreased clearance of bexarotene due to the extensive hepatic contribution to elimination.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F15796496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;display:inline\">",
"     If necessitated by toxicity, may decrease dose from 300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day to 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day, then to 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day, or temporarily hold. Upon recovery, may titrate dose upward with careful monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Hepatotoxicity:",
"     </i>",
"     If AST, ALT, or bilirubin &gt;3 times ULN, consider holding or discontinuing therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Hypertriglyceridemia:",
"     </i>",
"     Consider reducing dose or suspending therapy.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F7995542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Targretin&reg;: 75 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F7995445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7995527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Administer with a meal. Swallow capsule whole; do not chew or dissolve (per the manufacturer).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F7995446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7995444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F7995460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema (11% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (30% to 42%), fever (5% to 17%), chills (10% to 13%), insomnia (5% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (17% to 23%), exfoliative dermatitis (10% to 28%), dry skin (9% to 11%), alopecia (4% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperlipidemia (79%), hypercholesteremia (32% to 62%), hypothyroidism (29% to 53%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (7% to 42%), anorexia (2% to 23%), nausea (8% to 16%), vomiting (4% to 13%), abdominal pain (4% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Leukopenia (17% to 47%), anemia (6% to 25%), hypochromic anemia (4% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: LDH increased (7% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (20% to 45%), back pain (2% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (13% to 23%; bacterial: 1% to 13%), flu-like syndrome (4% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Angina pectoris, cerebrovascular accident, chest pain, heart failure (right), hypertension, syncope, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Agitation, ataxia, confusion, depression, dizziness, hyperesthesia, subdural hematoma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Acne, cellulitis, cheilitis, maculopapular rash, photosensitivity, pustular rash, serous drainage, skin nodule, skin rash, skin sensitivity, sunburn, vesicular bullous rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast pain, hypoproteinemia, hyperglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Amylase increased, colitis, constipation, dyspepsia, flatulence, gastroenteritis, gingivitis, melena, pancreatitis, weight loss/gain, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Dysuria, hematuria, urinary incontinence, urinary tract infection, urinary urgency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Coagulopathy, eosinophilia, hemorrhage, lymphocytosis, thrombocythemia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT increased, AST increased, bilirubin increased, hepatic failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, arthrosis, bone pain, myalgia, myasthenia, neuropathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blepharitis, cataracts (new and worsening), conjunctivitis, corneal lesion, dry eyes, keratitis, visual field defects",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Ear pain, otitis externa",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Albuminuria, creatinine increased, renal function abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Bronchitis, cough, dyspnea, hemoptysis, hypoxia, pharyngitis, pleural effusion, pneumonia, pulmonary edema, rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Monilia, sepsis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F7995456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to bexarotene or any component of the formulation; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F7995457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypothyroidism: Bexarotene rapidly suppresses TSH levels by directly inhibiting TSH secretion, and also affects thyroid hormone metabolism (Hamnvik, 2011). In about one-third to the majority of all patients, hypothyroidism occurs; monitor free T",
"     <sub>",
"      4",
"     </sub>",
"     levels closely. Thyroid supplementation is usually required; in patients already receiving thyroid hormone therapy, may require increased thyroid hormone doses to achieve therapeutic levels (Hamnvik, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Leukopenia: Leukopenia and neutropenia may occur (may be delayed); monitor for signs and symptoms of infection about 4-8 weeks after initiation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lipid abnormalities: Induces significant lipid abnormalities in a majority of patients (triglyceride, total cholesterol, and HDL); monitor lipid panel; may require dose reduction, treatment interruption, and/or concomitant antilipemic therapy; reversible on discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Liver function test abnormalities: Dose-related elevations in ALT, AST, and bilirubin have been reported. Monitor for liver function test abnormalities and temporarily hold or discontinue drug if tests are &gt;3 times the upper limit of normal (ULN) values for AST, ALT, or bilirubin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pancreatitis: Pancreatitis secondary to hypertriglyceridemia has been reported. Patients with risk factors for pancreatitis (eg, prior pancreatitis, uncontrolled hyperlipidemia, excessive ethanol consumption, uncontrolled diabetes, biliary tract disease, concomitant medications causing hyperlipidemia)  should generally not receive bexarotene (oral).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: Retinoids are associated with photosensitivity; mild phototoxicity (sunburn, sunlight sensitivity) has occurred with bexarotene. Advise patients to limit sunlight and artificial ultraviolet light during treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Visual disturbances: Any new visual abnormalities experienced by the patient should be evaluated by an ophthalmologist (cataracts may form, or worsen, especially in the geriatric population).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may enhance the actions of insulin, sulfonylureas or thiazolidinediones, resulting in hypoglycemia in patients receiving these agents (hypoglycemia has not been observed with bexarotene monotherapy). Monitor blood glucose as necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use only with extreme caution in patients with hepatic impairment; undergoes extensive hepatic elimination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vitamin A: Limit additional vitamin A intake (in studies, additional vitamin A was limited to &lt;15,000 units/day).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Bexarotene is a retinoid, a drug class associated with birth defects in humans; do not administer during pregnancy.",
"     </b>",
"     Pregnancy test needed  within 1 week before initiation and every month thereafter. Effective contraception must be in place 1 month before initiation, during therapy, and for at least 1 month after discontinuation. Male patients with sexual partners who are pregnant, possibly pregnant, or who could become pregnant, must use condoms during sexual intercourse during treatment and for at least 1 month after last dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F7995463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Induces",
"     </b>",
"     CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F7995464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: Bexarotene (Systemic) may decrease the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CARBOplatin: May increase the serum concentration of Bexarotene (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Bexarotene (Systemic) may decrease the serum concentration of Contraceptives (Estrogens).  Management: Women of childbearing potential receiving bexarotene should use two reliable forms of contraception (including at least one nonhormonal form).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Retinoic Acid Derivatives may diminish the therapeutic effect of Contraceptives (Estrogens). Two forms of contraception are recommended in females of child-bearing potential during retinoic acid derivative therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Retinoic Acid Derivatives may diminish the therapeutic effect of Contraceptives (Progestins). Retinoic Acid Derivatives may decrease the serum concentration of Contraceptives (Progestins).  Management: Two forms of effective contraception should be used in patients receiving retinoic acid derivatives.  Particularly, microdosed progesterone-only preparations may be inadequately effective.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Bexarotene (Systemic) may decrease the serum concentration of Contraceptives (Progestins).  Management: Women of childbearing potential receiving bexarotene should use two reliable forms of contraception (including at least one nonhormonal form).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gemfibrozil: May increase the serum concentration of Bexarotene (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Retinoic Acid Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PACLitaxel: Bexarotene (Systemic) may decrease the serum concentration of PACLitaxel. PACLitaxel may increase the serum concentration of Bexarotene (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: Bexarotene (Systemic) may decrease the serum concentration of Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May enhance the adverse/toxic effect of Retinoic Acid Derivatives. The development of pseudotumor cerebri is of particular concern.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin A: Retinoic Acid Derivatives may enhance the adverse/toxic effect of Vitamin A.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F7995468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Bioavailability is increased when administered with a fat-containing meal. Serum levels may be increased by grapefruit juice. Management: Administer with food. Avoid grapefruit juice.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Dong quai and St John's wort may cause photosensitization. St John's wort may decrease bexarotene levels. Additional vitamin A supplementation may lead to vitamin A toxicity (dry skin, irritation, arthralgias, myalgias, abdominal pain, hepatic changes). Management: Avoid St John's wort and dong quai. Limit the use of vitamin A supplements.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F7995447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7995453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Bexarotene is a retinoid, a drug class associated with birth defects in humans; do not administer during pregnancy.",
"     </b>",
"     Bexarotene caused birth defects when administered orally to pregnant rats. It must not be given to a pregnant woman or a woman who intends to become pregnant. If a woman becomes pregnant while taking the drug, it must be stopped immediately and appropriate counseling be given. In women of childbearing potential, therapy should be started on the second or third day of a normal menstrual period. Either abstinence or two forms of reliable contraception (one should be nonhormonal) must be used for at least 1 month before initiating therapy, during therapy, and for 1 month following discontinuation of bexarotene. A negative pregnancy test (sensitivity of at least 50 mIU/mL) within 1 week prior to beginning therapy, and monthly thereafter is required for women of childbearing potential. A maximum 1 month supply is recommended so that pregnancy tests may be evaluated. Male patients must use a condom during any sexual contact with women of childbearing age during therapy, and for at least 1 month following discontinuation of bexarotene.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F7995455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9770108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if bexarotene is excreted into breast milk. Due to the potential for serious adverse reactions in a nursing infant, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F7995526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with food. Avoid grapefruit juice.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F7995544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Targretin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (100): $8403.17",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F7995530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     If female, pregnancy test within 1 week before initiation then monthly while on bexarotene; lipid panel (before initiation, then weekly until lipid response established and then at 8-week intervals thereafter); liver function tests (baseline, then at 1, 2, and 4 weeks after initiation, then at 8-week intervals thereafter if stable); monitor thyroid function tests (free T",
"     <sub>",
"      4",
"     </sub>",
"     ) weekly for the first 5-7 weeks, then every 1-2 months (Hamnvik, 2011); CBC with differential (baseline and periodic); blood glucose (in diabetic patients); ophthalmic exam (if visual abnormalities occur)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F7995471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Selectively binds to and activates retinoid X receptors (RXRs). Once activated, RXRs function as transcription factors to regulate the expression of genes which control cellular differentiation and proliferation. Bexarotene inhibits the growth",
"     <i>",
"      in vitro",
"     </i>",
"     of some tumor cell lines of hematopoietic and squamous cell origin and induces tumor regression",
"     <i>",
"      in vivo",
"     </i>",
"     in some animal models.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F7995473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Improved 48% by a fat-containing meal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;99% to plasma proteins",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP3A4 isoenzyme to four metabolites; further metabolized by glucuronidation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: ~2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily feces; urine (&lt;1% as unchanged drug and metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Duvic M, Hymes K, Heald P, et al, &ldquo;Bexarotene is Effective and Safe for Treatment of Refractory Advanced-Stage Cutaneous T-Cell Lymphoma: Multinational Phase II-III Trial Results,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2001, 19(9):2456-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/11/28854/abstract-text/11331325/pubmed\" id=\"11331325\" target=\"_blank\">",
"        11331325",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Foss F, Demierre MF, and DiVenuti F, &ldquo;A Phase-1 Trial of Bexarotene and Denileukin Diftitox in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2005, 106(2):454-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/11/28854/abstract-text/15811959/pubmed\" id=\"15811959\" target=\"_blank\">",
"        15811959",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hamnvik OP, Larsen PR, and Marqusee E, &ldquo;Thyroid Dysfunction From Antineoplastic Agents,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2011, 103(21):1572-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/11/28854/abstract-text/22010182/pubmed\" id=\"22010182\" target=\"_blank\">",
"        22010182",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McGinnis KS, Shapiro M, Vittorio CC, et al, &ldquo;Psoralen Plus Long-Wave UV-A (PUVA) and Bexarotene Therapy: An Effective and Synergistic Combined Adjunct to Therapy for Patients With Advanced Cutaneous T-Cell Lymphoma,&rdquo;",
"      <i>",
"       Arch Dermatol",
"      </i>",
"      , 2003, 139(6):771-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/11/28854/abstract-text/12810509/pubmed\" id=\"12810509\" target=\"_blank\">",
"        12810509",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rupoli S, Pimpinelli N, Goteri G, et al, &ldquo;Low Dose Bexarotene and Ultraviolet A Photochemotherapy (PUVA) in a Prospective Phase II Clinical Study for Refractory and/or Resistant Cutaneous T Cell Lymphomas (CTCL),&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2010, 116:3953 [abstract 3953 from 2010 ASH Annual  Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Singh F and Lebwohl MG, &ldquo;Cutaneous T-cell Lymphoma Treatment Using Bexarotene and PUVA: A Case Series,&rdquo;",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 2004, 51(4):570-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/11/28854/abstract-text/15389192/pubmed\" id=\"15389192\" target=\"_blank\">",
"        15389192",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8996 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-11633CD92E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_11_28854=[""].join("\n");
var outline_f28_11_28854=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995443\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12995356\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995834\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995482\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995523\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995524\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995525\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15796496\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995542\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995445\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995527\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995446\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995444\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995460\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995456\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995457\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995463\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995464\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995468\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995447\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995453\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995455\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9770108\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995526\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995544\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995530\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995471\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995473\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8996\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8996|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/14/36069?source=related_link\">",
"      Bexarotene (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/15/28916?source=related_link\">",
"      Bexarotene (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/0/12293?source=related_link\">",
"      Bexarotene (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_11_28855="Management of the patient with syncope";
var content_f28_11_28855=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of the patient with syncope",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/11/28855/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/11/28855/contributors\">",
"     Brian Olshansky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/11/28855/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/11/28855/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/11/28855/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/11/28855/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/11/28855/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syncope is the abrupt and transient loss of consciousness associated with absence of postural tone, followed by complete and usually rapid spontaneous recovery. Although it can be alarming for the individual, witnesses, family, and physicians, it is most often benign and self-limited. Nevertheless, injuries associated with syncopal attacks occur in 35 percent of patients, and recurrent episodes can be psychologically devastating. In addition, syncope can be a premonitory sign of cardiac arrest, especially in patients with organic heart disease.",
"   </p>",
"   <p>",
"    Issues relating to the management of the patient with syncope will be reviewed here. The pathogenesis, etiology, and the evaluation of this disorder are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5272?source=see_link\">",
"     \"Pathogenesis and etiology of syncope\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18682?source=see_link\">",
"     \"Evaluation of syncope in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of the patient with syncope is the same as that for presyncope, which is the prodromal symptom of fainting. Such patients usually present with symptoms of dizziness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23223?source=see_link\">",
"     \"Approach to the patient with dizziness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment is based upon the underlying cause of syncope (",
"    <a class=\"graphic graphic_table graphicRef64301 \" href=\"UTD.htm?8/31/8701\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef76023 \" href=\"UTD.htm?23/58/24491\">",
"     table 2",
"    </a>",
"    ) and is directed at preventing recurrence",
"    <span class=\"nowrap\">",
"     and/or,",
"    </span>",
"    in some cases, death. A brief review of the available treatment options for each of the possible underlying disorders is presented below. Detailed discussions of the treatment of individual disorders are presented separately. The treatment options discussed are in general agreement with guidelines published in 2009 by a task force of the European Society of Cardiology [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28855/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Metabolic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although metabolic abnormalities (such as hypoglycemia or hypoxia) infrequently cause syncope, they can cause impaired consciousness that may be difficult to distinguish from syncope. Metabolic abnormalities, anemia, and hypovolemia can be effectively managed by specific therapy to correct these abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Iatrogenic syncope",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iatrogenic syncope resulting from drug therapy is a preventable and treatable condition. It is especially common in elderly patients and those with coexisting chronic diseases, and diminished or blunted cardiovascular reflexes. In this setting, effective interventions include the elimination of the offending agent, substitution of an alternative agent, changing the dose, or altering the timing of drug administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Orthostatic hypotension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identifying the underlying cause is crucial to appropriate treatment of orthostatic hypotension. Orthostatic hypotension associated with evidence of volume depletion should be treated with volume expansion and avoidance of precipitating factors (such as diuretic use). Orthostatic hypotension in the absence of volume depletion is most often due to an autonomic neuropathy or the administration of antidepressant drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28855/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management of orthostatic hypotension is discussed in detail separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/2/5161?source=see_link\">",
"     \"Treatment of orthostatic and postprandial hypotension\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cardiovascular disease with obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac diseases that obstruct the outflow of blood generally require surgical correction or attenuation of the obstruction. As an example, aortic valve replacement for aortic stenosis will alleviate symptoms, prevent syncope, and prolong survival. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31881?source=see_link\">",
"     \"Indications for valve replacement in aortic stenosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dynamic outflow obstruction resulting from hypertrophic cardiomyopathy is treated pharmacologically with beta blockers or calcium channel blockers [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28855/abstract/3\">",
"     3",
"    </a>",
"    ]. Refractory obstructive symptoms may be treated with nonpharmacologic methods such as septal myectomy or septal ablation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10105?source=see_link\">",
"     \"Medical therapy in hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7514?source=see_link\">",
"     \"Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The cause of syncope in such patients may be due to undiagnosed ventricular arrhythmias that may increase the risk of death and may require therapy with an ICD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=see_link\">",
"     \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Implantable cardioverter-defibrillator therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Implantable cardioverter-defibrillator (ICD) therapy is indicated in patients with who have syncope that is due to potentially life-threatening ventricular tachycardia that is otherwise not treatable (",
"    <a class=\"graphic graphic_table graphicRef73650 \" href=\"UTD.htm?39/52/40780\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    ICD therapy should also be considered for patients who have syncope due to an unknown cause but have underlying structural heart disease that places them at risk of sudden cardiac death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Documented, suspected, or induced ventricular tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with syncope with documented ventricular arrhythmias, primarily VT, with structural heart disease (often associated with impaired left or right ventricular function), long QT interval syndrome, Brugada syndrome, catecholaminergic polymorphic VT or other condition placing the patient at risk for cardiac arrest and recurrent syncopal episodes should receive an implantable cardioverter-defibrillator (ICD). Radiofrequency catheter ablation is effective especially in patients with idiopathic right or left ventricular monomorphic VT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30599?source=see_link\">",
"     \"Implantable cardioverter-defibrillators: Clinical trials of secondary prevention of sudden cardiac death\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar outcomes with ICD therapy have been observed in patients with syncope and no documented",
"    <span class=\"nowrap\">",
"     VT/ventricular",
"    </span>",
"    fibrillation (VF), but inducible VT, and those with documented",
"    <span class=\"nowrap\">",
"     VT/VF.",
"    </span>",
"    One report compared the outcome with ICD therapy in 178 patients with unexplained syncope, no documented spontaneous VT, and inducible VT, and 568 patients with documented",
"    <span class=\"nowrap\">",
"     VT/VF",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28855/abstract/4\">",
"     4",
"    </a>",
"    ]. Recurrent syncope was associated with a ventricular tachyarrhythmia in most patients in both groups (85 and 92 percent, respectively). At two years, the actuarial probability of appropriate ICD therapy (55 and 58 percent) and the actuarial survival was the same (91 and 93 percent).",
"   </p>",
"   <p>",
"    Therefore, ICD therapy is recommended for patients with unexplained syncope who have hemodynamically significant and symptomatic ventricular tachycardia (VT) induced during electrophysiologic testing (EPS) in both the 2009 ESC syncope guidelines (",
"    <a class=\"graphic graphic_table graphicRef73650 \" href=\"UTD.htm?39/52/40780\">",
"     table 3",
"    </a>",
"    ) and the 2008",
"    <span class=\"nowrap\">",
"     ACC/AHA/HRS",
"    </span>",
"    device guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28855/abstract/1,5\">",
"     1,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the efficacy of ICD therapy in such patients is uncertain. A retrospective analysis of data from SCD-HeFT found that while unexplained syncope was associated with increased risk of mortality as well as increased rate of appropriate ICD discharges, total mortality did not differ between ICD therapy and placebo treatment groups [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28855/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, regardless of therapy, some patients with syncope have an appreciable mortality risk. This was illustrated further in a report of 67 patients with coronary heart disease and syncope, 29 of whom had inducible monomorphic VT during EP studies and received an ICD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28855/abstract/7\">",
"     7",
"    </a>",
"    ]. Survival was significantly lower in the patients with inducible VT compared to noninducible patients VT (77 versus 94 percent at one year and 45 versus 84 percent at two years).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Other ICD indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In certain patient populations (otherwise well treated for their underlying heart disease), ICD therapy may be indicated regardless of electrophysiology study (EPS) results and regardless of the presence or absence of syncope.",
"   </p>",
"   <p>",
"    Patients with LVEF &le; 30 percent and prior history of myocardial infarction (with or without history of syncope) are appropriate candidates for ICD therapy, regardless of EPS results. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=see_link&amp;anchor=H29#H29\">",
"     \"Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction\", section on 'ICD therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with ischemic or nonischemic heart disease with LVEF &le;35 percent with NYHA class II to III heart failure (and some with class IV heart failure) are appropriate candidates for ICD therapy, regardless of EPS results. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=see_link&amp;anchor=H13#H13\">",
"     \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\", section on 'Primary prevention of SCD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ICD therapy may be considered in certain patients with familial dilated cardiomyopathy at risk of sudden death (family history of sudden cardiac death or LMNA mutation). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/59/5047?source=see_link\">",
"     \"Familial dilated cardiomyopathy: Prevalence, diagnosis and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Genetic syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment including ICD use for patients with unexplained syncope who have Brugada syndrome, congenital long QT syndrome, catecholaminergic polymorphic VT, arrhythmogenic right ventricular dysplasia or hypertrophic cardiomyopathy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=see_link&amp;anchor=H36#H36\">",
"     \"Brugada syndrome\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26682?source=see_link&amp;anchor=H13#H13\">",
"     \"Prognosis and management of congenital long QT syndrome\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37641?source=see_link&amp;anchor=H15#H15\">",
"     \"Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval\", section on 'Management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/56/6025?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment and prognosis of arrhythmogenic right ventricular cardiomyopathy\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=see_link\">",
"     \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Supraventricular arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although supraventricular arrhythmias can be treated with antiarrhythmic drugs, radiofrequency ablation has become a preferred therapy for the majority of such arrhythmias, especially those that involve the AV node or an accessory pathway. Patients with syncope due to supraventricular arrhythmias should be treated preferentially with curative therapy (ie, ablation). Surgery or antitachycardia pacemakers are infrequently used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24793?source=see_link\">",
"     \"Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15304?source=see_link\">",
"     \"Catheter ablation for AV nodal reentrant tachycardia (junctional reciprocating tachycardia)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Sinus bradycardia or AV block",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2008 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/Heart",
"    </span>",
"    Rhythm Society guidelines for device-based therapy include guidelines for pacemaker implantation in patients with syncope that is documented to be due to a bradycardia as long as it is otherwise not treatable [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28855/abstract/5\">",
"     5",
"    </a>",
"    ]. Similar indications are included in the 2009 ESC syncope guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28855/abstract/1\">",
"     1",
"    </a>",
"    ]. Permanent pacemaker implantation is indicated when sinus node dysfunction (",
"    <a class=\"graphic graphic_table graphicRef59797 \" href=\"UTD.htm?23/52/24396\">",
"     table 4",
"    </a>",
"    ) or AV block is documented to cause syncope (",
"    <a class=\"graphic graphic_table graphicRef81080 \" href=\"UTD.htm?23/23/23933\">",
"     table 5",
"    </a>",
"    ). In some cases, however, a permanent pacemaker is used empirically when baseline ECG or EP study strongly suggests a conduction abnormality as the cause for syncope as illustrated by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pacemaker therapy is reasonable in patients with syncope when clinically significant sinus node dysfunction is observed or provoked in EP study.",
"     </li>",
"     <li>",
"      Pacemaker therapy is reasonable in patients with syncope and bifascicular or trifascicular disease on the baseline electrocardiogram if other causes have been excluded, specifically ventricular tachycardia.",
"     </li>",
"     <li>",
"      Pacemaker therapy is reasonable for unexplained syncope in the patient with prior congenital heart surgery complicated by transient complete heart block with residual fascicular block after a careful evaluation to exclude other causes of syncope.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, pacemaker therapy is reasonable in patients with markedly prolonged HV interval (&ge;100 ms) or intra- or infra-His block that is not physiological, even if found incidentally.",
"   </p>",
"   <p>",
"    Empiric pacemaker implantation is",
"    <strong>",
"     NOT",
"    </strong>",
"    indicated for patients with the triad of syncope of unknown etiology, no documented bradycardia, and a negative EP study [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28855/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=see_link\">",
"     \"Indications for permanent cardiac pacing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Vasovagal syncope",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of vasovagal (neurocardiogenic) syncope is often difficult and varies with the pattern of autonomic dysfunction. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18442?source=see_link\">",
"     \"Reflex syncope\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Carotid sinus hypersensitivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carotid sinus hypersensitivity is often considered to be a variant of neurocardiogenic syncope and is known as carotid sinus syndrome; many of the same therapies have been used. Pacemakers are of benefit for patients with only cardioinhibitory responses but not in those with a vasodepressor response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/22/10598?source=see_link\">",
"     \"Carotid sinus hypersensitivity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     RATE OF RECURRENT SYNCOPE",
"    </span>",
"    &nbsp;&mdash;&nbsp;As many as 40 to 85 percent of patients with transient loss of consciousness who present to the health care system do not have recurrent episodes. Despite widely varying etiologies and therapies, the recurrence rate of syncope due to the different causes is surprisingly similar (",
"    <a class=\"graphic graphic_figure graphicRef60636 \" href=\"UTD.htm?11/44/11982\">",
"     figure 1",
"    </a>",
"    ). In a review of 433 patients, the cumulative incidence of recurrence of syncope at three years was [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28855/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      31 percent for patients with a cardiovascular etiology",
"     </li>",
"     <li>",
"      36 percent for those with a noncardiovascular cause",
"     </li>",
"     <li>",
"      43 percent for those with syncope of unknown etiology",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among patients with neurocardiogenic syncope, the time to first recurrence after a tilt table test predicted the frequency of syncope during a 6.5 year follow-up: 1.35 episodes per month when the first recurrence was within one month compared to 0.12 episodes per month when the first recurrence was later [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28855/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, the lack of recurrence due to an apparent therapeutic effect may simply reflect the natural history of the disease. While recurrences do not predict mortality or sudden death, they may be associated with substantial morbidity, especially due to injury and fractures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DRIVING RESTRICTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Driving restrictions are indicated for some patients at risk for recurrent syncope to guard the safety of themselves and others. Recommendations for driving in patients with arrhythmias and syncope are included in the 1996 statement from the American Heart Association (AHA) and North American Society of Pacing and Electrophysiology (NASPE, now Heart Rhythm Society, HRS) on personal and public safety issues related to arrhythmias and amended in the 2007 addendum [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28855/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Similar driving restriction recommendations are included in the 2009 ESC syncope update [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28855/abstract/1\">",
"     1",
"    </a>",
"    ]. Driving restrictions are governed by state law. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/22/10598?source=see_link&amp;anchor=H8#H8\">",
"     \"Carotid sinus hypersensitivity\", section on 'Driving restrictions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18442?source=see_link\">",
"     \"Reflex syncope\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30024?source=see_link\">",
"     \"Driving restrictions in patients with an implantable cardioverter-defibrillator\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of the patient with syncope is directly related to the underlying etiology of the syncope and the underlying comorbidities not the syncope itself [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28855/abstract/13-17\">",
"     13-17",
"    </a>",
"    ]. As a result, patients can be categorized into different risk categories based upon cause (",
"    <a class=\"graphic graphic_figure graphicRef53302 \" href=\"UTD.htm?23/2/23598\">",
"     figure 2",
"    </a>",
"    ). Those with an underlying cardiovascular cause have higher sudden death and all cause total mortality rates than those with a noncardiovascular cause. Overall mortality in the cardiovascular group after five years of follow-up has been reported to approach 50 percent, with a 30 percent incidence of death in the first year [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28855/abstract/14,18,19\">",
"     14,18,19",
"    </a>",
"    ]. By comparison, lower but still appreciable mortality have been described in patients with a noncardiovascular cause (as high as 6 to 12 percent in the first year) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28855/abstract/14,20\">",
"     14,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a major problem in determining the true mortality rate in patients with syncope is that most individuals with transient loss of consciousness do not seek medical advice. It is suspected that most individuals have a low recurrence rate of syncope and an excellent long-term survival in the absence of underlying cardiac disease. Outpatients never admitted for their episodes may be at less risk for recurrence and have a more benign long-term prognosis than those requiring hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28855/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Underlying cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is difficult to know whether syncope independently contributes to prognosis since such patients also have other associated chronic diseases. In particular, patients with a cardiovascular cause for syncope have a high mortality rate that is due in part to their underlying cardiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28855/abstract/22\">",
"     22",
"    </a>",
"    ]. One study, for example, stratified patients with and without syncope who were admitted to an intensive care unit and reported that long-term prognosis was independent of syncope but was dependent upon the underlying disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28855/abstract/23\">",
"     23",
"    </a>",
"    ]. Similarly, data from the Framingham study found that patients with cardiovascular disease and syncope had the same mortality rate as those with equivalent cardiovascular disease but without syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28855/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Age, gender, and other comorbid diseases are also important determinants of prognosis. Patients admitted to hospitals tend to be sicker and older, and tend to have a higher mortality independent of syncope or its cause. Men are more likely than women to have underlying cardiac disease and a cardiac event during follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28855/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <strong>",
"     INFORMATION FOR PATIENTS",
"    </strong>",
"    &mdash; UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (See",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/5/36946?source=see_link\">",
"       \"Patient information: Syncope (fainting) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/46/8931?source=see_link\">",
"       \"Patient information: Bradycardia (The Basics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Beyond the Basics topic (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?4/9/4245?source=see_link\">",
"       \"Patient information: Syncope (fainting) (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment is based upon the underlying cause of syncope and is directed at preventing recurrence",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      death (",
"      <a class=\"graphic graphic_table graphicRef76023 \" href=\"UTD.htm?23/58/24491\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef64301 \" href=\"UTD.htm?8/31/8701\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rate of syncope recurrence is variable among individuals although similar among groups with different causes of syncope. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Rate of recurrent syncope'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Driving restrictions are indicated for some patients at risk for recurrent syncope to guard the safety of themselves and others. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Driving restrictions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prognosis of the patient with syncope is related to its etiology as well as any underlying cardiovascular disease (which may or may not be related to the cause of syncope). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28855/abstract/1\">",
"      Task Force for the Diagnosis and Management of Syncope, European Society of Cardiology (ESC), European Heart Rhythm Association (EHRA), et al. Guidelines for the diagnosis and management of syncope (version 2009). Eur Heart J 2009; 30:2631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28855/abstract/2\">",
"      Robertson D, Robertson RM. Causes of chronic orthostatic hypotension. Arch Intern Med 1994; 154:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28855/abstract/3\">",
"      Bonow RO, Rosing DR, Bacharach SL, et al. Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy. Circulation 1981; 64:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28855/abstract/4\">",
"      Pires LA, May LM, Ravi S, et al. Comparison of event rates and survival in patients with unexplained syncope without documented ventricular tachyarrhythmias versus patients with documented sustained ventricular tachyarrhythmias both treated with implantable cardioverter-defibrillators. Am J Cardiol 2000; 85:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28855/abstract/5\">",
"      Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28855/abstract/6\">",
"      Olshansky B, Poole JE, Johnson G, et al. Syncope predicts the outcome of cardiomyopathy patients: analysis of the SCD-HeFT study. J Am Coll Cardiol 2008; 51:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28855/abstract/7\">",
"      Mittal S, Iwai S, Stein KM, et al. Long-term outcome of patients with unexplained syncope treated with an electrophysiologic-guided approach in the implantable cardioverter-defibrillator era. J Am Coll Cardiol 1999; 34:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28855/abstract/8\">",
"      Krahn AD, Klein GJ, Fitzpatrick A, et al. Predicting the outcome of patients with unexplained syncope undergoing prolonged monitoring. Pacing Clin Electrophysiol 2002; 25:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28855/abstract/9\">",
"      Kapoor WN, Peterson J, Wieand HS, Karpf M. Diagnostic and prognostic implications of recurrences in patients with syncope. Am J Med 1987; 83:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28855/abstract/10\">",
"      Malik P, Koshman ML, Sheldon R. Timing of first recurrence of syncope predicts syncopal frequency after a positive tilt table test result. J Am Coll Cardiol 1997; 29:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28855/abstract/11\">",
"      Epstein AE, Miles WM, Benditt DG, et al. Personal and public safety issues related to arrhythmias that may affect consciousness: implications for regulation and physician recommendations. A medical/scientific statement from the American Heart Association and the North American Society of Pacing and Electrophysiology. Circulation 1996; 94:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28855/abstract/12\">",
"      Epstein AE, Baessler CA, Curtis AB, et al. Addendum to \"Personal and public safety issues related to arrhythmias that may affect consciousness: implications for regulation and physician recommendations: a medical/scientific statement from the American Heart Association and the North American Society of Pacing and Electrophysiology\": public safety issues in patients with implantable defibrillators: a scientific statement from the American Heart Association and the Heart Rhythm Society. Circulation 2007; 115:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28855/abstract/13\">",
"      Middlekauff HR, Stevenson WG, Stevenson LW, Saxon LA. Syncope in advanced heart failure: high risk of sudden death regardless of origin of syncope. J Am Coll Cardiol 1993; 21:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28855/abstract/14\">",
"      Kapoor WN, Karpf M, Wieand S, et al. A prospective evaluation and follow-up of patients with syncope. N Engl J Med 1983; 309:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28855/abstract/15\">",
"      Eagle KA, Black HR, Cook EF, Goldman L. Evaluation of prognostic classifications for patients with syncope. Am J Med 1985; 79:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28855/abstract/16\">",
"      Morady F, Shen E, Schwartz A, et al. Long-term follow-up of patients with recurrent unexplained syncope evaluated by electrophysiologic testing. J Am Coll Cardiol 1983; 2:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28855/abstract/17\">",
"      Oh JH, Hanusa BH, Kapoor WN. Do symptoms predict cardiac arrhythmias and mortality in patients with syncope? Arch Intern Med 1999; 159:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28855/abstract/18\">",
"      DERMKSIAN G, LAMB LE. Syncope in a population of healthy young adults; incidence, mechanisms, and significance. J Am Med Assoc 1958; 168:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28855/abstract/19\">",
"      Kapoor W, Karpf M, Levey GS. Issues in evaluating patients with syncope. Ann Intern Med 1984; 100:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28855/abstract/20\">",
"      WAYNE HH. Syncope. Physiological considerations and an analysis of the clinical characteristics in 510 patients. Am J Med 1961; 30:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28855/abstract/21\">",
"      Costantino G, Perego F, Dipaola F, et al. Short- and long-term prognosis of syncope, risk factors, and role of hospital admission: results from the STePS (Short-Term Prognosis of Syncope) study. J Am Coll Cardiol 2008; 51:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28855/abstract/22\">",
"      Middlekauff HR, Stevenson WG, Saxon LA. Prognosis after syncope: impact of left ventricular function. Am Heart J 1993; 125:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28855/abstract/23\">",
"      Silverstein MD, Singer DE, Mulley AG, et al. Patients with syncope admitted to medical intensive care units. JAMA 1982; 248:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28855/abstract/24\">",
"      Savage DD, Corwin L, McGee DL, et al. Epidemiologic features of isolated syncope: the Framingham Study. Stroke 1985; 16:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28855/abstract/25\">",
"      Freed LA, Eagle KA, Mahjoub ZA, et al. Gender differences in presentation, management, and cardiac event-free survival in patients with syncope. Am J Cardiol 1997; 80:1183.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1032 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-A277839E2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_11_28855=[""].join("\n");
var outline_f28_11_28855=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Metabolic disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Iatrogenic syncope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Orthostatic hypotension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cardiovascular disease with obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Implantable cardioverter-defibrillator therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Documented, suspected, or induced ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Other ICD indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Genetic syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Supraventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Sinus bradycardia or AV block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Vasovagal syncope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Carotid sinus hypersensitivity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      RATE OF RECURRENT SYNCOPE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DRIVING RESTRICTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Underlying cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1032\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1032|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/44/11982\" title=\"figure 1\">",
"      Incidence of recurrent syncope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/2/23598\" title=\"figure 2\">",
"      Mortality with syncope by cause",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1032|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/31/8701\" title=\"table 1\">",
"      Classification of syncope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/58/24491\" title=\"table 2\">",
"      Conditions incorrectly diagnosed as syncope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/52/40780\" title=\"table 3\">",
"      Indications for ICD in patients with unexplained syncope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/52/24396\" title=\"table 4\">",
"      ACC AHA HRS sinus dys",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/23/23933\" title=\"table 5\">",
"      ACC AHA HRS AV block",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23223?source=related_link\">",
"      Approach to the patient with dizziness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24793?source=related_link\">",
"      Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=related_link\">",
"      Brugada syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/22/10598?source=related_link\">",
"      Carotid sinus hypersensitivity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37641?source=related_link\">",
"      Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15304?source=related_link\">",
"      Catheter ablation for AV nodal reentrant tachycardia (junctional reciprocating tachycardia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30024?source=related_link\">",
"      Driving restrictions in patients with an implantable cardioverter-defibrillator",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18682?source=related_link\">",
"      Evaluation of syncope in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/59/5047?source=related_link\">",
"      Familial dilated cardiomyopathy: Prevalence, diagnosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30599?source=related_link\">",
"      Implantable cardioverter-defibrillators: Clinical trials of secondary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=related_link\">",
"      Indications for permanent cardiac pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31881?source=related_link\">",
"      Indications for valve replacement in aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10105?source=related_link\">",
"      Medical therapy in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7514?source=related_link\">",
"      Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5272?source=related_link\">",
"      Pathogenesis and etiology of syncope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/46/8931?source=related_link\">",
"      Patient information: Bradycardia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/9/4245?source=related_link\">",
"      Patient information: Syncope (fainting) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/5/36946?source=related_link\">",
"      Patient information: Syncope (fainting) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26682?source=related_link\">",
"      Prognosis and management of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18442?source=related_link\">",
"      Reflex syncope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=related_link\">",
"      Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/56/6025?source=related_link\">",
"      Treatment and prognosis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/2/5161?source=related_link\">",
"      Treatment of orthostatic and postprandial hypotension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=related_link\">",
"      Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_11_28856="Benign macrofollicular thyroid lesion low power view";
var content_f28_11_28856=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F76239%7EENDO%2F64419&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F76239%7EENDO%2F64419&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Benign macrofollicular thyroid lesion: Findings on fine needle aspirate",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low-power view of a fine needle aspirate of a thyroid nodule showing an intact macrofollicle (a) and a macrofollicle that has been broken apart by the biopsy forming a flat sheet (b). At this power, the cells appear uniform in size and are not crowded. Not shown, but commonly present in macrofollicular lesions, are areas of cystic degeneration, cellular debris, and hemosiderin-laden macrophages.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Benign macrofollicular thyroid lesion: Findings on fine needle aspirate",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 237px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADtAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5WU4IOAfrSUlFMD1nwrBbaf4ZsPNZZri43TDuEU8du/tXa67NDp/htI7OaBXddzgr8xPpmvLPCcV7f6Nb29o53xTts28EZGeT/nrXpWj/AA+1u9t0a8hJjXBLE9B7V68akYwi27HjVk+dnofwv1IPodvG6Kro4bcw+b8M1seMNaXTGP2U+ZIjbivrn2q34f8AD+maVYoNjK0S7gc4ycc5ryXxBc3er+MriO23IhfAbqFHT8O9cNJU69aVTojSCcYqPcPi3r723hy5uLsl9QulWKBlOPKBGTx9OM1845ydzc+ue9fQvjLwhd3uhyQJdRLKj+ZHLO/3jjkY/KvH4fBGuzTRxi1VS7bVJkXGfzratFytyK6OqhKEE03qc6doLZGCRkbTwK9C8NPex/CvxBFmRYpZIzGvTIGd31rZ8F/By61TU/L1K6CQRrucRLnJ7KDXXeN3trJE06OARJahYogp+XaB047/AM806ELzcWXUrxtofOhBI3Hp0pAcDgkZrutd8Gme4MuinhxvMDnGPXaT/KsePwpdxqZtQdLe2XlnHzHHsKwq05RdmjWFSMldB4LtN93Jcyx74UHl49S3HH0616FbyC1hZoyZEj4bec/jXGReIdKsIktbW3uJoIxwxIUs2etaWn+IbK7hMC3X2QORvMg5Ptn+tSrtco5Rs+ZHYWzXNxGzWyGViOqn1966MaUht/NuXZJAgAiQkoxB43Cuf07xXY+E7VZJF81FbIUHLOT0I9B71Xh+Llmxlgl0uRoWclWWUbyfT6V1wXs7IwmpVHtuSeJvDmnagkbXNqVIwDLHw+ff1pvhT4TaVq7JK890sQO7a+BvwenHPIruPC9xY+N7L7ZYygSQ/Lc28g2sg7E13Hg6xtbe8d7korjlAMYHoKzxFaKi3bVHPecXy8x598VvEV98P/CunWfgm0l0iKeRjJPAnTaMYJ9fc14THrGmXEOqXet2Nxda1dKWimRwkcbkj5yB1PWvsbV4V2TpJJDPHMpDQyHcrA9iK41/hB4SulN1Fo8au/8AyzWdtqY77fT2rjjiIpao66dRQWu58v2tnqX9kXesTQ3ZsWbyvtAJCNIexPfisU5VsMPzr720b4f6TaaC1nqMIvrRUKxWrriJAfRf69a+f/ip8KLeyvYn8My2kcUgKy2xYl4yBnIYnkH2qqOJhWk4w1sUqy2loeISRy+am5BGHHAHyjHrX094Z8G+Lpf2d7oWiNFeTW5eG3HyyvEGLHHGclc4HU/jXBfDrwDHF4ghu/FwYuBm3tciQO/8JfBxtGM7e/evsXw3qkWoaVHKsgZ0/dvgbcEcdKyxteph4qUUQ6lOtPlTPzTlUq5Vs5HGD29qVHMcoe3d0ZSCrA4IP1FfYPxx+Bdh4jkn13ww8dhq7ndPbtxDck/xD+43qeh+vJ8m8O/s9+J7y6I1C80zTVQbmZ5PNOPov+NFPF06kOe5pzqLszs/hZPea/oGi3rlPtkUrWwlD7nmwMknP1616fd6fqD+GrhtPuXa8jhl8qO4XYGcg9D7c4q74M8KaF8P/CsEK3Rkjt1ebz51AcNjLPx0B/lXzP4r+OPiy/1a8bRbw2NgshMMaoGKp0yWPc9ajDSlUvy6JMyrR9pNNanlGpXP2m8lcx+WCcFQxPPcknqetVtjN0x7cYzWpsl124xAm6/kYsYlGPMJ6ke/tSnRtZur5bVdMvfPQiMRCFsrz6dua72dLaW59Mfs2a0ll8Mr7VNXdntdGml37vmKoVBCj3z0rhvFfxt8Q6xqMkem3MXh/TQzFYoCBK3pvfrn2GK6S58IXGifA2LS9k1pdz3kUuo4b5HLEgKT0wPl/GvHNY08WqNAIEu71QW82MEiMA87hjGawjGMpOb1ewsNh4STqbq50fhb4teK9H1iC6vdZuL6zVgZbW5czRuh7AHkH0NfSdtfWeuaPb6nZZa3vI/OVh2z1H1HT8K+Lr27nngh8/kpH5amNRgjPT619D/s+axJqPhi+0+UnbZurqxzuG8HIOe2RXDmUPcVRdGbxhCL909HY+SgdYzwMOFOM57+5rWWQOjOj7BwNhGTnuajtdGuJEE1wY44G5XzGALD2WriwRhRbJhFxux369K46UlyWZz4hq+hDBvnkU7yqg464xjirTuXbByG3ct1qCJWG9GAHqT0FKk2cfeLqfu461Und6GCXVmr4cmCXktuW5AyK6P/AB71x9pkahHcA7Wzhgx4rsBggdwa8/Er3rmsBPY00gf/AF6fSGue5TRGevSgjnPGacelNPUc9+aLmbQxyvCFsM33RnBOKKeaKOa24uW5+ZCWtw6qyQSsrdCEJBq3ZaPe3sgWC3lCAbmkddqqO5JPGK9w+G7roPw8ivbhIwJQdh4yd2fxNcB4/wDEz3NgLGB8RStuYLwMD1r7aNBKPO9kXGpF6dS/4d8baZ4Qt1trKJL7aOW2Y+bucmvbfhb8RI/GFtfQrHFavGATGTzj1x6V8g1s+EtQu9O1+ylsZZY5GlVD5bEFlJAKn1BrOUlW92SMalHRuL1Pt6633u77EC8PlgqQcDHfmuNu9LtNIWfUJH2y7c4IyAM8D3NbWj39vCrxWkyII+qMxA6VxXia/vtc1b7LZrujA+ZVHH4Gqw1Gak47ROZSVr9Sv4nvdL1Kys7y6mkjViDIrDt/UfX9amg1Dw3Y2kbAQpchs+Y3HmL6fT/CuP8AGCSeG9HuJdXeKS6UbbeHg8kYB+g5PvXiN3fXN3KXuJ5JG926fSuuq4U4pamtKLm27f5n2PoPijQLO0aeOVld1JZUw3J6cDn/APVXLa7ocd7qUN20gFpKTIC2duT2zXy7HPLEwaOV1I5BViK+j/hbrEniD4fqlxM7y2MvlytJ3B5HNYUnGMnKN7s0dKx0V5o9hpsODtLOowMDlewzjivIfjHqhvrOyMMRSJ3KlhgA47YHWvU/E1/Jc2EMdl5byowAwOw9fauA8Q+F7/WtBeOWLZcxSGWFt2FJPUHn9a2lFunzS3JipRqJSeh4zNC8L+XIhVx1qIcZ75qW4jmt55IJgySISrKexq3oumzaxqUVpbAKW6sRwo9TXI2jsdugyCT7TLG1/NIIFG3PUkAcAVa1eLTI7mGHTJnkiIDPM46E9se1U5IDBMY7gPtjbawHBXmrd5ZQhYriHAtZDhEWQNJgdc+hrVXaKtpaxvfC/X7nQ/FYa1k4uY2gbd0ORxn8q9XfxBeSgPFLKd8eP936V4do0sFheNqJyyQH9zG/V2Prj0611MPjq2aym821dL3GVcNuUn0INdFKUUrSOGvTcpXR6TDr0um2sMl9drb24xmWRucew79f0rf8OfFTRrXUVSPUopFZQpaRCAMds18yanqN3qcxuLyV3YnueB7AVXt871HmFFY4JHP6VlWcKis1oEKDS1ep+gml+KLW+U3iXkIjdePnyBxx06Vw2u6Ppl3etcKjtG/yuT83PqPqa+Z/AeuXWj69bW6zFrOaZI542PyMCcZ9se1fYp0iG20uVZ48BjtPYKK4IwhhJc0G9dLGdak5aM810y0tkN1Z2EcyOoVyzcYIORz/AJP4V6d4HWN7ORrKNlYR/vCWJBavmzxv46uPC2t31hohDzlsO8/zBF7AD3FUvCnx28T6JFNAYtPuYpWGRLEQQPYg8CujGwdWDhF6mdCl9tn2IJHMkW6ffvGCPT61nR3SRRyBY4z5bF3IPJ9K5b4d+PtO8TeHxeLBsuC2y6hRwTGexGex7Vf1/WbHQvCep6vNGPssERdkJ+aQnhV/E4rxlh5Qk4tGzd3oY/jMzN4Y1ohjLeXFrJiFeSMg4T6EV8UzEDAEe2RfvKe49MV6RdfFvxfqGqtf293bWqxcrCka7SOwYHk1W09NO8fNJGgtNN8TPI8ojYbIbpz2U/wtntXRhY1MMn7XVfkekoxktDzsSvFcq6vJC8Z3R7eqHORj0r6W+Fut3/iSG1n1W/8AOkuExIMEu5X5SxPbj069a8js/hh4hm1hbbVtOutNQ8yyyqDt9cc819D+DdHGl6Nbw2lmI1hAt1ZMF2QDJYnpkknNeopcsXI8vFyjK0VudnHpen6ho95oFx++067TBm7oeoOfUHGK8I8f+FfEHhG3utPaW4n0yRlkN7HADG4znBYcqfY8V7NZS/ZIHWJ3eP77sykcnoB2qfTPE/lxXMV2qmFl5EnJx+PU1xWqwblHVf1qa4LFuiuVbM+SdYtba7htbiCSKCYy7HRE/eEYyGwvftXufw3sbD4Z+C1ufF959k1TWHM6WPl7pmjXhAR/D1yc+uOtd0q6JNcRXFlY2sMpBYH7Mqt05JwMjGPrXzV4+1y48ReIb25vrsyuZSkMjA/LCCQu3Pbv+NOpH20eWSsj0FUWIndadz1TUPjRYQ3rbdHuZVU7W8+YDjtsGD+tej+E/FOi+MNPnuNGZ3uoV/0i3k4eI+vuvuK+StVNyIc3Bjwqg5HJYDvxxnFW/h1r1x4X8W6VqUDzJGJl8zk/PCxwwx345/CsI4WHL7mj9SMZTSeiPsSMFLd0k2l1PzYJ/nSKUAO5SXB5A7e9TzIqyMUYeWzZGeeD7fjUJVHDkAs0ZwE9feuK/U4lsPs8eXkkA4wvrXV2Unm2kTHqR0xiuQKjY+yM7X+7t4xXTaGxawQMcla5cUtLl037xoH6n/GkpSKQ9PWuE3Y00006kP5UiGNHOfQ+lFHP4UUXsI/P3WvGkN1plvp1pHOltbqEjGcDAGMkZ5rndatJ2trbUMK9tMu0OnQMOoPpWNW14b1EWczxzndA6n5G+6W7ZH519xGs6vuS0JcFD3omLXafC3RZdQ8RQXhCrb2beZuk4V3HRfz9KltbTTvPDz6WqRyHcjEnBHHTnBrrjqFpDaJHbIigLwioF29sDHQZzW1HCNSvJmFfEpxcYnWXhuIYprpm3zMx805yOf8AJNZei63d2HiG5gTaY/JDb++OuM/411OnTrfeHyzKiJKuSq9SBWVB4cs7G93l3xIp754I7/hXXzLZnLTTnGxD8YZdP1vwGtwGg/tCMq+UbhtowQR649K+dK+jJfBFpqhCEvHE/Efzd/8AOa09B+D+gXQjWeASzDIc7iF/DFcVdQSvfY7KcvZ6M+ZIIpJpFjhRndjgKBkmvU9GuLzw74bbQ3aJJ5ZBcSBCNwJ6Anv9K9Q8eeFNB8I6HLf6bZx27LHt37ckgfXpnpXzte+JdQu5zPlFAbOAoP4E9+lOg4RiqhU26qtE9W8I+IIY7zyr5XjgK8uUzzjtXp9tpseq6dHHBdwiLB+buPrXgOh+LItSuVtb1IbKV8bZU4Td2BHavQ9E8RS2lq9u3EikDcuMYH9K0nNT1i7NEKnJ+7LUqeMvB2jTSEXBkacc741wfofWuatbO00yRLawREJXczA5J+prZ17VovssuoX12Yow2FUj5nb+6o+neuRTxXolxqDyPbXVqjDBIw6jj0qKyio3T1Kp817W0OrvvD2j67Zu1yWs7tULGeLkt3+Ze/4VyWh+EEudXiW9u4o7NBtJtlJeT+gJr0Xw/sm0oy2QiuklC4lHzAen0rf0/wAKXKBJJZoUeRizLjhfT+lRhoxUbz7lYitUvaB84+KE8nWrm2RdkVu5jRR2A/rWTXp/xd8H3tpqrarZwtc2kwzM0SHET+h46Hsa5Lwh4XvfEmrx2lvG6x5zLKRhUXuSelKUbydjSMrxTZQfTLpbS3n8lzHKCVYDIIp9no2qXqFrLTry4VepigZwPxAr6u05PDmh2Gk6d5CtBCoC71G4gdc/U5NdlZ/E3QdMslF262dtzsKqFQD2rGtOtFXp02zJVovdnzH8Mfh7rl7rFnd6np97Y6dFIHeWaLZuAOQqg8kk19gXMAl0KO4hBdgQzNv+bPTn6Vz9r488J+Kpfs1nq9g90w+USz7AvPv1NdBowGmXMySs72ly/wC6bO5Tx2/WvNxFao7OUbNa27iclL0Phn4k6dfW3jjV47+NxctcM5B7gngj9K5lbdiQUyfXA6V976r4N8O+Kp7iLxJpsM06sVtrjHlyBe20jnivN7j4NeFNC1ON71JzZgYdZJiRIfpXXSxkKkuXr/WwnPkjdnmvwSaTQri4vLuN/s1x5aRq648wBvmYE+mcfjXrv7RO2b4TxvZuCr38Ucp6DGGIHvzis3xUsSXFtZCIQW8EI+ylYsAR4+4B6flXSPZWHiPwdPo2qEJBIgxJuy8U38Lc+n8q2xEPdhV7GNCsnVd9mfGl3Z+VLKjAhxxgHJ+po8Pzm01/TrjYXMFzHIVBxnDA4zXsOtfBjxPa/aBHALrICpPayIIyvXknBB4rS8D/AAbksrhL7xA8UlxGyvBZxNuDNnrIeBj2FNVYPVM7ayUV6no/iu5trnxgF86R4r0K21W+WJyvQ89frXaWFmVRuYtsK7AowNw7/jXmniDSbqC7g1O0RmfzMSIG3ufUn06frXommTxKVto5HuFddyYGVXjn6/WscUmqceR7focEIrmsyHW7S7lMUtjsNrEP9Vgce/1qKHTrOxsJNQ1dUtYIsbw7DbGPUV0S20a2scxDeWuWO3Pfr9a+dPjj41j1i+uNMt7jbY2O1YkRWHmSd2Yeo6DNYUZSqrkWy3Z00cOpT1fmejL8UvAMFz5P26cSgFI5haN5bev+cV4R42tItG8Sz3FldJc6fPm4srmP50dCeVU+2SCK4SZlKMJI2Zyc5JJIFdn8Mb20utXh8M6zH52i6pII9jfegm/hkjP8J9cda6FQUXeLZ3Upqjc5/VdQ+0OzW6SrZMA7wnhEzxxXQfC3wxdeKvFFrZyfJp6ETT3B+7HEvOM+pxgCvW7v4LeFpNR/0LWtUEYPly2p2OVb03e/0/KrY1/wh4Rs49D0rVbGxgGXeKNmkcy9N0jAfeHTrxRGXMrQX4GFbEqbve569HdWszSBJQHx8qY6dMDP0qlDGBMCoPzcls881yPhy7Ooaba3Ed/BPsLqJYDwxJ43ehx+NdjBPgqp279uDzxn0FebWo+xdlqcsG5aSI5pAJUKOwXv710Xh6TfbswYlc4we1YXyeYWdW5Hy4HStrQThpFC7ehxXFiHeBrDSRtZ9KSjGBR+VeadImO/pTaCAWBP3h0waOnQU7kMaRyMdvailOfTpRS9SWfmDSgZNXdW0260q68i8QK+AwIYMCD3BFUq+xcXF2ZobXh7V5LK4SCUhrV2AZW/h9we1dfYebG0zx+VIVJ+Tj9BXnEal3CqMk17J4FsFsNHm1XVnjhWNdytI33hxzXo4So3FqXQ4sRTvJWNawklbSozNF5DBSRkkHPr9a5OXXb2C+2CeYorfMX7/WnXvj6wmeRH8+VfuoypjA9RVPQ7qTV9bhTT08zzDtwRz+VdXPGWiZjJSitFY9+8ExxTaHb3l/gAjIZ8jj6dapaz8RdO0S/FrYxxvufbvHAH+f6VH43mm0TwxZ2CEi6kUDaBjbketfP2rAR3m68uFMjN83z9PwHNc0KMKl6ktUxzurR6nsPxf8Upq3w5leQrI08yxKydFbr/ACr5yPysY95CE9xj9K9DslS+0e4sL5wtlK4kjuUORHIOAa5W58L6uJ38u2a4U/MJIyCGHrUV4KnblWh2YbWGm/UwyMHg8+1epaHqEl/ZWMr8zNCVbjAJU4zXC23hvU5biKN7dohIcbmIr2Hw54RktImZIwZIU2pCW5x6n69azhHRzexXxTUVueT+NtTmvtXeEjZb252RoOg9T71gNwobj5u3pXW/EDSWsb/7UNxWVvmyPuN1wa5RpC8pdxuJ5yOMVNjVpHbfCbW20jxAsPnGOG+/0aQnJEe7AEmPY19NWfh6aGATajcRuyMY4/mxub1x04r5u8BeB9Z8RQnVY41ttNt3B86ReZCDnC+tewax4nmkgLandraafCuXkA6nsB71sqc5q0XZdTircnOjvdPb+0LnypZlHn4twsIwWAqt4w0rTNHuVhmaRjtDmFVVQW7ZIA4+tfPy/FE22oKbY3QiifdHMr7WX3wK7geMf7e0QXKyfaSrbmZyfMLdt2Pephhn7VSjLTsS3aNpI5/xBqFxeakXikZoFBVlPVcA8CvLNf1G6vbt/NkLRBiVTPyj6CvaYrKSWXzZowoeMybwuBntkHr19K8l8XeHL3SL5nnjP2d+Y5ByGH19a6q/w6CpRXNc56N8Ed8V9F/s3fEK7/tqLwxrV201jKjfYZ5TkwOBnbk9j/OvnqNMr8+VI4BPXHpXT/D+C4XxBbTWzDEEqSb+m3BrgnSVWLpvqbVLJXPuJ7qJLlJb05cMCh6AD0rM+I1xBFa2kMKhpLhjlQMkccc9qi0tjrmn24dd83QlzhQfSl1vw7fi2lEe3LhVDAk8+3cV5NKFOlXXO7NGMrzg+VbnE3mu6Fb2wbVLwJDAvlszHcVODn65I7Vyg+Mvhe2iW1s9Bub6NDxPNLtLHtxzWH8dfD2o2trYXUsOzT8tG4UHCyD/AB4rxloGjb5CFmXkI3H+TXryjTkvd1Xr/kFGhbWR9b+H/i/4N1aIW1xNcaVctwIr0ZQn03iusdzPbBY4QGC74pYsOCp9T6V8NedcQuxk4k5G0qMHPrX0L+z74xea2uPDlxOHtVTz7bfkmLH3l+lcVTCxiuambziup6XptqbZ5PkmKDJkzg/N3Gap6zaXOnXgurKSYQSKMIMDockCupjud98ywMV2EEZXKtmqOopI0N1EJIxgtuw3Qeqjr3qadaXPd/M5pQVrENhrlxfwpFOPJZztMSNkqOxPqa+c/jfoU2kfEK6cIZbDUAJ4NhxnPDKD6gj9a9msLVJJXnDvGy/LhTt3j1rRvDp3iDShbapawXECDcgbllboSp7fhW7gqUrwWnU6KM+V2kfI8kLeYylfJU/LjO8j2A7n1rV8A6Rdah410m3szslW4WTzSOERTkt+A7V9CP8AC3wzLK9wtxqsYk42q6kgH0bbmul8IeF/DvhISHTbWQPKR5s0/wC8diOQCT0HsKTxMVqkzorTi17rPIPjt40utPu5NB0yQwFsTXU6fLI5YcIMdBjGRXiMMibt4LrtyR3+btn616p+0PpzReN3umO2G/hS4Qp90uo2kfXgV5VbndKm5vJX+JtufxxWsXeKMYJJKx638GPEbaPqUKyXUphmnSKeHI8shuA2P7y8civpSNEsZnjOCCx2gDkV8l/C2xF34qsVnltoLeO4WZ7m4lCIyjnbz1Jx2r6tDxagqSWF7b3Clt2YJgwA/DnFceLirpmlRJ2fkSTSSyXCuUzEvUEcGtzQBsmPoRxgdBWMk2bVi3yMrYKe3t65q/4dmD3a5XBI4Ga8qunyMzjudTRQPpS968s6RhwcgHpSEc0uACSAAT1x3o/WkS0NxRS9+lFO1ydj4V+J9laz6bYrbOxu4EBYSLtIyOR9M/hXmS2dy7qqwSEscD5eD+Nd34/abUNXnuWkC5P3mPy4Heud07Xhp6BEUuwJ+f8AHg1+hV6VNyTk7HPCrJrRXO6+Hvw3uby5hnubZ3t8ZeTGAPZf8a5b4la3Le63Lp8LFLCyYxRxg8ZHUn1r1XQvi3cXXguTT7S2iN6BtMmArAfQdTXgusxPHqdwJTlmctnHXJzUVXKNPRJLpYqi9W3uU+o6gV3nwSureD4haaLyVY42f5SxwC3YZ964I0qMUYMhIYHIIOCDXHGbjK5tOPMrH078db5rRJ7mY7WjXbGp4LMemPUf/Wr5kZ2dyzEsxOSSc1p6h4i1bUrVLbUL+4uYU+6sjlgtZVazqXjGMXoiKdJQu+5e0u8e1ukVnc27MBLGp4Zc816LopAaa2ZpFTfhC392vLY8mRQDzkc16Df3ttbRytczIyqoWOPPLHHXHpThJyTQ37sro34MQyOwjVlXgAfMw9P8+9dHpt5qtnFZX5tpUhlGCxGQ6ivD5dbvXlZ0mMeegXtVyDxjr0GntYx6lMLRl2+UTkAe2eldEK0YfFqZTpyl8Oh6tqd3ZX891BqUCziVs4YcY7H61Z8JfDbRtU1JHjtN1srAukjsRx1ryHRtfniuYFuZnaNSNrMeVPrn0r6M0LWl0nSbdAqzm6XeJIj8v4etZSpOetIcqrgrTPSh4ft7bTov7OEcSxfuxEnG3jgAdMV82/Hq3uLNLCJiyxPI+9SMZYHg/TFerX3jyTT5Et5IhKrcMC/3D7f49qw/HFhb+O9JntVdPtPE1rNn7r4+4fY8U6NKvTT59UzGDg5+Z8xZxU1tO8RIV3VT1Ctilv7O4sLyW1vIniuImKOjDBBFPtrZjEbiaOT7MDt3gcFvTNQr3OxK56V8LPHCWMo0zXp3ksrmRUBK7miP94H0z1Fey6zpmlT3tnEZYWsX4lhmwU9c18n25HmlsDI5A/pXuumOt9BEZ5d0ssCmRM7RGQOx7HiumlFze5yYj3FodmPh34NuWluZrSLg798ch25zjlewrbk8AQW+mSS6fBbyQodqrEm3H+NeP+K/Fcfhxo47C7hupJFDGFG3JGPcjq3at74dfHv7FFNY+I7Zvs0hGya36xf8BPUVzVo1KetKV32Zm+aS99aHpEcl3o9lGEnkO5tzKASSR0rp/DXiq+SNl1QefCD8u0YZfp61ykmq2OrS29/ZzLNaXB/clGxk+/pXUNB5sISONWdR9xTjAxzxXLiVGUV7SO46UbLRnY3ltpPivR5La7jS7sp12tG/BH+Br5x+IXwH1a3uPtHhmVdQtSdkcLMElj9ASeDXsujO1g+9MxoTuKt3PTiugvNaFvol/crEZEtrZ5trD7xAz/OvMi6mFnalrFnXCfMuVnwVrHh/U7TUJbeawmjmhO2UPyAR15q34P17VPDGq/atPli+0mPZtlj3IyHqPY1seLoLkwwpNdubp1E9xa785LHKhfXIPSuRvWYmb5ZDIMEk4+X24r2zetRUHY+sfAXjaz8SaI13A32SWAKtzC7EmNx79SD2rcvb06tGk0KxqdhidmOGx9PpXzt8E08zXdQiBke3FqJG+bG5gRzx169K9rtCTelGkeUZJlBGMd8Af56VnKjBPnW5xezd2iae1Y3Es1vPCkroIyr5JAH6dqitrOe8nhdJvLCEjY2QSe/PetWbT/tSIgm8wnnGME/X6U4Ws8cDqkPmfLk98Y757CpVVWsnqVyyvc1bSSE2yW9yCGTHfP41Wnn8mYRSldkoyWUEkGufs9UsE1QJJrdnd4iJKGZUdP8AZAzzWzb38EqI8DO0ZxlW52fj9awnT9n73QzUnflZV1/w7Y+JdHNrrEEcpikDKv3CgH91uxNeXeJ/hl4f8I6E2s3IvdTuGcfZrN/ljLZz85AGQB16V7YkYyJgjKGGW77u1ec/Hi1abwtZXIE/2e3vB5rDBwrDAIH17muKGLlOooJ2TZ30KXK9dTwC8a6uJpJLjyIonPmJFgIo9AB2HtVjSddvtNvGvLEzW91GMxTQkqUx0OOhHt0qp9qiRAjOI9rk4ZSWOO/0p9xcRsrGIzLBKNoTpkd8fj2r17uxU0tWmfQ/gPx7L4r0SSLUYydY0+NWmdQMTqxxvGOh9RXpnglo3dXjJIORnOQfpXzz8ELKJtau7hppJLaO02naNodmYAK35Zr6O8NII7qFEjCIqnCjsD615eOUY03GKscfLaodf60h4z60tIa+cbOsT8qSjpRSTJYhooPIopptEn5465e3+paDLnZLbwurGROcLyMe3J71xtWrW5mgSZYpHVJV2Oqn7w9DVWvuMRU9o1ImEORWNfwtqH9na1bSvvMDOFlVTjcpPIr6L8WeBdH1PR5LyXZDaQ2pmDP9/GMkg/h+pr5hiRpJFVBlicCvdPiBqF1pvw4tbDUp3lvHtIowycDBOcN+Fb4ZycbdEZ1V7yZ4ZcCMTOICxjydpbqR71FS0uPWuJ+87m46GN5ZUjjUs7EAAdzXV+IPCkOnQqY9TszehQZLPzAWHHOD0/Cqc00Fjolrc6fbCOa4DJJK53MpH930+tc6SSSSck96t+7owTN99Dl06NLq7aIoFEiqh3Z9jWHNI00rySHLsck1ctL6VYJLV2BikGAW/gPqKpOjRuVcEMOxpytZWF1G0tFXU025fT/tkab4d/lnbyQfpSjFvYLlMZ7V7B8MJ7q+8Iahb3EWLK0lEiXDHasXqCfTpXlWn27TXiW/lu0sp8tFHHzE4Ga+jfH3hLTfCnwu0vS0uW8yeVVu3QcE4yT7DP8AKuqhL2bSe7MqqU7Q7nlt/wCLrO01FlSN71M4Zi20fga7fwteafrsSNo1+yXZOHt5GwefbPI/rXh+pQCLUJ4EcSCNiFdejAd6TTbq4sLpLq0mMU0R3BlOD9K3+sSvrsZywitZbnufjbwGmuXAls/3WrwjEoflZeOCfeuLf4ZeKLpxBDZmKNBmQyzjywx6sAO1ekeE/EdvLHY6v9ptYjcpteCWcZVu4wenY5NdEPG9vpl4wWFUBBK5YFG+hHBpVISk7wVzKNdwjaRyHhb4GzW6xXl1MNQQrkGNCI0f8euPWuM+LFpeeGbuDS55WxIplO1uepwM+lfTXhLXrDVomu9MuCg8sxtCrYUt6ivB/j/pN/O8GoTRO0KyNH5pXJyfX0HpXLSrVLypy0/McbTakzw9jliachwaAuD610fgnw//AG5rVvBJHc/ZAwNxJEudidznoKe50Skkrs9b/ZnMtxHrlu8AlgjWOQFx9184wPfFfR1jp8NtKZG3/aSMkn+I47fSuS8DWGi6Jaroui2K28LASFy2ZJW/vM3r7V24SWJAsrbwwIDAfd9s15OMqvm5diIxvqc74n1iz0uGS/1WUWtpbAs+5T07BR3Jrz2D4/8Ahk3zQy6Tqb2UoMUrYXoRg/LnnrWb+1BPdRWHh2ZJW8n97nPQycYGOnT1r5wkZ2mEbqck8/U100aFOdNOSuUo21vqej61pbIbzU/B99HdWWCojcbpxHzycjjFcLZ2ournyI0l3SL/AKrBbJ7dO9W/D+pSeH9VguS8yvC5+RD94dwfwNfUVlfRRaP9pisrRcxo5ZEXeoYZ5OOorrd1srnXVqxaWlrdOn/AOI+HXg+TwvYG91CMw6jegLFbs2WSLryPUkflXUpFPI/2sMqTLxIF/iGeh/LtUMt5LNbsxiLOJRGrMuSik8EHPrxin6nbSQSpbgZZhnaGySex/A//AFq0jHvuefOo272O80QWP2JJY3UTYyQeTj15+ma+f/i/8R9Q1DWprHRLzytGiBhItePtDfxEnqR6DpXtN2F/4Ra/js42m1RrZ4llX5fm2YwM+nNfITvIEdmURvAAhdR9498k9646VNczm/xOii7opT3Cy7MLyh5bJ6V9DfBPxI2vaQLSePN9p4WOR9/+uiJ+RiO5HSvn2aCJIR8zmRgMMOR9MCvZPgBpkkMWrazIGW2Crbq4GA7A5b9MVOKl7jZbh3PcWuEtUC+ZJv3gBdpOQfTA/wA4rg/iL8QtF0q0vNK/s9NbkljMdyPN2Qx+q7upYe1bnjHW7jRfBOo6lYmNbvb5IkfnYGO0Nj1Ar5hv5I5UiXErBY8uFbJPqfpXBhcLGo+eXQ1pv3Xf5FV54rmbdb+dbx7t4V/3gQDoMnkivTfB3w21HxNbR3N/qem2mkOwYTwOJZHPQqo7H2OK8oaIeQoUn7wCqGyfxFe3fs7SSvpuu2k0fnWyOkqBhgo54PPboK9Oo7RbRjKpJK3c9a0jR9F0PRo9L0O2aOGIFw0oy8pHVmPcn8q6vwq4nmEioVwOQT0rLjKozySrldoCKqZ4FbPhdVE0vlptBOSMdDXiYl/u2ZQk2zpqQ0ZI70dq8U6xpqrp9sbGzjtzcXFyUBHm3D7pG5J5OBnrj8Kt9vrSHr14oUmly9CGuo00UpOOxoqWI/MCpLaMS3EUbEhXYKSBzyajIqzp0ckl9AsKM0hcYCjnrX20YtySE9j1j4b+GNPtfFiGdLiSSLJjEyABiPQdzjNd98XdKXUtBdY41WVgAQoy3Xjj6muUs/GV9faNYtc6elpcwSeUhkUgv3yDgfQ54pt54saOV5r+9WzEYwVJLs5yeg/TPTivWjS2ktEee5y5mr3PHNQ0m/0+RUu7WaPccKSpw30PetfT/CN9dWP2t3ijiHLR5zKo9dtb+qePba6vd6QXEibt2+ZgefUL0FdH4b1OKfU2mEL3cMudxtTyQR0Yd/pjtWEKFJttO5tKtNKzVmea6oEGnm1jVlEDBlDDkgjkmsGvQfEmiXE2qyLbQOoJ24Ydaq6h4SsbPTBd3t/9nkHDRhd2T7d8+1FbDSk7xClXSVmcXEhkkRBnLEDgZr1STStH1GzQXoVpooFRdpKOcd/59a4XRtTsNL1AyxWsky9FeRgGX3wOK7QSprEQnsG8x1YruC4P4jtx+HvRhqVNpqWrFXnUTXLojAufBqo6PFeExSn92pjO4+31r1HwD4NhTSnW4jZ0ByqlsfN6nv8A4V5kPHdzbNthtLeQJlQ8o3bh9OnYV6J8MPHkOtXMWk30cdpcscxyq+Fc+h9P5VpzU43VPcmUajV5kuvA6Rdo8Fki3cZLbgnI69xyKx9Z8VXHiSwfTbq8gBmBXZ5gySOn41J8c9cvLG5i0aFjGzp5k7L94g9Aa8ZB8tweuDng05Vkug40JSak2T3dvNZ3kkN4jpKhwQeDUayNHDIgYbZMZH0Oa7P4b3ljeeI4rDxJF9osrshFaRN5jOeCM84+ld78Svh7pcejXMnh6FUuLc+aEVTmRO/qeKw5b7HS6lnY8L3MBjJx9a07XXr6Cz+yiQPBnOHGcfQ1lupUkHqOtIKy55Reg3GMlqeheCfHE2mX8PmARMCAssfA/wCBDuK+pdD1IeJ9BWHULKKOC4UJcKyBhKhH3hx+tfEEGA4DHaD1OO1fXXwq8228KacLm583zYlUFxyg7fpU4le0hd7rY46i9jJOOzMO4+A2mxatJMDcSwGf93bhgFZD23DmvXdF8G+H9A0EWVrp6WxwZHJPJIHO41PBNAIIrWKdwiHzElxkyEdh6VjeO9euhozQlMCQff6YrzXKvXlGne34AmrNvUdYxWU2tZjeMIxAXacEj6+lddfxPaWyx+bubPzfSvJ/BV9Isq+VEZuCQr/wr7ew5rqNRv5503TO8akfKA3LCnicNJ1FG+iN6WquYvxJ0qx8S+EJdJvpYkuGLT2cpbPlygd/r0x718iaraXFhcfY76J4JoiQ24YNfWxFtdRBrqUeT5mQyjH0/l1rz/xDrmi6W0ba/Z219I0jFRMm5mXsMd/X2r0aNPljYXPrynlfgrw/feJ9TtrSOHNrES0txtyAvU89z7V9FXs9pZeGLomJUtbWLzJHPHyhcKM+pwBXnejfErw9FrKCW1ntLBhtOxBiPpyEFdj8Wb/T7r4fTyaeUuLWaaD5oXyjL6s31wMdqU78yVjVSvJJng2r6nrerRtqEt5IIWbakAfaoBPAwKt+DfGtzoOqI81zNcW5YLNE75Ur3wTyCPasrUoTcQwvbtGLgK4eHpgD+LPTpWCq7owuUC9ckYNaXZdSCjsfXt9NJeW0E9rKn2bYtxHt6ODyATXnXib4ZQeJrmW8sJIdHupMubZlYxS46uMcg1f+FNxeT+AFQzEva7o1XPJXPr6DPFdjpginjjBDvIIXiOGw2T6n0rN+7HQ51JxbR443wru9PdHvtV082y4DNali5U9QMjgmvXNDltrXw3Hp2lQwwWqj93sOQp/qT3PeprLSwphEoLiNdgDnKj1JFbNrYW8KBICi9X2Rjp75rCt7N6PUrnk1ZmdqmnP4q8I3mkytFE11hvOcECNlOQCT9K+adc0y/wBDuvL1Gwnh25UCSMhJF6bgw619USrE6tHckuJBlVj4A+pFQSaNNdGeBo/OVRkRSKHXb7Z4FZ0pRp36JjjVa90+UNK0zUNSvUXR4Jbm4GNotlyR9fT6mvpf4U+HB4a8Pywylrm7uSs147pgI3ZQfQevc1srax2ZZVgjLqMSLEioB6ZK/wBa3LRSYD8n3sAndnPtU16t42Qm09ERXty+WhjDIwUEv7fWup8MJhcDOBySev41y93EhklYTDd1Afpx711nhaMm2edmDOxwcdK8rEu1Icfisjd6GiijHGea8i50jJXEaF25A4wO5rPaa9OJBsRR/CF4P41Z1DiKNznajgkDv2pRcwAYMqKR1BNYybbsnYrboJaz+fGdwCyDqo9PWioYHV75vLZShQ9O9FaQleKbMp6PQ+AdB8JrezbJWmdSQF2jG31JqLx/p03hTxP/AGfa3MQMEasslq/94Z+91zWrpWqvFE0kcpDYAP8AhVHxVp9xrM0VzaRGW6CYlCZO4dsZJycV+j1YPk/dmEJq/vbnNx63qHmhpruaVScssjkg+vFRaxdSXd88sjbs42+w7VONA1RreWaOymkSFtkvlruMZ/2gOldFqPhC5g8N2Es0DQ6hICyxsMF1J4B9D7GueKqTi4P1LcYxkpHEVoaJq97ouoRXmnTvDPGQQQeD7H2qi6sjlXBVgcEEYINNrlTcXoW0mrM+y/h1rGjeOPDUOrz2MMV7ECkxVRxIPT+deTftEWMNpbWDrsSSSUkIndcHk1g/C6+urHw5qQJdbeSRSgHUsOpFbviTSrnxfoSLcSlbmElrUnkH1Un0Pr2r0aeHlyOd9+h5ymoVVA8RzxjFWrG/u7HzRaTyRCVDG4U4DKRgii+sLqwnMN9bywOMjDqRn6UyyiM1xGmDt3DccdBXNGLUj0G1a7IDkE5p8TvDIskbFHUhgynkGvSdT+Gl5qukT634Wje6hi5ntQB5kYx94eo9uorhToWppcLDLY3ETscASRlf50/ZyjJoXNFq99Db8Yzah4gS28QyxO8csSwSyLyFdBg59M9a5eERkt5rMoAyABnPtXu3hPwdPYeGUEdwLh3UtcW+OBnsPXj9ao2fwXOr+bJb3Ulu7ElYwgIFb1IWSlcyp1k20eX+Ey9x4k0iHzXXFygVs/cGecV9IeJrBrW7W5iuiohYlUJ3Z9QQevBPevOPDPhy18G6y1zqkbF7fLefNjCEZ5A7n0putfFyCa4YJpn2lV4WZ5Ch/If1q4xcGnLYyqTlUd4CSeCNL8TXV3JbSG0vWJIjjxsHuQen0rzjU/DWqaZqMtncWcjSxnGUGQfcH0r0Lw/4m02/1KWS086zmZP9USTuPcg16/oENnfWQnuVgmmkVQzKgYsPSirGNudbChVnbla1PGvhX8MrnW9RW51uMwadF82G6OfSvoPVfChsIY/7JmP2ZEwyKcbePT09qy9Zu7TTLi2W2ZIs4Uqo+RSe57ZqDx/4zGneFjO1zGhRwpER+aY9sVyyhUcoyhovMl1W9GV9P1+eG4VrkyeVFJjzZCQq46iupt4Rq2mSFCz+cp2ySPv4yeTXyR4r8Y6p4ivXmnmaGEniCIlUX8PX3qLw74m1bRb23uLG/nQxMGC7yVOOxGcUVYRk7x0ZrGEknc+xNIsXik+aBY71EHPADL3wPSotWWRhK6MCsTbimOSCKl8Ja3Za9oUOrqwVZE+cEcq6/eUVX8QahbJKs0CyKScOmMlehGR26VyQcpVbNCvyq3UwNWc6PpGoajqEp8qKHIt1OQCBkfqa+Wtd1KfUtRku7iZ5pXbJZug9APSvp/X7W41fSb+1vm8n7QgjZlcAoCOCwHUV83+KdBu/DmpvZagIhcgbwUcEMh6HHb8ea7L6am8UnsYTb1lV24B74r1j4Uk6tp+r+Gy4k02aETu7A5jYHBK+/SvMI/3kaxyy7EQFgHOck+mOpr274Q+H5bXSze2t3bXUF+o810U/IVP+rP8AM0JrqOdoo841jRm0q7vrW/glW5QqEaY/Jtz1BHXIrImtt00phVJIBKFQxc8ntzyRX0bPYqizyz2dvdofkaMoHVR0zg1VsfCnhyKaHU7S0gikjYiPI53DuR+NJtJXK9om+WxR+Gtg+meGltblZEv5ZmeQfxKnRR7dK7+KyRo0IJhYLhjtAG73P41m2axWrRPjMz/KpK/cGc5J70+bVIp9S8v94beLhYwQA7dzz71hVld6bGfI27I2BLujMYVZPJOxmyBzVpJUkeNI8hnCqcr8oA7Z7VyVxerdXaIImjhRgVXoA2ed3rXQ6HbX1y+FdWidvl2AAR4965pxildsrkko7GwjQWtpe3IRIrSBGmlmYj5QOv1zXzH478ean4jv5Y47yW202EhY4EcgSDPBO3qa9V+PeovpnhiwsZpJhbXl2WmjiIUlUXPX3Jr5wiuFS4LsvyZ3IG5Oc8VWGhpz9yo8qj6nQ+H/ABJqGnaw91o97cQXDfJtU7/MHoQcg819N+DNej1zwxBqRZInZSJUx/q5FOCMe/X8a+Y7OKa5dZdOVbcmT5pHxyRz8pxXunwe02ePwveSyxmNLm53xqDg7QuCR7Z/OniUnG7NJ0rR5juVuoJ40MqnLvtJHY+pHpXd6BH5VqygDYTlSB1GK4iC3VITvBbBwQRzn0+ld/paeVp9unogrxMdJcqUTCEXzXZbzS03NHH0ryrnSDYYEEZB4INY95o3nD91dGIdOU3f15rYNNqJwU9wU3HYo6dYCyUsZWmkYYZ2GOPQDtRV3oOKKtaaIzlq7s/OvRWEmoNbMoCbcgnnP1rooNQn0uaaJUMgdQo2jlPftz1rHs9JEMbzNMsTIPnLc4HfHY/SsbWNbnlka3tLiQWaHCdi3ua/SJTVJXkcjTqaI9s8O6vHYo93ZW32WRhmUsDm5P4/n14rO8UyP4jCSPMtveN9xeMY69fyryvRfF+r6UVWO5M0GRmGb51P4GvTfE2sab4j8FzanpdrLDcrAEeNMt5b9+fT0p0asJu6RnOlPRM821nV7J7h4PsNvdKg2G4bKu59cjt6ZqPwzHoM8xXVTPFNvHlAEeU3PRj1ArnjzxSdK4pVby5mjsUbR5Uez+Jr2LTfDiTx2phjRfJjhjGEVvfv05z3ri9N+I/iLTSotbmIQq27ymiVlP171p6Tc3viX4eajYMpnn07bLGScsUz0HuP5V55gHO44NdNerJpcuzOelQjq3qz2XwX4s0rxrrtvpfjK3gjjnk/dv0j3HjBz932Nes618ENAknnl0q5FpBGuVUqCNw7A18gIxRwykhgcgivtL4S6hqmt/DW01O7uk4hMXzHk7eMn8utcVatUSU4ytbQipSUXZbM860uW48MarJHFNL5IyJo8YUgDt78U3xLf2etzQPEBG1tg4BzjngH1/UcU/xgl/JOdpTfuIKp3Hr7VzlvDHDJuEbwRHhh2P1r0J1Y6NbkQpOKu0b2m6/Lbs0SXA81uWLDAA9q9b8Nu9/4e81FEDKpbKnlv614bqbjTrS4upCiQxDDFec5zxSeEfjjdaIrwHRYby3ZMANOVbA7n3rnrr2kPd3LcJN6I6L9pCxu7fwvZXJTELSrG7AY5xn8/wD61fOGQM5Gf6V9BfEj4h6F8RvBK6dYQ3VhrCusyW0/KSY67X+nQGvn6VWV2DqVYHkEdKmDk4Lm3OilBxjqWdMuJLK6hukwArY57+or6F0W6bS1jiimAFwgljz905HrXgGiaXNqN3HGkZ8okbnIOAO/Ne0eJ7Y6d4We8iBDW0IjViMEcADp3rroL3XzbGFdpySW4y/8R6Zb3nl3t8QV+8PU5z26delZniLULPxRoEkOk3UNzcRN5gtyCrEAY4HfA/nXj0jtI7O5Jdjkk1NY3ElrdxTwPskRgwOf51Mq/No1oVChyap6jXhdXIKlecYbt9asWsCkjzQ2dwXYgyx+lez2en6fr2g/bLu0ilmuYQ6blxh+hwRzxR4c8NWthq9obSzWOWTG5i28qO+M9DWbpPuX7WNrnS/Dq7m0TwZb2t4JC91IZNjA/ICOPoeK7HS/KniuZbl8GTDbpBgkD09q5Txbp0eiXkTWsmE2hyhJO0npgVr6vH/ZPgOfVndC1nEcBxy+e36/zpSjDlTT3Oac25WOruDpmh6Ne6uXtZNQ+yl44XdQ0qoM9M18datqVxrOo3F9fPvuLl97uwzk+ntxVTWNSudRv5bu6lZ7iQlmYseOe1VxLI4ZtxUdP/rCsVGzetzrox5VqXni8p9ka/N95STkgCvZ/wBnbWGl1O+0NmIsZoTdMD2kBAyPQEdRXj2j6Pqmt3kVvptlcXU7jhYgScdyT2HqTX0f8NfBFt4a0e4JkSXVWYfaHU4299q+oHr3qKnwtMurNfCjodRiEEjfZwoTJQgnpnv/ADrE1OC5N7FNbLHCkY2vhs719fc1oarIWvpktZRJhQAy8tz1JrIkN3GZWzI8aEIYAccg/erNVPZxTZt7PndkaAvhdTlCQQo4yccewqKHT3ktjdRKyhX3YONzY4B56VmNJJBatcQxT+R5RLPIvzIcnI/+vS6Rqn27Q8LOqTzOYV8wnAHXOex7VyzpVamsXZHRHlgtDRgdpLiCBsxyS88/eI7nFbNhp17BrKTXN7dw20Q3C1xhGH4Vi+DbX7DLLcahMLmUfc3A/LjqBXVXksskavOZppCAwjz8v0qrKD5Y/eY4ic7NdDI8feHrPxtpsNpNcG2dd0kEpG5lfpg+3FeB3/w28SadM8bae1ygYohgKyBj7g8179Prmlw3MUd7qNlHdgglZJlV09vxrUdLK4Im09km8whmmjbKg+gI4NUp+z06Hnxk47o8o8DfDy/WSBteDWCMhBhVtzkdwOy/Uc17DYRi1gWPy3CLtSL0AH9MUXZVZ0ByRwgkU9T3xVi3iRpHXcw/56HBrnqVXJXkb1KrnZdEaVnB5l8Btb73C13EY2ooxjA6Vz3hy2O37RIST05610AAznABPU14WKqXlbsVDXUfSdB/KgGjPY8VxmotMJ470pJA46j14FN5I+Yc+gORTuSxf84opoIdRg8UUE3Pzn1PVluLG48o7S+1CCMk985rmqkaRmznGD2A4ojieVsRKWOM4Ffd1p+1a5SYR5VYjrpPBfii68N3zmLbJZ3C+VcwSDKSIeDx61zdKKyhJxdyzrNU8F6qtpJqum2M11ox+dZ4huCrnoe4xXKhSzBQCSeAK+k/2eb573wjNp09yEQM6KcH5VPODV5vBtnqdvqRaG2FxbbmgeJFRjjk5OPWunljJu+m34nK67jpY5j9nfSI/L1FLkbJrhRnPUJ2GPU1x3j/AOH09pr1ydIImjaTiE/KwJPbtXZvrFj4LWO6knmWWTH7vGHPPJ/n9ajtviH4a1TW7eRxc27u4DvOBsPTk4PFdLpxi+V7WOeNSrrJI8d1Lw/q2mPNHf2E8HlcvvXAH412WnfE+40XSbLTtJtEWGGERyb2OJG7nFeo/tN2tunhLw/NaFdly5f5OcqF9vrXzQUzkr0zXLdTheK0Z2wfOlJnsPhzxlpmqW839pStb3p+6p5U5549OatJrR+ytBK5ltmz1G4rz/SvGLONpbyGNchmcAfnXvFj4btrq/t4i3lo7CMF/wC9gf5zSjFSfvGdWbhomefeOdRZ9KSBGfy3lyeMAgDiuGyQCa+3/wDhVeg3fhC503UbeKR5VLLdjhom/vL75r438VaDdeHtaudPu8sY3IWTHDrngippV4Vr+z6FU3ZJMzoLiSMqyuwIYYPpjmvofwzpWk+LbfT5n0e2a5a0AnkZcAMP4jjv0r5+0ixub+/gt7OPzJZXCKuM9e5r6WsdKn8Kadb3djdEW8MIFzFJ8u9QuSfx5rojt5k1ptKyMvW/B66VJaeU4BA3kBcKB/kfjn3qSQ2mqaRe6ZfSbTOm2NZOAGxww9q818b/ABX1fX5fJtUgs7GM4RY1yxA6Ek/0qtpnji91XV7JNXdDtXyVkCjAzwCRWsat48s9znjSnBqdjitV0+40y+mtbyNo5YmKkMOvvSafZTX95DbW0ZkmlYIqjuTX0Nd+GovEWjwR3sCSrCAnnEAH86Twd4X0zRtchksLYb8FPOk7H6np/wDWrGUbX8jrc1bQ6HwN4USw0S3tbz5niQKyjrnqcD0zXQTeGltpHutOKsEGZsHqeuM1b0m1kl1BTA65PGxX5X1rdvZktLRrS4K27yKzA8YyMYGfXmuGpiZxno/kYyipJJHlXi7Uo7zUIY7e0dbtMqWzwxI6Z78Dp/Wq2p339qeFdU0G91Cy064uosq0r8MQc89SM4xjtWd8QdYl03Srm92n7Q2Y0Pl8L/tZ7HFfP9zdSXUzzXDvJK/JJNb08Q6sbKNkvmWsMoWbY7UbOeznMVwgB5AYEENj0I61NpOkXWp3CxW6YTq8j8Ig9Sa0/ApsLjxRpVrrsEl1przBHhWTYTn0PavW/jC9tofgnTtE0Syj0vT7m4knlG3dLKyHABY8gCrbZoprnUTf0L4u+FfC2ijR7TTr+7bykgLxxpDvwOWPfntmqVv8XtFN67zafd2yu+Mbg3ydifWvBI1ldhJOpbcceYTyMdvyrf0rTbEI1zd38iqvMMaJks3v6Vl7OCu+5pTw/NK8fx/r9T2+9hXXreCXQNSSC3myzyL0J7bu4I44qzpE2oaXYrb3bpc3aSMGlGPnGOACemPeuT+DdvcDSPEbNG72zSxhXbhVlPOBj2rrbcM7SkpG53ZkKc/if5VlW5uRqJtCUZy5Z9CaIGeEeY3kooIO4gZ78/rUVnb214pDCMshHljYB8wHbjIrRu7MSwqtvF5sjYBLDASpNEhWGdGkMW0H+LoecZBrioRqSTm5PU6a1aNONki/ZafKb8C5Ibc2/bngnjiuP+MfiWew0qex03dBdMpNxKG5hhJ4Cn+8eOleoLOILgBdpQAEtjGSe+fWvn74029z/wAJfqcU0rSRyJC9v/01GMf41rQScrPojjjUdWT5jyjatzJkyKG6DOST9Sa6zwX4l1HwjfQ3FjdO9qxAuLPPySJnn8fQ1iWWluHQzmCI5cmOfPb+ee1WLTT5r5UitQTMJBGERckljhQRXY7PRk+ydttT6a0/VLbVZoLu3XbCU3wocd+h+vWup0yAuqAZCHOM9Sc1R8O+HBpVlZWsrLcSwQxx88BSBz9aoa38RdA0G5VEgvL5d5UyW4CxBgeQHYgE9eBXlVpe0fLSVznhSlJ6dD1S2xbwRqoGc8irYYN04PpXknhf40eGNTvEtJ473Smlb5JrxV8piemWUnb+PFeo/aPLCedwTyrKRhhXi18PUpv30aRlbcufzo7VGHDjKEHIzmnswBAJAJ/WuZqxqncQ4zgU05zntTiQOppnUnIPHA96SExT1/8Ar0U3jdwDRVakn5iVc0mf7NqVtKTgK43d+O/6VTpa+0i+VpjaurGv4gFm9/cNatsYOQUx8p+h/pVKy0+7vpBHaW8kzf7AzVWtXw5qtzpeoRtbzGJWcbs9OtbKUalS8la5D5oQ01Z6n4Itrvw1p0K3YeMSkv8Au+ufr9K9C0FBql/5TNuQLlYw+N+e/wDSvLfHniKTVbKCR4o4DAPLDo3Dt64rm/DvimXS7+CSG5KlWA3gnIFehJJLl2Z58eaWrVy78b76S68e3cTxLCLVRCqr0wO/41wANet/FTwXfajKfFOkB7uzuoxLMADujYAbsDuO+a8kIINcUrp6HpI9B0vxJqviHwd/wjrytPNpytJZ55fyyPnQHqegxXBlCBuyAwONvcV6b+z3a2zeNPtV8P3UMZCE/wB88fyzXqPjj4b+HNQ1O91CO2W1XbvzC2FLepUf0qlJXUXpcxdblbj0R4r8JfDz614tti8Rkgt2DuuPvHsK+lG8HahbXE93CyMhbfHEqgkD29Oa5D4d3Gn6G8kVusasUJQhNowOpJ9a4f4ifGXXNSnNno0z6fYIxUeSdskmOMs3X8KKsasJWha3W5zqTr3se1TeMNTt7dLeOBYIthiMZ5cn19s9aq6b4CTxlpEo1S2EEj58ieRcqO+MdRXyta+Ktatr1LtNSuTMrbsu5YZr6/8Ag/8AE618TeG4ndhDeWilbqLGcv2ZfY1zYiUqNNvDxVy1TcbKT0OD+FvhGLTdcv4Li2gt7u2Z4RJjIYjjcD6Vv/FPSLxvD1y9uolBtn37PUD+VZuv6i0Xidr23uPLmnbeUyMe3A/Gt6012F5fsd5bz3qlczDHyrkYwPz/AAronzqSqLa2xNODs03c+NyDuIPWp4Y3DI6dc8E+ort/in4HufCur+fHGzaTdkvbyjovPKE9mFXPhJ4DvfFOqx3LwOulWpE00rrhXx0UHvk0OSWt9Dp5lbU9et0ksPDFq1xJhms1mmaQ4SPjpn1rkofiN4etI4bdodQnl3+ZLcJhQzdsDOcZ5rC+OfiiS61r+xLRkWwssB0Q43vjnP06V5ntjluo18wbeuRz+FPmbVmNQi9UfRfhHxjGXfUbGdLgbtpBX5k78/p/jXWvq76pE5uIlUzRlQRkMue4/wAa+f8A4X3SWPjrT0Adre6/cPHt3Ft3TA9QcGvop4tsqIYxJKg2hCy7se4FZ1eR6tamcouMrJHlvxD8MahLoYjhiaT7IQ+3GdyH29vWvDLpLdZ3WNHC5/i6ivsqa2t7oqZZG4GC3QgfSseTwD4a1OaSWfTLWeSVsO/KM3uMHg1gq0Vub83uaI+c/hVosuqeMrKRUf7NZuLiZx0UA8c+pNfU3ijwVaeMPDEWlyyiO+jZpbW9kTgO33gcdjXM+LvsngDwzcT6dp8NqsYEccaL8ruejHucV4bf/EvxdcXAm/t66WRWyqxHao+gFFRSqpSg7WMlGV1PYu+J/BvibwTdfY9Rs1S2kcxx3ATfFL77u3481k6B4e1LV9Ra30uznludwQyDlFJOCSegFdHp/wAbPFTyxW/iG5i1WwBHmQTQqCQPQgcGvqTSH0ObQ7DWdHh8u1eFbmBdoQN7MO5rKriJ0YrnjdvtsbSq6W7HHeFPDdv4Y8Mx6VE28o/nSyHjfKRyw9uwqeGIBPMZQGfkOoC5Nat5I13cyO7LhzuOOg9hWdqSKjgCL5eON3b1HvWUJuT97dkJJRbRdisXuo4mfflRlwSAOelVLe1iRrkIqJLtBUOeB9BUR11La1EUrEYbAIGSD2/Gqc83nR8l18zP7xm+b8B/jVRhNb6IScpXR0PN2pXcDIuCwPJBrA8Z+ELLxRZrDdt5V7EuYrhPvL/skd1P/wCqtjTQix4XeE4JJ6t71HqUiAQxDy/O5cGRiCcc1inJTtFgnyao8ju/h1rCxC2a3t7mzg3OHF0AW46ZIzXYeAfh5Bot1Z31+Q99AvmJHHxHET0Zj1Zue/SuhsjLJOHG+VZXJYdFQ+ldIjIVZFypPHHc++KuvWnFcpo8ROqjl/ifqsmn+GiLNvImv3+zK7N90YyxB9SMj8a87tPDmkeIJPLF99gSxiAaC2uMyOSclhu42/QV2fxjiluPCFlqSW7eTptwXmIbDLuXaG9wDivC3Fvb3DXdz5hL7lRVbJdCOu4e9PDr93Zf1/SOuhKPsrff6G3e+G4k1S5t9H16yvbaI7Y5bmNk+UDkk4x1BHvXp/wh8S3Oi+Fry38TXL3kcEkf2SMsXaKNmKkA/wB3oQK8Usnu7COO/sYY0+zSbSGBbeOzEHg/hXtv7O9rd3U2vajq8EbWcwAQtF1YtuIU9MD0HQmjE8qpNz1St6mNdQcVdO/4Ht+m3UVxbRy25YROoZAeMCrokU9evcGqEMrPOsUUSm12fK4GMH0NWChXjAJ6DJ5xXzE0rnNFtFgkEHofWk4x61EEJXG/8akJBBOe9QUI2MgnIxnp/Wimkk5574OD0ooEfnDHo8c9yiQ3BWJ+julaOueHbfTtEhnguBcXDNlyp4A9MfrV20hS6t4rmJibqUbio4HFbEF/puDbXlxDC2fmJIP51+jRpU7PTc5nOonpqeYUqKXcKoJJOABXqeq6PY3Nqs8draTW68edGfmfjjkHrVLStI0OJJzLOIisZkVmGSGHYn/PWsFhHffQt4pW21OG1O6lmdIWkLRwqEUdsgYNURU12FFxIYyChYkY9K1PCXh6/wDFOvWmk6VGHurhwoz0Ud2PoAKxndybZurRifT37Lz3954IkWZRNEs5hjMmGCpjketdV4k+GHhfU3nutT0+0jEQ3B4V2E/UDrXVeCvD1n4G8H2OjwmJWhjxNKBgSyH7zc+9Jqe241A26MZIXTBYcbjjNeOsVOVaUqbsv8jknor9Tyqx+Flxp8ovPD7JcxvH5giJ2YGOwxWdJNqkF266tuhikzG8RAxj1+v5dTXsJup/DenxxieJrzGyJH5BT0471wXxHiOo+GRqmQpibzJMtgr9AOlevhMVUqStUs4vRM5pRj8+p5d4uuVt4biFLszXEUTDMS5UKR0JHfrzXhrFmyxPI9TXeJ49NnfXTNYw3SupjKzcqR05x1rl9ttrGpYhEVg88g2qT+6Uk+vYV21ZKVkmdeHi4puRk9TzXrnwIuZLO61CREcwsArnb154qrafCPULZmfV3DQbN6NbHcrDGQd3TGPxqhqfjW50NvsPhd0trWD5N20MWPcgkVEY6XZc5c/uxPVtcuomuAywRygtxKP+Wf41ueDpYb29VLy4dZ4TuVlHD+x9+1fP+n/ETXImZL2Zbu3c/OrqM474Nex+Drm18i21DT7kNDcESDcAGUg8q3rVTtODjHc55ynD4j1bVtBs7/RBFcxGaF23GKUAp16jNHh3SLKwsIYLaE2q/Mu1W+TaT09qTTc2cd48jNM8/wC8B3ZVFI6D6UafIzWTvFI0kjD7h6EdcV4952avpcmUrO1z5m+OHhmXSPGl1dBWksLxvNjmA79wfQ1wFlC3nBsbVBwD3zX2TqWn22raeIdVhSWwlXEkD8kn1z1HPeuKh+EvhMXjM1jclSd6RfaSBjvn2rrjVVtTenXW7PBftU1vDavbziJkkJhlU4KnucirVnNcNqfn22oOLxQTkSlOnPDE9a1/jTpFvonjSSzsYY4bNbeLyETICqRzz3571xSyCO3KXERJOQjDg/X3rXmuro7o1IvVn0X8MPHlz4lMmkan5L6jDHujn2jM6Drn1Ndzp072zhGiIZTkkjgCvmr4PyTf8LG0MxZKm4+Yjj5dp3Zr6UvLiKKdlgEh+TcFbq57ADqR61x1YJOyWjM+dOVjH+L2nXniTwFNYabE8l0kizog6vjqB718l3lvcWdw8N3FNDMhwVcbWB9Oa+zbB7maNIypRmALAEAj/wCtXIfGqVLbwxYxzRwSX1zMVSeWJS6IOTtPqelTRnyfuy1Hnlyny3bxtNMqIu5mOMV9nfD6fQJfA2jaKutWd5dWlsqukUuGDE5I2nGRzXyhKPs1yk1vb8IchXGcnPG4U+O/kkv3uZk2uW3fIu3yz7egFa16XtUle1gdFLR7n1u/yyzQL8iDlA9Z6QxlyzPkls4Y459AK5/4X6ld+ItDzfyNLdWMgieVzhpEYZVj/LNd4tsuZi80UcES7pHYhQgA5OfbrmuOcvZuw7ez905+XTyJWW3TaJAGUA9fep/7Pjgi3eVvmXq4659Sa4HXfjJoWjXDwaNp0usCNtv2t38qMn/Z4JP14q1ovxg06/gkbUdLmtE4EhifzNo65YHB9Omat+1fTT+vMSV9EegW8MlsR5cchZkIZm6EGidVuJ4zJbj93ncxHCn29a07W8hnsIZbKYS2sqLJG8R3qwI4+aomjCvuk/e5OGXrtrm9q73e5z2W4yxQoGCJtQcjn5j71YMxghkY7io7gc9ahujI3EY2qD0HXAqSKB7mRQyERHGVrlqVUnzSN1DTQ6K0tIL/AEqaG8RHt7lDFKjDhlI5H1ryHxd8D7tJjN4Y1S1ezQ7ltdQU7oxnO0OPvDPqAfc17Npf7y2FvKFOzlAOARVu6tBcRqm9lKnPB6+orjpYydKV4PRkXlDY8C8OfBW9v5g/iTU7eC2WXcLeyBeQp/dDnAUH6GvcNL0q10uwtdO0y3W2srdSscanO0dTyeSSaupDHAAETCkYyPSlHJ4PI/SivjJ1t3oTJuTvLcdA4RjknJ6gVOsqMzIGTemCyg5IB6cdqrxxln49eR6VZH6dhXHNq5UbhyDyaQnB6n60p9uc0w5z7H2pABPIyBk/pRTGAIw2DnnGKKNxH5zvcy2Wmw28TkTS5YsG4C9sfXmsbBY+pNaGrak2qzLNNDBC6KEAhj2giqAGSOQPevvpPmLSsX9I1S40y5DxMfLPDxnlWHoRXa+NbhF8J2qwoirOyuMKdwGCeSRXnXXr+de8eG9G8K+JfD1npl9rtnDeNbqCC2Csg6HPToa0p1LRabOatHlkpo8Gr1D4A+I4dE8Wm3meO3N8nkpclfmRuwz2BrlvGfgfXPCWoPBqdjMsPWO4VCY5F7MGHFT/AApayg+IugS6x5a2Ed0rzGbhAo7n2ziuV6J9UXUanB2PtWQahqIaZolktEQYycBmHU1n3+o21volxrGq3KwR2q7t27G1c4/En0FdZb61pl3bs2nyxTQvwpiK7cHv6V4v+1BapB4Btzp2Uia9U3APP8PB+ma8rCy9pP2co8v9fqczpXa1uY2rftA6HaSMNM0m51C4jyIbqdwgGR/dxmuXvvjImueH7rRJNDS3+0xti5SbOHOeTx0rxhw85SWRwZG6kjgL60yVAnzW0xZM4xnBFe1ClCGqR0/Vo7lVgdxB60CtdtD1KfTxqMNnJLas5QvEu7aw5IOOnrWpovgPxDfQLejSLwacDlpzHhcd8Z61XLqXKSim2et+A9cu/wDhVjzN50skUMsKlyTgDoQfbNfP0pdmJf7xJJNfYXhCxhfwpYWAhRLYKFVQOW9dx7//AF68k+IPwa1ey1Jp9AEVza3DkpAjYaM56HPWm6kebk6nNRqJq6PGShUDK8k16X8J9YitLbUI9Rliiskw4Z22gMeDj1NR6Z8IPFtxHI81nDaxx8sbiUD8gOTXL+MdKOi6u+nM7Mkaht+0gOxGSRntTi+qNZcs/dPddI+J3h+10j7O2p/vUPllSrHevYg/p1FelabqFvO9nJHNHsnhXaYvmHI6giviR42jbblGOM5U5Fer/Br4it4Vtr2z1RGn0xImnjiHXeeMA9gawq01NOy1OadBwV4n0ndpCvywXALHhm7j3p0WnNJZXEzF2uWyFc9QtfPmo/HvxBJeIdLsdNsbZCNsZiDsw9CTXoXw6+OFlr1z9h8SWcNlqEp8u3ljJELkjo2fu1wzpVoR93X8xez/AJh/xL8DWXivSwVmFtrVkii1kblbhTyUb0x2NeZn4N+M7gW8c9ha+UFwjm6TAU88kV9GXFu88n2qCMYjXYQ6/wCePepbZrfTNON1eXNtboeWaWYKo9ACcUniZRj7uprSqyj7pwHwx+Gv/CHbru6KXOrSoY32jKwp6L3LHua6q/tUkvLee8UZgyBuXGB/nHFLbeIrPUXmji1XTt7NiJY51dz6kYP4e9WkuLW8t3gU71Ynk5DH6n1qG6nNzTRUa13YqWMUKOWglZickk/eP4dq5r40eGJ9e8M2uo2EUjHTXMkkcak5jbqfqOuKn+Jev2nw90G0bRYAdY1EMYmc79oH3nbPX0xXgOqfEDxNqXmpPrl8baQgtGkmxST2IHUVrShOo1Ui/v8AxOmlaErrYw55GhmV5JFPzMrHaePT61XMssrvNHv4bbJgdF7HNNe62Xzfvd6E7XBO5SD1Ir2jw/8ABM3mnW9/d6/bSadcRrMgtEZmdOpGWwAffmuqpVjTV5OxrOa7m/8AAjT7mPTL/VLiJlhuSsFvHIeXROdwz2HSr/7R+pfY/B9jp+nz+VNqUpWcg4BjVdxXPuccV3UKRW2j2dvapGltaosEflHhFUcfh/OuZ8a+G7Lxbpi210R9pifzoJh1DYxj6HvXm86nWVSWyIj+8ld9T5ZtrdXQgqQygtkdqmheWG6jcsQjZjJJG3sOvtXXa98PdesZZQuiatHIDtkl2iaIg9CGUZ5rS8G/BrxDrpQzQtpunk5ea7XYxPT5E6n8cV6Eq0Ix5nJWLfuaLoehfAM3p0rWRIkkunLcqsG1/wB2r4+cqfyNesJApUSfKpPVcYFVNC0O38N6NZ6RpQkjsrfIO4AmV+7EjuTWmyyuC6gg7snHpXhV6yqTconNJ3k2UZAqAAgfSmRu0gJQAYPOOmBU93aE/wCrJeMkbsf4Vf0zTwT/AHoickHvXmVbt2OiMoqNyzpMJVVlcuuQRGn973rTdJBjaDj2FeTfHL4i3Xhb7PpmhSRpqMqh7iX7xhQngexIzz9K8Ot/EGrX1yk99q+q4EhMgW4lOQemDnpXbh8slUpqV7L7/wDIlQlN6f1+Z9j7NrFSD3znihlUZxkY64FfPfgr4i6zo62K6hevqtjKWL208ivNGueNrnByB2NfQkMkcsMUsJ3RyqHRx3BGRXPicLPDtc2qZMqcoaSRIiY2k5z+VUtb1a30ayN1e7hFkL8ozyatuxAHJweMiq89vDdxBLuFZFByAw4+tc0bcycthN9EO0++hv7ZZ7fJVjxkY/nUqkdAScdzSRRJDEscSqsajjHGKcwx1HJpu13y7C1tqNbGckcZ60Uo6jHPp3opCPzQXumM+hFejJ8LNTvvDtvq+mywNC8JnlEz7GjA6nBrZ8PfBy8i1m1/ty7iSz35cQkszj2x0r23VfCcWpaHfWdpdvDK9ubeCNTgFccA19tLEQhZNludmklc+OLkgOEDKxT5cqMA/wCNTQ25jcee/k8ZDf4Yq9rmmz6HfSadqVmYriFiHyMMaz5YwMnucMPmBwPeunzL0ep75+z58SWb7d4d8XahBLpSWzS2sl6QdjL/AAZPUEdq8S8S6zJres3V7MEAkdiiqoCqueAAOgxXo3wH+H58W6teXNw00VhBbsouM7QZm4VfcdzXFeJNAv8Aw9rt1o+sW5aS3fA2dCv94H0IrnpxpqrLl30uv6/EzjZNq5U8NeK9a8N30d5pF7LbvGeADlT7EdDXsGh+P7z4rWc3hXxCIYJpYyYJYEwGZTnkev0rxSSwugnzIyo2TGvUEV2nwc0S+vfHmnNaxmM2zF5TkjYADyfTNaSjH43uupFWnZXWjIvEHwo8R6RHeXLJbtp1uNxufPUKw7DBOc+1efwxSTzLHEpd24AHevoz426Pq0vgoywCR7eK63XCKMkLjCnA7Z/nXlvhPwHe6xJaEXdnaibkmZ8BfYntTU01e5VDmqK7RzOi69q/h29WTTrua2ljYnaDxnoeK+m/hb4iHjHwveXUCvaXNriKWGN8gsRneo7A+lfM3iDSH0nUbqzupovPt3Kr5fKOM9VNem/s26k9p4k1G1DsILi1O8A9WByMD1qaqbjoZYmmmrnqtrdS6LL5FuuYpGBVnG0g55APf/69dTpepx3m5ZlXywQULHnPrXl/xu8X2/ha9t9NsNtxqpXzJ0Y5+zZHA/3u9eeeG/ixqUN9CmtiO50/7jRooVlBPJB9amUI1oqXVnLClOEbpH1kRBcQENaiR2XJJxXjPxV+FcmtxXGs6GWe8hGWtD/y1UdQvoR6d69Y8P6vFdaZbSWp85HQFJVAyVPQnFaUlxHDNGjgqm35gTy2e59q82FapQk4pFRktJHwZdWUkNwYZo3jkBIKOpUr+ddPZeEtUHh281uWyni084gheZSu4nByPb3r638RaPpt9ewNdWKTOvzHdCrD+VM1bSJtY0S90a88pbae3MSSt/yyP8JwPfFdaxsWk7G3tGnY+JIzGBtmRiVyBjufetGJU8uMWqu4PzsvdHHTmug8SeCdZ0rVpoLrTLgSK4RfJjLpL/tKR1zXqvwr+Cd5I8WseJD9mt0beLA/flAOQG9B7VvUrQpR55PQ05lsej694tt/DPw6g1bVI/8ASxZwstuOskzLgA+3f6V8m69rOreKL2W+1KSWeeRi2BnaB6Ko4AFfRv7QUV5deCCVXdGl7E8zIo/cxjOCB7EgV8226y6dFFewX1rv8xlSPOXIB/iHYHtWGFilHnXUVGKlqyraxTxSrFCknnykbNoKlSPSvqb4UanPrHhiO7vdsl3BObOZtvzKwH3zjqSD1rwnTfF6i0ks5rOGacnba3Kx58ok84Xuewr6C+GPhe98M+CgzHy9QuJftLow2lQwGAR/ex1oxM+WGvUvEQpqPuu7PMv2izcP4zhjuY2aCKxj+zkYAIJOSMe/FeQy2ZWUQKoU+XuYk9M//rr6++JHw/k8c6LF9lnWHVLAN9nkkQbZVI5Q+nNfOt14C8U2L3C3Hh+9BRctIV3Kg9Sw4x1/OpwteE4KKeqLhJbM4CKGUSCMQZCEZG3nnoPevsj4XaPe+H/A+j2GrKY7hUaRkYZ2IxyFPuBXjvgTR/Dvh2a11/xvqUM94suLWyiYSKhXGHkx1x2Fel2/xk8IXeoNBdzXiwl/lu2jGwn1wORWOMc6i5IRuv62FUhbc75rGG609o/K2Lk/KDjBPvXH25e1vVhlcjy2Ix2IrttMvLfU4Y5bFlngmAZLiPlG9Kbc6Ek92srshOeo/wA+teXCt7NuMyqU0o2KtrdSTssahgmAG549jW3YRu8jiU5QHjnj8TVCPSo4phK0zKfYcY965/43avJo3wu1prMlJSiRgqSrAOwBIP0zWbSqzUIddDJtJ3PMfG/xqmtdVvLTwk9pFawS+SbqRfOeVgfmKqeAmeAT1rE0z4leL76eCODUp2vGZtju6rb542qylcADnvzmvK45Hu5Y/KCTLJIoEYQJ0HQnt2rQF4z2fl+ZFJJITCyuC2weu32PQ17qwtKKtyr56nZRpxtr/X5/gfWPw68Yv4q0We6ns4bfVbKU219DG4K7h0ZfY110FxHK3lbWjcEllIPT6187/s/yN/bWpwwI5s7WxEMjAfK8hcEE+h64r3i0uUUxI80iMTuCsfmJzXjYvDxpzaicE/dm43PBfjL54+IesvaqjwuipJISCwARd8fPTsR9a4S9ttPTTLbZeO9vI4fyMHfGQeQRn8jzx6V6x8ZdOksvEkuo3Nt5+i3xSQurbdkoUKwJ7HAyM8HNeQaktrJqReyWSANNiBQGaQdx8vcDFexhXzUoW7L8D1IySp3T+8tJFbnTrpY4RKEZQ0Ep8uQDOcjIzivrXwRLLL4P0Tz4DA/2OMFN+4LgYAz34xXiPw7+GGo63eSav4rkvLaJ3DATxAS3PrweUBA7iveWgnS6h8iVI7NAB5O37oAwAK8rM60JpU09VqclaopNNfp/X4miBjoAKXHPufU03pz074NIc9vrXi3IF57HgUw8c5wvcetG7OMYIPvTd+WbJ6HHFNCAyMkUrou91UsB0BIFFVdVulsNPkkxumkBSJQerEH9KK5a7fNZHRRj7t2cZa6X9psoJ3he0l25Mcg5BqB7S5gmjaWEptHyk9T9D+FdqfmwSTxz9adsR0KuoYA4wa9pY2V9jijBxW55t4h0bTtbLf2rpNtes33mlT5j7gjmuUtfh14PtLl5JPD6SnjCzTOVH0Ga9ovbSFMOq44BxWDd2yzcKdhII6Aj8q76GKbXKm7epbl0MbTzZ2VvHbabAtpaRcpDbqFUZ9u9VPFOl6b4kRPt8YM6YVJl+WQD+7nHT2NW7iBEnjT1HUcVBfQsIiwk4PbbyPxrpg0pKSeooxtK8WcVrPwss9SvxPY6n9iH3hE0e5c9yOePpXaeFfCOl+FrSaKweb7TNh7i4lbc0re/t7U0SSrADvyeCDjoTSS3D22+MEvldxZjk/hW0pTmuVsmq6knds6GBmjgcJtkLAKRKNwZe4xXm1vDoXiK41qy8N2x066HEjKdySYJ3EDt9K2be9uh9nHnvtkVzjuKwNDFv4YttSvrW3EkspB+Zj8pJOcHn3/OtKVKUG2nr0/4IQvFXW4vxG+F15q3hvS4PDthY3N3Gd0txNII5VTGAvPBGeahsPBk3w1+Hl/fwRw3mvpAZpZ0GViB4Cg98ck/SvS/DOozazYvdTHYQMKg5Awa6OOTfE0c6JNBJGVeJ1yrKRyp9RzXNLFVKb5Za2epM5yk/fPz5vLia7upbi5keWaVizu5yWJ71Gow1fRXxi+DGj2F/Hf6Bcvp9tdKHNmY/MSMn+6cgge3Nc18N/hjY6jqCTX920oikyI/KwrY9eeelejTqRqQ9oti51VFanqvwAjvk8J24ujLhI87AMYXPAz6812Wq3Aa/mRsABQomA5yATjmr2g2kcVgoG5VRh8qHaPTGPT2rjf2gtTuNJ8CfatOIglubj7M7Drt25yD68YrzOeNTE276HNGDlG3zNLVfiJ4W0u/QXepQ/aIoh5qQ5kwf7vHGa2tD8XeG/ErrDo+rW812y7vso4kH4HrXyZ8ONDj8UapNBNL5AghMuQu7cwOMnmt+DRorG9vrqymmt7y23GOWFtpUgdsdM1vLL6ctm00d0cNJxvFn1RJbJbPCJJxtUkBSckn29Kvz6zZ6dbq19c2tqAC2J5QmVHfmvN9H8WzxfBuLxdLbRzX8Nq8mxz8ryBtu4/zxXzH4mv77XtTgu9Tvbi4urg7neRtyjPYL2HtXJHAOs2pvRaGNGEppuJ9pTT+HfFEAGn3lheLImHEEiyZXuCteVa18FfD9zqjyO97bQMxIgtyuwfQkfpXzzol7e6VrEd1pV09nfRS7o54hgjtjHQj2r7E+E3ii48c+D5rzWbeH7ZazG3aSMbRIQPvY7fSrqQqYON4SvH8UOdKUdTE+H3ww0Lw1r1pexxSXV4pby5bpgwTj+FQMA+/Wu/mjtbJmFxcw28ckh+e4lCBj6AmsDxlrknhzwNrOrx28VxNYqskSScLvzgE/TPSvk3VfEuqeJri61PWrmS6mKnKyHKKDzhB0THtURoVcXJzlKy2/X9Qow52fbltdrKG+xPFcCM4LwyBgp9GweDWX42trjUfBWtx6eGM8ts+xQOXYfw/pXxp4O8aar4O1iG80aeSNTJmSAufLlTPKsOh+vavujT5xcWdteRoIjcQrNtzu2lhnFcmJw0sHKM1rr+RSdpWZ8HeIr2e+laWS3ETvKXAiiCBOMEAenFZU1rKbhHwg3gMOQDt9SK94/aS+G9jpSf8JTpt1JALuUCaz2ZTeedynPH0wa8KtYg5EXQthC/U4z2r3KNWNaCnDY0lLmk09z6N/ZS1OSaw17THlkMcDx3CKx/1e7IIHscCvfW8pAxKgKBwcc14z+zZ4et9KsvFU0cjySm9W03OBnYqg/zb9K9gWZpbZ2YDKtjPr7189mFnXbXl+RHK4Nxfn+DOM13XVtRKbq9jhSEebPJINixrnoT9K8o8b/HPwxqWjarokek3t/a3kTR+e7BNp7EA88HBrW/a0jMHhXRp4XZDd3BWYDgPtXI/KvlR3LRAdCG6+tethcPSqwjO39fL0MYRfM7s37eWW43C1i85Qp3tHnIXuSo5z+ldr4U+HvinxNMtxa6XcR28g+a8vMQIV7EZ5PHoOa4Dwxqd1ouvaZqOnytFcxSowYd+cEH2Ir7itklupXd52wzBSMdsDgelb4qs6Kuv6/r1NaleSfKjO8H6Rovg/RYtK05t8Sjzp5nGWnlIwW+nGAO1WvsLXDP5SHe6/KSxzGCecVpx6VbwMwALlQDufk9a0ptsMM0zLuCDO0HGfxrwp4jlfNF3bOfkc/iKdvZKlqltMitBt2SCQhg49waW20/TtLm82y061id2wHihUMc981JYyR30ZaKMw7RuGW3/ANBToGZ5ACfujGRXNKUne5rGyVkRyTXEgPJLZxu9vWpoZnA2kHcBkg9xUxhUOCCVA6gd6hmVkG5HIB7EZ96z5k9B2e5PZ3cU5O3/AFg7fSrfXGBx6elZFshS6BVsK+DtA6Z61qKcqPc5rOcUnoVFu2orMR25pN3zE4Ge9Ix+WmH+I46DpU2HczNaieXULfahKLH1PQc80VoTxx3EMkUqkoeDhsHn0NFZOm76WNVNW1P/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High-power view of a fine needle aspirate of a thyroid nodule. The follicular cells are small, uniform in size, flat, and noncrowded, with smeared colloid in the background. These findings can be seen in a normal thyroid gland, benign sporadic goiter, or a true benign macrofollicular monoclonal tumor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_11_28856=[""].join("\n");
var outline_f28_11_28856=null;
var title_f28_11_28857="General principles in the use of immune globulin";
var content_f28_11_28857=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   General principles in the use of immune globulin",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/11/28857/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/11/28857/contributors\">",
"     Arthur J Silvergleid, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/11/28857/contributors\">",
"     Melvin Berger, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/11/28857/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/11/28857/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/11/28857/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/11/28857/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/11/28857/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/11/28857/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/11/28857/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune globulin is used in the treatment of an array of disorders, including primary and secondary immune deficiency states and a variety of autoimmune and inflammatory disorders (",
"    <a class=\"graphic graphic_table graphicRef82262 \" href=\"UTD.htm?38/61/39900\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28857/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the indications, proposed mechanisms of action, production, composition, administration, and pharmacokinetics of immune globulin. The use of immune globulin in the treatment of specific disease states and the adverse effects of intravenous immune globulin are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17175?source=see_link\">",
"       \"Intravenous immune globulin in hematologic disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=see_link\">",
"       \"Immune globulin therapy in primary immunodeficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7369?source=see_link\">",
"       \"Overview of polyneuropathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/16/265?source=see_link\">",
"       \"Treatment and prognosis of Guillain-Barr&eacute; syndrome in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42025?source=see_link\">",
"       \"Kawasaki disease: Initial treatment and prognosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/32/38409?source=see_link\">",
"       \"Intravenous immune globulin: Adverse effects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/9/31896?source=see_link\">",
"       \"Subcutaneous and intramuscular immune globulin therapy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Routes of administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune globulin may be administered by different routes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenously (immune globulin, intravenous [human] will be referred to as \"IVIG\" in this review, because this term is commonly used by clinicians, although the abbreviation used by industry and various regulatory agencies is \"IGIV\".)",
"     </li>",
"     <li>",
"      Subcutaneously (SCIG will be used here, although IGSC is the term preferred by regulatory agencies)",
"     </li>",
"     <li>",
"      Intramuscularly (IGIM)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Multiple products are available, which vary in concentration of IgG, additives and stabilizers, and IgA content (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Production and composition'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Most products are labeled for a specific route of administration: intravenous, subcutaneous, or intramuscular, although several 10 percent IVIGs are approved for subcutaneous routes. Anecdotal reports suggest that most intravenous products are well tolerated by the subcutaneous route [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28857/abstract/3\">",
"     3",
"    </a>",
"    ]. Subcutaneous and intramuscular products are generally more concentrated than intravenous preparations and should not be given intravenously. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/9/31896?source=see_link\">",
"     \"Subcutaneous and intramuscular immune globulin therapy\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune serum globulin preparations made from pooled human plasma became available during World War II, and their efficacy in preventing hepatitis and measles was rapidly appreciated [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28857/abstract/4\">",
"     4",
"    </a>",
"    ]. In the 1950s, passive intramuscular immunization with the immunoglobulin fraction of pooled normal human sera was found to have a dramatic impact on the frequency of sepsis and severe invasive bacterial infections in subjects lacking immunoglobulins [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28857/abstract/5\">",
"     5",
"    </a>",
"    ]. Intravenous preparations of immune globulin first became available in the 1960s, although these contained impurities and protein aggregates that caused severe anaphylactoid reactions, presumably by activation of the complement cascade, and were not widely used [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28857/abstract/6\">",
"     6",
"    </a>",
"    ]. Subsequent refinements allowed for safe administration of higher doses intravenously that more closely approximated physiologic levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INDICATIONS, USAGE PATTERNS, AND COST ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune globulin is approved by the United States Food and Drug Administration (US FDA) for use in the following conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28857/abstract/1,7,8\">",
"     1,7,8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Immune thrombocytopenia (ITP)",
"     </li>",
"     <li>",
"      Primary immunodeficiency states",
"     </li>",
"     <li>",
"      Secondary immunodeficiency in chronic lymphocytic leukemia",
"     </li>",
"     <li>",
"      Pediatric HIV infection",
"     </li>",
"     <li>",
"      Kawasaki syndrome",
"     </li>",
"     <li>",
"      Prevention of graft versus host disease and infection in adult hematopoietic cell transplantation",
"     </li>",
"     <li>",
"      Chronic inflammatory demyelinating polyneuropathy (CIDP)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the above approved uses, there are many other disorders for which immune globulin has been administered (",
"    <a class=\"graphic graphic_table graphicRef82262 \" href=\"UTD.htm?38/61/39900\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28857/abstract/1\">",
"     1",
"    </a>",
"    ]. One medical center reviewed the use of intravenous immune globulin (IVIG) during a single calendar year. A total of 194 patients received 48,230 grams of IVIG, at an estimated cost of four million US dollars [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28857/abstract/7\">",
"     7",
"    </a>",
"    ]. The six most common conditions for which IVIG was used included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chronic neuropathy (29 percent)",
"     </li>",
"     <li>",
"      Secondary hypogammaglobulinemia (18 percent)",
"     </li>",
"     <li>",
"      ITP (10 percent)",
"     </li>",
"     <li>",
"      Primary hypogammaglobulinemia (9 percent)",
"     </li>",
"     <li>",
"      Renal transplantation (6 percent)",
"     </li>",
"     <li>",
"      Myasthenia gravis (5 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A 2010 analysis performed in Canada concluded that the estimated cost of treating one patient with chronic neuropathy (eg, chronic inflammatory demyelinating polyneuropathy or multifocal motor neuropathy) was approximately 70,000 Canadian dollars per year [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28857/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hyperimmune globulin preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several immune globulin products, both for IM or IV routes, are prepared from plasma of individuals with high titers of specific antibodies to certain pathogens",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    from plasma of hyper-immunized donors. These \"hyperimmune\" globulins impart temporary, passive immunization to the target pathogen, or can be used to neutralize certain antigens, most importantly, the Rh(D) antigen on fetal erythrocytes of Rh- mothers.",
"   </p>",
"   <p>",
"    Preparations have been made available for use against hepatitis B (HBIG), cytomegalovirus (CMVIG), varicella zoster (VariZIG), rabies, vaccinia, tetanus, and botulinum toxin. Certain animal antisera are also used, such as pertussis and botulism antitoxins, and in some countries, tetanus and rabies antisera. It is theoretically possible to produce a hyperimmune globulin from convalescent plasma to any organism, which can safely be used as passive immunization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32039?source=see_link&amp;anchor=H10#H10\">",
"     \"Plasma derivatives and recombinant DNA-produced coagulation factors\", section on 'Hyperimmune globulins'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MECHANISMS OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune globulin is believed to have multiple mechanisms of action, most of which are incompletely understood. It has two primary clinical applications:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Protection of the recipient against infection, and",
"     </li>",
"     <li>",
"      Suppression of inflammatory and immune-mediated processes",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Congenital or acquired hypogammaglobulinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;IVIG is given in congenital (primary) hypogammaglobulinemia and other primary immune deficiencies to protect the patient against infection by providing adequate concentrations of antibodies against a broad range of pathogens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=see_link\">",
"     \"Immune globulin therapy in primary immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IVIG is also used in patients with secondary immunodeficiencies, although less uniformly (",
"    <a class=\"graphic graphic_table graphicRef82262 \" href=\"UTD.htm?38/61/39900\">",
"     table 1",
"    </a>",
"    ). Examples include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Progressive hypogammaglobulinemia is common in chronic lymphocytic leukemia (CLL) and is associated with an increased risk of bacterial infections, especially of the respiratory tract. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35017?source=see_link\">",
"       \"Overview of the complications of chronic lymphocytic leukemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients undergoing hematopoietic cell transplantation for malignancy are sometimes treated with IVIG to prevent specific viral infections.",
"     </li>",
"     <li>",
"      Certain complications of chronic parvovirus B19 infection and HIV infection are treated with IVIG. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/1/31767?source=see_link&amp;anchor=H6#H6\">",
"       \"Treatment and prevention of parvovirus B19 infection\", section on 'Chronic infection'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/12/27848?source=see_link\">",
"       \"Diagnosis, treatment and prognosis of HIV-associated neuropathies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients can be treated with IVIG to prevent antibody-mediated transplant rejection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/52/4938?source=see_link&amp;anchor=H20#H20\">",
"       \"Acute renal allograft rejection: Treatment\", section on 'Intravenous immune globulin'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Autoimmune disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanisms by which IVIG acts as an antiinflammatory and immunomodulatory agent are believed to include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28857/abstract/1,10,11\">",
"     1,10,11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IVIG may reduce immune activity by interacting with Fc receptors on phagocytic cells such as splenic macrophages [",
"      <a class=\"abstract\" href=\"UTD.htm?28/11/28857/abstract/12-14\">",
"       12-14",
"      </a>",
"      ],",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      by the presence of anti-idiotypic antibodies directed against idiotypes on circulating autoantibodies. Thus, the efficacy of IVIG in immune thrombocytopenia (ITP) may be mediated by prevention of reticuloendothelial uptake of autoantibody-coated platelets through the blockade of Fc-receptors [",
"      <a class=\"abstract\" href=\"UTD.htm?28/11/28857/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      down-regulation of their function [",
"      <a class=\"abstract\" href=\"UTD.htm?28/11/28857/abstract/17\">",
"       17",
"      </a>",
"      ] or inhibition of autoantibody production. (See",
"      <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=see_link&amp;anchor=H10#H10\">",
"       \"Treatment and prognosis of immune thrombocytopenia (ITP) in adults\", section on 'Intravenous immunoglobulin and anti-D'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      On the other hand, anti-idiotypic antibodies directed against antineutrophil cytoplasmic antibodies (ANCA) and HLA-specific antibodies may be responsible for the possible benefit in patients with granulomatosis with polyangiitis (Wegener's granulomatosis) and highly sensitized patients awaiting renal transplantation, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?28/11/28857/abstract/18-23\">",
"       18-23",
"      </a>",
"      ]. These anti-idiotypic antibodies provide a negative feedback signal capable of downregulating the pathogenic immune response; this effect is mediated by direct binding either to circulating autoantibodies (leading to increased clearance) or to B cell immunoglobulin receptors bearing the specificity of the autoantibody. Anti-idiotypic antibodies directed against anti-factor VIII antibodies are believed to account for the ability of IVIG to neutralize antibodies to factor VIII (ie, factor VIII \"inhibitors\"), which have developed in hemophilia patients treated with exogenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/12/198?source=see_link\">",
"       factor VIII concentrates",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/11/28857/abstract/19\">",
"       19",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      It is not clear whether, in any given disease state, all the IgG molecules present in the polyclonal IgG preparation, or only a small sub-fraction are responsible for the clinically beneficial effect. For example, when IVIG is used to neutralize certain autoantibodies or anti-HLA antibodies, only that small fraction of IgG molecules with specific anti-idiotypic activity are likely to be needed. In addition, laboratory evidence suggests that some IgG molecules with heavily sialylated Fc regions may preferentially exert antiinflammatory effects. Nevertheless, at present, commercial products are not characterized for, nor differentiated by, their content of antibodies of different specificities or chemical compositions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other possible mechanisms of action include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IVIG may promote solubilization and clearance of immune complex deposits [",
"      <a class=\"abstract\" href=\"UTD.htm?28/11/28857/abstract/13\">",
"       13",
"      </a>",
"      ]. This may be important in an immune complex disorder such as membranous nephropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?28/11/28857/abstract/23\">",
"       23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/41/37530?source=see_link\">",
"       \"Treatment of idiopathic membranous nephropathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      IVIG may contain neutralizing antibodies. In diarrhea-induced hemolytic-uremic syndrome, for example, IVIG may provide antibodies against the Shiga toxins that appear to be responsible for the disease [",
"      <a class=\"abstract\" href=\"UTD.htm?28/11/28857/abstract/24\">",
"       24",
"      </a>",
"      ]. IVIG also contains antibodies to staphylococcal toxin and streptococcal \"superantigens.\" Superantigens are proteins that can bind simultaneously to MHC class II antigens and to the non-antigen-binding region of whole families of T cell receptors, thereby stimulating large numbers (up to 20 percent) of T cells to produce cytokines [",
"      <a class=\"abstract\" href=\"UTD.htm?28/11/28857/abstract/25\">",
"       25",
"      </a>",
"      ]. Anti-superantigen antibodies may explain the apparent efficacy of IVIG in staphylococcal toxic shock syndrome, severe group A streptococcal infections, and Kawasaki disease [",
"      <a class=\"abstract\" href=\"UTD.htm?28/11/28857/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]. Their possible role in the treatment of the hemolytic-uremic syndrome is unproven. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=see_link\">",
"       \"Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      IVIG may accelerate the fractional rate of catabolism of IgG by increasing the total plasma concentration of IgG, thereby preferentially eliminating pathogenic IgG molecules by saturating the transport system, which preserves IgG in the plasma with normal IgG molecules [",
"      <a class=\"abstract\" href=\"UTD.htm?28/11/28857/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. At normal plasma total IgG concentrations, IgG appears to be protected from catabolism by binding to the molecule FcRn receptor on vascular endothelial cells [",
"      <a class=\"abstract\" href=\"UTD.htm?28/11/28857/abstract/26\">",
"       26",
"      </a>",
"      ]. When this receptor is saturated, as in hypergammaglobulinemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      with high dose therapy, IgG is no longer protected, and is degraded according to its relative serum level.",
"     </li>",
"     <li>",
"      IVIG may alter the number of T cells and T cell subsets [",
"      <a class=\"abstract\" href=\"UTD.htm?28/11/28857/abstract/30-32\">",
"       30-32",
"      </a>",
"      ]. One study of 46 patients treated with IVIG found an approximately 35 percent reduction in lymphocytes in 95 percent of patients, with a selective reduction of T cells, but not B cells or interleukin 2 receptor positive cells [",
"      <a class=\"abstract\" href=\"UTD.htm?28/11/28857/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      IVIG appears to reduce certain proinflammatory subsets of peripheral blood monocytes (CD14",
"      <sup>",
"       +",
"      </sup>",
"      CD16",
"      <sup>",
"       ++",
"      </sup>",
"      ) and to suppress the generation of cytokines by these cells in response to LPS [",
"      <a class=\"abstract\" href=\"UTD.htm?28/11/28857/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      IVIG may increase the effect of regulatory T cells, which are engaged in dominant control of self-reactive T cells, contributing to the maintenance of immunologic self-tolerance [",
"      <a class=\"abstract\" href=\"UTD.htm?28/11/28857/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      IVIG can serve as an alternate binding site or \"sink\" for C3b, diverting it from binding to targets of complement activation [",
"      <a class=\"abstract\" href=\"UTD.htm?28/11/28857/abstract/34\">",
"       34",
"      </a>",
"      ]. IVIG may also neutralize the inflammatory actions of the complement fragments C3a and C5a via a physical association between these anaphylatoxins and the constant region of F(ab)'2 [",
"      <a class=\"abstract\" href=\"UTD.htm?28/11/28857/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PRODUCTION AND COMPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Production of IVIG begins with pooled human plasma from several thousand screened volunteer donors. Cold alcohol fractionation (by the Cohn or Kistler-Nitschmann procedures) is used to isolate the immunoglobulin-containing fraction. This is followed by further purification techniques, including additional precipitation steps to remove non-IgG proteins and ion exchange chromatography. Most IgG preparations also undergo several specific treatments to inactivate or removal potentially present blood-borne pathogens. These include low pH treatment, fatty acid treatment, solvent-detergent treatment, heat-treatment (pasteurization)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nanofiltration.",
"   </p>",
"   <p>",
"    The World Health Organization has published minimum standards for manufacturing IVIG preparations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28857/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      IVIG should be extracted from a pool of at least 1000 individual donors.",
"     </li>",
"     <li>",
"      It should contain as little IgA as possible.",
"     </li>",
"     <li>",
"      The IgG molecules should be modified biochemically as little as possible and possess opsonizing and complement-fixing activities.",
"     </li>",
"     <li>",
"      It should be free from preservatives or stabilizers that might accumulate in vivo.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are slight differences in the manufacturing procedures utilized by the different producers, and different stabilizers are used in the excipients (",
"    <a class=\"graphic graphic_table graphicRef68573 \" href=\"UTD.htm?0/29/478\">",
"     table 2",
"    </a>",
"    ). However, the final preparations are highly purified (&gt;90 percent) polyvalent IgG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Constituents",
"    </span>",
"    &nbsp;&mdash;&nbsp;IVIG preparations contain highly purified (&gt;90 percent) polyvalent IgG. Products differ in storage requirements and shelf life. Stabilizers may include sugars, such as sucrose, glucose, or maltose. Some IVIG products contain amino acids such as glycine or proline. The sodium content of different products also varies.",
"   </p>",
"   <p>",
"    The resulting products are generally believed to be equally effective for treatment of the autoimmune and immunodeficiency disorders. However, they differ from each other in ways that may be important in a particular patient. As an example, the variability in IgA levels may be important in rare patients who have selective IgA deficiency and anti-IgA antibodies. There may also be variable titers to less common infectious agents, such as strains of enterovirus; this is important if the IVIG is used to control enterovirus encephalitis. Certain stabilizers may be associated with adverse effects in some patients: sucrose can cause osmotic nephropathy, maltose can alter readings of certain glucose meters, and glucose may be problematic for diabetics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=see_link&amp;anchor=H8#H8\">",
"     \"Immune globulin therapy in primary immunodeficiency\", section on 'Constituents and production methods'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     OVERVIEW OF DOSING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dosing varies depending upon whether IVIG is administered for the purpose of preventing infections in immune deficient patients or suppressing an inflammatory or autoimmune process.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lower intravenous doses are usually used in immunodeficiency disorders involving immunoglobulin deficiency or dysfunction. Typical starting doses are 300 to 500",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every three or four weeks, although doses as high as 800 to 900",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      are needed in order to keep some patients infection-free [",
"      <a class=\"abstract\" href=\"UTD.htm?28/11/28857/abstract/38\">",
"       38",
"      </a>",
"      ]. Doses are then adjusted, because some patients may need higher or more frequent doses to remain free from acute infections, to control chronic infections,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      to maintain target serum IgG levels. Subcutaneous preparations are widely used in immunodeficiency because the gradual and steady introduction of immune globulin into the patient's circulation appears to have advantages. In addition, subcutaneous immune globulin (SCIG) is frequently self-administered at home, which is more convenient for many patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=see_link\">",
"       \"Immune globulin therapy in primary immunodeficiency\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/9/31896?source=see_link\">",
"       \"Subcutaneous and intramuscular immune globulin therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Higher doses are given when IVIG is administered for its antiinflammatory or immunomodulatory properties. In many cases, the intent of therapy is to flood the circulation with immune globulin with the goal of interrupting the pathologic immune process. Intravenous administration is usually required to administer the desired quantities. As an example, patients with Kawasaki disease are usually given 2",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      as a single dose as part of initial therapy. In older patients and those with underlying conditions, we advise giving these larger therapeutic doses divided over several consecutive days so that no more than 500",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per 24 hours is given. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42025?source=see_link\">",
"       \"Kawasaki disease: Initial treatment and prognosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42025?source=see_link&amp;anchor=H3#H3\">",
"       \"Kawasaki disease: Initial treatment and prognosis\", section on 'Intravenous immune globulin'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Dosing for specific diseases is discussed in the appropriate topic reviews. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17175?source=see_link\">",
"       \"Intravenous immune globulin in hematologic disorders\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17385?source=see_link&amp;anchor=H3#H3\">",
"       \"Chronic inflammatory demyelinating polyneuropathy: Treatment and prognosis\", section on 'Intravenous immune globulin'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/51/41781?source=see_link&amp;anchor=H7#H7\">",
"       \"Treatment of Guillain-Barr&eacute; syndrome in children\", section on 'Intravenous immune globulin'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Serum trough levels of IgG are often used as one criterion of the adequacy of treatment in patients with hypogammaglobulinemia receiving IVIG. In contrast, it is not established that this measurement is relevant in patients with autoimmune disorders, where the endpoint is clinical improvement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=see_link&amp;anchor=H16#H16\">",
"     \"Immune globulin therapy in primary immunodeficiency\", section on 'Trough levels'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pharmacokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bioavailability is, by definition, 100 percent with intravenous administration. The fate of an administered dose is entirely dependent upon its distribution, degradation and excretion. Studies in both humans and animals have shown that the degradation rate of IgG is dependent upon the serum level of IgG, with higher serum levels resulting in more rapid catabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28857/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Thus, patients with high serum levels may need higher doses to achieve a similar protective antibody levels.",
"   </p>",
"   <p>",
"    Subcutaneous administration of IgG is associated with a decrease in bioavailability to approximately two-thirds that of intravenously administered IgG [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28857/abstract/41\">",
"     41",
"    </a>",
"    ]. This may be due to catabolism",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    binding in the tissues. Because of the decreased bioavailability, the total monthly dose should be increased by approximately 50 percent to achieve an &ldquo;area under the curve&rdquo; of serum IgG concentration versus time. It should be noted that the steady state serum IgG level on the appropriately adjusted subcutaneous dose will be approximately 30 percent higher than the &ldquo;trough&rdquo; serum level obtained just before a monthly IVIG infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28857/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rate of metabolism of IVIG may vary with the clinical state. One study, for example, evaluated 15 patients with chronic lymphocytic leukemia who were given 400",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of IVIG every three weeks; the mean half-life was 39.1 days (SD = 9.6 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28857/abstract/39\">",
"     39",
"    </a>",
"    ]. This is longer than the half-life of approximately three to four weeks observed in patients with primary immunodeficiencies or in normal volunteers given IVIG. The rate of metabolism does not appear to increase with chronic administration. However, detailed pharmacokinetic studies are not available in patients with autoimmune diseases given repeated high dosages of IVIG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SELECTING A PRODUCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients tolerate most products with a minimum of adverse events, when simple premedications and an acceptable infusion rate are used. Thus, for many patients, selection of a product to conform to local dispensing or formulary preferences is fine, particularly when a limited duration of therapy is anticipated. However, there are some circumstances in which one product may be more suitable than another for a given patient.",
"   </p>",
"   <p>",
"    A table of the properties of the IVIG products currently available in the United States is available (",
"    <a class=\"graphic graphic_table graphicRef68573 \" href=\"UTD.htm?0/29/478\">",
"     table 2",
"    </a>",
"    ). Some products contain higher titers of antibodies to human blood group substances than other products, and may cause Coombs&rsquo; positivity, although clinically significant hemolysis is unlikely [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28857/abstract/41\">",
"     41",
"    </a>",
"    ]. Primary immune deficiency patients, who generally require life-long therapy, often tolerate one preparation better than others. Although most people tolerate most products, once a patient has found a product that is well-tolerated, it is advisable not to change products unless there is a compelling reason to do so; administration of alternative products should only be done with the clinician&rsquo;s approval. If an alternative product must be given to a patient on chronic therapy, it is usually prudent to use slow infusion rates and monitor the patient closely. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=see_link\">",
"     \"Immune globulin therapy in primary immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Examples of patients who may be better served by certain IVIG products include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with severe IgA deficiency (ie, serum levels below the limit of detection of standard laboratories) can produce anti-IgA antibodies, which have been implicated in causing anaphylaxis to IgA-containing blood products, including IVIG. Such patients may require products low in IgA, although this is unpredictable, as most IgA deficient patients tolerate products that contain IgA.",
"      <br/>",
"      <br/>",
"      Nevertheless, most clinicians choose a product with very low IgA content when treating a patient with undetectable levels of IgA. (This may be less important in patients with X-linked [Bruton's] agammaglobulinemia, since those patients cannot make the IgE and IgG antibodies that cause anaphylactic reactions). Alternatively, IgA deficient patients could receive immune globulin by the subcutaneous route, as serious systemic reactions are rare with this route of delivery, and induction of tolerance to IgA in treated individuals has been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?28/11/28857/abstract/43\">",
"       43",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/9/31896?source=see_link&amp;anchor=H27#H27\">",
"       \"Subcutaneous and intramuscular immune globulin therapy\", section on 'IgA deficient patients'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with renal impairment should receive products with low sucrose due to an increased risk of osmotic renal injury with this particular sugar [",
"      <a class=\"abstract\" href=\"UTD.htm?28/11/28857/abstract/44-46\">",
"       44-46",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/32/38409?source=see_link&amp;anchor=H16#H16\">",
"       \"Intravenous immune globulin: Adverse effects\", section on 'Renal complications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with diabetes should be careful with maltose-containing products, as certain types of glucose meters cannot discriminate between maltose and glucose. Diabetics should also be careful with glucose-containing products. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29641?source=see_link&amp;anchor=H7#H7\">",
"       \"Blood glucose self-monitoring in management of adults with diabetes mellitus\", section on 'Sources of error in SMBG'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who have trouble tolerating increased intravascular volume may do better with preparations that are low in sodium and albumin. Some products may contain as much as 30",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      (3 percent) albumin, in addition to the IgG itself.",
"     </li>",
"     <li>",
"      Patients with hyperviscosity syndromes (eg, cryoglobulinemia, monoclonal gammopathies, or polyclonal hyperglobulinemia, including some children with HIV); extremely elevated lipoprotein concentrations; or who are bedridden may be at higher risk for thrombotic complications and should be given preparations with lower osmolality. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/32/38409?source=see_link&amp;anchor=H26#H26\">",
"       \"Intravenous immune globulin: Adverse effects\", section on 'Thrombotic complications'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adverse effects due to amino acid stabilizers, such as glycine or proline, have not been reported. However, proline-containing products should not be given to patients with hyper-prolinemia.",
"   </p>",
"   <p>",
"    It should be noted that the use of subcutaneous immune globulin (SCIG) has not been extensively studied in",
"    <span class=\"nowrap\">",
"     autoimmune/inflammatory",
"    </span>",
"    disorders, but several small studies in neuromuscular disease have shown promising results [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28857/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ADMINISTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the US, IVIG is usually administered in an infusion center or health care facility. However, IVIG may be infused in the home setting, usually by an experienced infusion nurse. In some situations, this practice has been found to be more cost effective and result in improved quality of life measures [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28857/abstract/38,48\">",
"     38,48",
"    </a>",
"    ]. The first few infusions should be administered with medical supervision, regardless of the longer-term plan.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Consent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many institutions require signed consent before any blood product is administered, and we document in the records of all of our patients that potential risks have been explained and that the",
"    <span class=\"nowrap\">",
"     patient/parent",
"    </span>",
"    has received this information, has been given the opportunity to ask questions, and has given consent to receiving IGIV before initiating therapy. Potential complications and risks of IVIG therapy are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/32/38409?source=see_link\">",
"     \"Intravenous immune globulin: Adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Pre-treatment testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of transmission of viruses and prions from IVIG treatment is felt to be extremely low. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/32/38409?source=see_link&amp;anchor=H30#H30\">",
"     \"Intravenous immune globulin: Adverse effects\", section on 'Risk of transmission of blood borne pathogens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nevertheless, patients should be tested for exposure to known blood borne pathogens before starting IVIG therapy. Serologic tests for exposure to or infection with common pathogens such as Epstein-Barr virus, CMV and Hepatitis B will become positive in recipients of immune globulin therapy because of the passively transferred antibody. Therefore, if it is important to know if a patient has been infected with one of these organisms (for example, CMV in a potential transplant recipient), antigen tests, such as PCR, should be done before IgG is administered.",
"   </p>",
"   <p>",
"    We perform testing for HIV and hepatitis A, B, and C, and measure complete blood count, hepatic transaminases and renal function before initiating immune globulin therapy by any route. In hematologic disease, Coombs&rsquo; testing should be done prior to IVIG therapy. This may identify preexisting infection or Coombs&rsquo; positivity before the immune globulin was administered and not transmitted iatrogenically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Product handling and storage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liquid products and reconstituted solutions of lyophilized products that have been stored in refrigerators should be allowed to come to room temperature before administration, to minimize adverse events. However, immune globulin solutions should not be microwaved or otherwise heated because the immunoglobulin protein could become denatured. Reconstituted lyophilized products should be inspected before administration to assure that the product has been completely dissolved and that the solution is uniform, although vigorous mixing causing excessive foaming should be avoided. All products should be inspected for the presence of particulates and evidence of tampering before pooling or administration to the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Premedications",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    or NSAIDs (with the exception of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , which is not recommended for children) may relieve",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prevent inflammatory and anaphylactoid symptoms and are therefore frequently given 30 minutes prior to the infusion. The following are commonly used:",
"   </p>",
"   <p>",
"    Pediatric doses apply to infants through age 11 or weight up to 35 kg. Adult doses apply to children &gt;age 11 and weight &gt;35 kg.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      , 10 to 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (max 500 mg) orally for children or 650 to 1000 mg orally for adults,",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       Ibuprofen",
"      </a>",
"      , 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (max 400 mg) orally for children or 400 to 800 mg orally for adults",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    H1 antihistamines are also frequently given before or at the beginning of the infusion. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"       Diphenhydramine",
"      </a>",
"      , 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (max 50 mg)",
"      <span class=\"nowrap\">",
"       orally/IV/IM",
"      </span>",
"      for children or 25 to 50 mg",
"      <span class=\"nowrap\">",
"       orally/IV/IM",
"      </span>",
"      for adults,",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/25/19862?source=see_link\">",
"       Cyproheptadine",
"      </a>",
"      , 0.08",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (max 4 mg) orally for children or 4 mg orally for adults, which may be helpful in preventing headache",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Glucocorticoids are also frequently given, particularly before the initial infusion, or when changing products. Their mechanism of action suggests that they might be most effective if given one to two hours before the infusion is initiated. This may be done conveniently by dosing after the preceding meal or when the patient leaves home to come to the infusion site. Commonly used oral regimens include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       Prednisone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      in children, 0.5 to 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (max 40 mg),",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       Prednisone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      in adults, 40 to 60 mg",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some clinicians administer intravenous glucocorticoids (instead of oral) as soon as IV access is established and then wait 30 minutes before beginning the IVIG infusion. The following agents and doses can be used in this manner:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       Methylprednisolone",
"      </a>",
"      , 0.5 to 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (max 40 mg) IV in children or 40 to 60 mg IV in adults",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       Dexamethasone",
"      </a>",
"      , 10 or 20 mg IV in adults",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Hydration with intravenous fluids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients receiving IVIG should be well-hydrated prior to the infusion. This is particularly important for patients with risk factors for thrombosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    renal complications of IVIG therapy, such as preexisting renal insufficiency, diabetes mellitus, age greater than 65, paraproteinemia, heart disease, and concomitant use of nephrotoxic agents. Hydration should be given before IVIG preparations containing sucrose, as well.",
"   </p>",
"   <p>",
"    Hydration can be accomplished by ample oral fluid intake or by administration of normal saline before giving the IVIG. Most clinicians administer intravenous fluids before starting high dose IVIG, as therapy may be associated with adverse effects due to hyperviscosity, and preparations containing sucrose have been associated with osmotic renal damage. Normal saline, 10 to 20",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    is suggested for this purpose. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/32/38409?source=see_link&amp;anchor=H16#H16\">",
"     \"Intravenous immune globulin: Adverse effects\", section on 'Renal complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Infusion rates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many infusion-related adverse effects seem related to the rate of administration. Therefore, it is customary to start each infusion at a slow rate, such as 0.01",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per minute, which would provide 0.5 or 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of immune globulin per minute depending upon whether a 5 or 10 percent solution is being infused, respectively. The infusion rate may then be increased at 20 to 30 minute intervals, while monitoring the patient closely for alterations in vital signs or subjective symptoms.",
"   </p>",
"   <p>",
"    If the patient continues to do well, the rate of infusion may be stepped up to 0.02",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per minute, then 0.04",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per minute and in one or two additional increments until a maximum rate of 0.08",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per minute (4 or 8",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per minute if 5 percent or 10 percent solutions are used, respectively) is achieved.",
"   </p>",
"   <p>",
"    Higher rates may be tolerated in selected patients and with preparations that are low in sodium",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    free of high concentrations of sugar as stabilizers. After it has been established that a given patient tolerates a certain product at a specific rate, fewer steps",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    shorter intervals may be used during the \"ramp up\", but patients should always be monitored closely because lot-to-lot variation in tolerability may occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine monitoring for development of complications of IVIG therapy and blood-borne infections is recommended every 6 to 12 months. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Pre-treatment testing'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Serum creatinine (to evaluate for changes in renal function) and a complete blood count with differential (to evaluate for neutropenia and anemia) are also suggested. Since several IVIG products have been associated with positive Coombs' (direct antiglobulin) tests",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    frank hemolysis, the Coombs' test is frequently also used for monitoring. When high-dose IVIG is to be given over two or more days, it is prudent to check for Coombs' positivity before proceeding with the second or subsequent doses [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28857/abstract/49\">",
"     49",
"    </a>",
"    ]. If a previously negative Coombs' test becomes positive, options include using a different IVIG preparation and delaying or fractionating the remaining dose; the patient should be well-hydrated and monitored closely for hemolysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Record keeping",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although all currently licensed IVIG products in the US are believed to be safe from transmission of blood-borne infections, the risk of disease transmission is always present. The dose, brand, lot number, expiration date, and manufacturer of any immune globulin product infused into any patient should be carefully recorded in the medical record, as done for blood products. In addition, patients should be encouraged to keep their own logs of this information.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11541199\">",
"    <span class=\"h1\">",
"     VACCINATION OF PATIENTS RECEIVING IMMUNE GLOBULIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients receiving immune globulin therapy may fail to respond to vaccination for several reasons. Individuals with immune deficiency may not respond because of their underlying immunologic defect, and those being treated for other disorders may have disease states or concomitant medications that inhibit normal vaccine responses. Furthermore, the antibody in the immune globulin will bind the antigenic substances in the vaccine, and this may prevent an adequate antibody response.",
"   </p>",
"   <p>",
"    If a patient has been given immunizations during or within weeks of receiving immune globulin, and subsequently stops therapy, then titers should be checked three to six months after stopping immune globulin to determine if the patient has protective immunity. If titers are not protective, then the immunization(s) should be repeated or, if necessary, immune globulin therapy should be resumed. This is particularly problematic in patients who receive live virus vaccines such as MMR or varicella vaccines while on or within months after receiving immune globulin, since the passively transferred IgG may prevent the viral replication that is necessary for inducing the desired immune response.",
"   </p>",
"   <p>",
"    The American Academy of Pediatrics has made specific recommendations for live vaccines against measles and varicella. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=see_link&amp;anchor=H25#H25\">",
"     \"Standard immunizations for children and adolescents\", section on 'Immune globulin recipients'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many clinicians give",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/61/985?source=see_link\">",
"     inactivated influenza vaccine",
"    </a>",
"    to patients receiving IG therapy to stimulate T cell immunity to the virus, which may help in recovery from influenza.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immune globulin is used in the treatment of a wide variety of disorders, including primary and secondary immune deficiency states, autoimmune disorders, and inflammatory disorders (",
"      <a class=\"graphic graphic_table graphicRef82262 \" href=\"UTD.htm?38/61/39900\">",
"       table 1",
"      </a>",
"      ). It can be given intravenously, subcutaneously, or intramuscularly. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Indications, usage patterns, and cost issues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immune globulin has two useful clinical effects: to protect the recipient from infection, and to suppress immune-mediated or inflammatory disease processes. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Mechanisms of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multiple intravenous immune globulin (IVIG) products are available, which differ in concentration of IgG, additives and stabilizers, and IgA content (",
"      <a class=\"graphic graphic_table graphicRef68573 \" href=\"UTD.htm?0/29/478\">",
"       table 2",
"      </a>",
"      ). They are considered equivalent in efficacy, although certain products may be preferred for patients with particular disorders. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Production and composition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lower doses of IVIG (ie, beginning at 300 to 500",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per month) are given for replacement therapy in immune deficiency states, although doses should be individualized to keep patients free from infection. Higher doses (ie, 1 to 2",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      per dose) are usually given when IVIG is administered for its antiinflammatory or immunomodulatory properties, often in daily divided doses. Trough serum levels may be monitored to help assess the adequacy of replacement in patients with immunodeficiency, but this is usually not relevant to treatment of autoimmune diseases. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Overview of dosing'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=see_link&amp;anchor=H16#H16\">",
"       \"Immune globulin therapy in primary immunodeficiency\", section on 'Trough levels'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Most patients will tolerate most IVIG products, although there are certain concomitant conditions that should prompt consideration of specific IVIG preparations. These include severe IgA deficiency with undetectable levels of serum IgA, renal dysfunction, diabetes, disorders of hyperviscosity, and disorders that predispose patients to volume overload (eg, heart failure). The experience of patients on chronic therapy should be considered since these individuals may tolerate one product better than others; it is advisable not to change products unless there is a compelling reason to do so. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Selecting a product'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Informed consent, recording of brand, lot number and dose, and baseline testing for HIV and hepatitis viruses, as well as renal, hepatic, and hematologic disorders should be performed prior to IVIG administration. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Consent'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Pre-treatment testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients should be well-hydrated before IVIG is administered, and premedications are often given, at least for the first few infusions. Since most adverse reactions to IVIG are rate-related, treatment-na&iuml;ve patients and those in whom brands are being switched should have their infusions initiated slowly (ie, at approximately 0.01",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per minute) under close observation. Rates may then be increased stepwise as tolerated. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Administration'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/1\">",
"      Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006; 117:S525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/2\">",
"      Provan D, Chapel HM, Sewell WA, et al. Prescribing intravenous immunoglobulin: summary of Department of Health guidelines. BMJ 2008; 337:a1831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/3\">",
"      Stiehm ER, Casillas AM, Finkelstein JZ, et al. Slow subcutaneous human intravenous immunoglobulin in the treatment of antibody immunodeficiency: use of an old method with a new product. J Allergy Clin Immunol 1998; 101:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/4\">",
"      Berger M. A history of immune globulin therapy, from the Harvard crash program to monoclonal antibodies. Curr Allergy Asthma Rep 2002; 2:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/5\">",
"      BRUTON OC. Agammaglobulinemia. Pediatrics 1952; 9:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/6\">",
"      Pierce LR, Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev 2003; 17:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/7\">",
"      Darabi K, Abdel-Wahab O, Dzik WH. Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature. Transfusion 2006; 46:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/8\">",
"      Knezevic-Maramica I, Kruskall MS. Intravenous immune globulins: an update for clinicians. Transfusion 2003; 43:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/9\">",
"      Blackhouse G, Gaebel K, Xie F, et al. Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada. Cost Eff Resour Alloc 2010; 8:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/10\">",
"      Kessel A, Ammuri H, Peri R, et al. Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol 2007; 179:5571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/11\">",
"      Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med 2012; 367:2015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/12\">",
"      Teeling JL, Jansen-Hendriks T, Kuijpers TW, et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood 2001; 98:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/13\">",
"      Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/14\">",
"      Anthony RM, Kobayashi T, Wermeling F, Ravetch JV. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature 2011; 475:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/15\">",
"      Fehr J, Hofmann V, Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med 1982; 306:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/16\">",
"      Crow AR, Song S, Semple JW, et al. IVIg inhibits reticuloendothelial system function and ameliorates murine passive-immune thrombocytopenia independent of anti-idiotype reactivity. Br J Haematol 2001; 115:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/17\">",
"      Kaveri SV, Lacroix-Desmazes S, Bayry J. The antiinflammatory IgG. N Engl J Med 2008; 359:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/18\">",
"      Dietrich G, Kaveri SV, Kazatchkine MD. Modulation of autoimmunity by intravenous immune globulin through interaction with the function of the immune/idiotypic network. Clin Immunol Immunopathol 1992; 62:S73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/19\">",
"      Kaveri SV, Dietrich G, Hurez V, Kazatchkine MD. Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases. Clin Exp Immunol 1991; 86:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/20\">",
"      Tankersley DL. Dimer formation in immunoglobulin preparations and speculations on the mechanism of action of intravenous immune globulin in autoimmune diseases. Immunol Rev 1994; 139:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/21\">",
"      Jayne DR, Davies MJ, Fox CJ, et al. Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet 1991; 337:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/22\">",
"      Glotz D, Haymann JP, Sansonetti N, et al. Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg). A potential tool for transplantation of immunized patients. Transplantation 1993; 56:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/23\">",
"      Palla R, Cirami C, Panichi V, et al. Intravenous immunoglobulin therapy of membranous nephropathy: efficacy and safety. Clin Nephrol 1991; 35:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/24\">",
"      Ashkenazi S, Cleary TG, Lopez E, Pickering LK. Anticytotoxin-neutralizing antibodies in immune globulin preparations: potential use in hemolytic-uremic syndrome. J Pediatr 1988; 113:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/25\">",
"      McCormick JK, Yarwood JM, Schlievert PM. Toxic shock syndrome and bacterial superantigens: an update. Annu Rev Microbiol 2001; 55:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/26\">",
"      Takei S, Arora YK, Walker SM. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens [see comment]. J Clin Invest 1993; 91:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/27\">",
"      Norrby-Teglund A, Basma H, Andersson J, et al. Varying titers of neutralizing antibodies to streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G: implications for therapeutic efficacy. Clin Infect Dis 1998; 26:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/28\">",
"      Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999; 340:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/29\">",
"      Bleeker WK, Teeling JL, Hack CE. Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect. Blood 2001; 98:3136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/30\">",
"      Tsubakio T, Kurata Y, Katagiri S, et al. Alteration of T cell subsets and immunoglobulin synthesis in vitro during high dose gamma-globulin therapy in patients with idiopathic thrombocytopenic purpura. Clin Exp Immunol 1983; 53:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/31\">",
"      Delfraissy JF, Tchernia G, Laurian Y, et al. Suppressor cell function after intravenous gammaglobulin treatment in adult chronic idiopathic thrombocytopenic purpura. Br J Haematol 1985; 60:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/32\">",
"      Koffman BM, Dalakas MC. Effect of high-dose intravenous immunoglobulin on serum chemistry, hematology, and lymphocyte subpopulations: assessments based on controlled treatment trials in patients with neurological diseases. Muscle Nerve 1997; 20:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/33\">",
"      Siedlar M, Strach M, Bukowska-Strakova K, et al. Preparations of intravenous immunoglobulins diminish the number and proinflammatory response of CD14+CD16++ monocytes in common variable immunodeficiency (CVID) patients. Clin Immunol 2011; 139:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/34\">",
"      Spycher M, Matozan K, Minnig K, et al. In vitro comparison of the complement-scavenging capacity of different intravenous immunoglobulin preparations. Vox Sang 2009; 97:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/35\">",
"      Basta M, Van Goor F, Luccioli S, et al. F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med 2003; 9:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/36\">",
"      Appropriate uses of human immunoglobulin in clinical practice: memorandum from an IUIS/WHO meeting. Bull World Health Organ 1982; 60:43.",
"     </a>",
"    </li>",
"    <li>",
"     Requirements for the collection, processing, and quality control of blood, blood components, and plasma derivatives. WHO technical Report Series 1989, No. 786, Annex 4.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/38\">",
"      Lucas M, Lee M, Lortan J, et al. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 2010; 125:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/39\">",
"      Chapel HM, Lee M. Immunoglobulin replacement in patients with chronic lymphocytic leukemia (CLL): kinetics of immunoglobulin metabolism. J Clin Immunol 1992; 12:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/40\">",
"      Waldmann TA, Strober W. Metabolism of immunoglobulins. Prog Allergy 1969; 13:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/41\">",
"      Kahwaji J, Barker E, Pepkowitz S, et al. Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients. Clin J Am Soc Nephrol 2009; 4:1993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/42\">",
"      Berger M, Rojavin M, Kiessling P, Zenker O. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. Clin Immunol 2011; 139:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/43\">",
"      Sundin U, Nava S, Hammarstr&ouml;m L. Induction of unresponsiveness against IgA in IgA-deficient patients on subcutaneous immunoglobulin infusion therapy. Clin Exp Immunol 1998; 112:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/44\">",
"      Ahsan N, Wiegand LA, Abendroth CS, Manning EC. Acute renal failure following immunoglobulin therapy. Am J Nephrol 1996; 16:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/45\">",
"      Chacko B, John GT, Balakrishnan N, et al. Osmotic nephropathy resulting from maltose-based intravenous immunoglobulin therapy. Ren Fail 2006; 28:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/46\">",
"      Welles CC, Tambra S, Lafayette RA. Hemoglobinuria and acute kidney injury requiring hemodialysis following intravenous immunoglobulin infusion. Am J Kidney Dis 2010; 55:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/47\">",
"      Misbah S, Sturzenegger MH, Borte M, et al. Subcutaneous immunoglobulin: opportunities and outlook. Clin Exp Immunol 2009; 158 Suppl 1:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/48\">",
"      Hachulla E. [IgIV at home:experience of a center--economic aspects]. Rev Med Interne 2007; 28 Spec No. 1:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28857/abstract/49\">",
"      Daw Z, Padmore R, Neurath D, et al. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Transfusion 2008; 48:1598.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4431 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.16.9.173-04C97D187A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_11_28857=[""].join("\n");
var outline_f28_11_28857=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Routes of administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INDICATIONS, USAGE PATTERNS, AND COST ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hyperimmune globulin preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MECHANISMS OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Congenital or acquired hypogammaglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Autoimmune disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PRODUCTION AND COMPOSITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Constituents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      OVERVIEW OF DOSING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SELECTING A PRODUCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Consent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Pre-treatment testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Product handling and storage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Premedications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Hydration with intravenous fluids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Infusion rates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Record keeping",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11541199\">",
"      VACCINATION OF PATIENTS RECEIVING IMMUNE GLOBULIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4431\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4431|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/61/39900\" title=\"table 1\">",
"      Potential uses of IVIG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/29/478\" title=\"table 2\">",
"      Immune globulins for intravenous administration",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/52/4938?source=related_link\">",
"      Acute renal allograft rejection: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29641?source=related_link\">",
"      Blood glucose self-monitoring in management of adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17385?source=related_link\">",
"      Chronic inflammatory demyelinating polyneuropathy: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/12/27848?source=related_link\">",
"      Diagnosis, treatment and prognosis of HIV-associated neuropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=related_link\">",
"      Immune globulin therapy in primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17175?source=related_link\">",
"      Intravenous immune globulin in hematologic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/32/38409?source=related_link\">",
"      Intravenous immune globulin: Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42025?source=related_link\">",
"      Kawasaki disease: Initial treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7369?source=related_link\">",
"      Overview of polyneuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35017?source=related_link\">",
"      Overview of the complications of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32039?source=related_link\">",
"      Plasma derivatives and recombinant DNA-produced coagulation factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/9/31896?source=related_link\">",
"      Subcutaneous and intramuscular immune globulin therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/1/31767?source=related_link\">",
"      Treatment and prevention of parvovirus B19 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/16/265?source=related_link\">",
"      Treatment and prognosis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=related_link\">",
"      Treatment and prognosis of immune thrombocytopenia (ITP) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=related_link\">",
"      Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/51/41781?source=related_link\">",
"      Treatment of Guillain-Barr&eacute; syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/41/37530?source=related_link\">",
"      Treatment of idiopathic membranous nephropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_11_28858="Initial treatment of acute promyelocytic leukemia in adults";
var content_f28_11_28858=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial treatment of acute promyelocytic leukemia in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/11/28858/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/11/28858/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/11/28858/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/11/28858/contributors\">",
"     Bob Lowenberg, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/11/28858/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/11/28858/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/11/28858/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute myeloid leukemia (AML) refers to a group of hematopoietic neoplasms involving cells committed to the myeloid lineage. Acute promyelocytic leukemia (APL) is a biologically and clinically distinct variant of AML. APL was classified as AML-M3 in the older French-American-British (FAB) classification system and is currently classified as acute promyelocytic leukemia with t(15;17)(q24.1;q21.1);PML-RARA in the WHO classification system [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17976?source=see_link\">",
"     \"Molecular biology of acute promyelocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Without treatment, APL is the most malignant form of AML with a median survival of less than one month [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/2\">",
"     2",
"    </a>",
"    ]. Registry data suggest that many patients die before reaching an experienced hematologist. Thus, those patients who enroll in prospective clinical trials may already be a selected subset. However, with modern therapy, APL is associated with the highest proportion of patients who are presumably cured of their disease. The treatment of APL is distinct from that of other types of AML and is comprised of several stages which, in total, may span one to two years of treatment (",
"    <a class=\"graphic graphic_table graphicRef77537 \" href=\"UTD.htm?20/41/21148\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Remission induction",
"     </li>",
"     <li>",
"      Consolidation",
"     </li>",
"     <li>",
"      Maintenance",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The treatment of APL in adults will be reviewed here. While not specifically discussed, treatment programs as enumerated below appear to be equally effective in children after minor modifications [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/2,4-6\">",
"     2,4-6",
"    </a>",
"    ]. The clinical features, diagnosis, and prognosis of APL in adults are discussed separately, as is the treatment of patients with relapsed or resistant disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/12/200?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/37/12888?source=see_link\">",
"     \"Treatment of relapsed or refractory acute promyelocytic leukemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EMERGENT PRETREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute promyelocytic leukemia (APL) represents a medical emergency with a high rate of early mortality, often due to hemorrhage from a characteristic coagulopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/7\">",
"     7",
"    </a>",
"    ]. It is critical to start treatment with all-trans retinoic acid (ATRA; tretinoin) without delay as soon as the diagnosis is",
"    <strong>",
"     suspected",
"    </strong>",
"    based upon cytologic criteria, and before definitive (cyto)genetic confirmation of the diagnosis has been made [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/8\">",
"     8",
"    </a>",
"    ]. If the diagnosis is not confirmed, ATRA can be discontinued and treatment changed to that used for other types of acute myeloid leukemia (AML). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=see_link\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29146?source=see_link\">",
"     \"Treatment of acute myeloid leukemia in older adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with suspected APL should undergo studies to evaluate for disease extent and comorbidities as described for other patients with AML. While important, these studies should not interfere with the rapid initiation of ATRA-based therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=see_link&amp;anchor=H2#H2\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\", section on 'Pretreatment evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INDUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Induction therapy aims to reduce the total body leukemia cell population from approximately 10",
"    <sup>",
"     12",
"    </sup>",
"    to below the cytologically detectable level of about 10",
"    <sup>",
"     9",
"    </sup>",
"    cells. A key component of this therapy is the use of ATRA, which promotes the terminal differentiation of malignant promyelocytes to mature neutrophils (",
"    <a class=\"graphic graphic_picture graphicRef66640 \" href=\"UTD.htm?25/31/26097\">",
"     picture 1",
"    </a>",
"    ). However, ATRA must be combined with other agents since remissions induced by ATRA therapy alone are short-lived with a median duration of only about 3.5 months [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/9\">",
"     9",
"    </a>",
"    ]. The largest experience has been with ATRA combined with anthracycline-based chemotherapy (",
"    <a class=\"graphic graphic_table graphicRef51345 \" href=\"UTD.htm?19/44/20173\">",
"     table 2",
"    </a>",
"    ). The combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/47/16119?source=see_link\">",
"     arsenic trioxide",
"    </a>",
"    (ATO) plus ATRA should be considered for patients who are not candidates for anthracycline-based therapy.",
"   </p>",
"   <p>",
"    Primary resistance to treatment with the combination of ATRA and chemotherapy is unusual except for patients with the rare t(11;17). Such patients are generally treated as if they had a non-APL variant of AML. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=see_link\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17976?source=see_link&amp;anchor=H7#H7\">",
"     \"Molecular biology of acute promyelocytic leukemia\", section on 'Variant translocations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     ATRA plus chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concurrent administration of ATRA plus cytotoxic chemotherapy produces a complete remission (CR) in 80 to 95 percent of patients of all ages with APL [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. The median time to CR ranges from 38 to 44 days, but may be as long as 90 days. Almost all treatment failures are due to early mortality (approximately 10 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/14\">",
"     14",
"    </a>",
"    ]. If an ATRA-based regimen of induction, consolidation, and maintenance is used, rates of two-year overall survival range from 69 to 88 percent. Rates of 10-year overall survival range from 58 to 85 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This combination is supported by randomized trials that demonstrated that patients who received both ATRA and chemotherapy had superior rates of CR and disease-free survival when compared with patients who received chemotherapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized controlled trial comparing induction with",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"        daunorubicin",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"        cytarabine",
"       </a>",
"      </span>",
"      alone or in combination with ATRA was stopped early when the first interim analysis showed lower relapse rates with the addition of ATRA [",
"      <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/10\">",
"       10",
"      </a>",
"      ]. When compared with those treated with chemotherapy alone, patients who received chemotherapy plus ATRA had a significantly higher rate of event-free survival at 12 months (79 versus 50 percent) and a lower relapse rate (19 versus 40 percent). ATRA was also associated with a higher CR rate (91 versus 81 percent), but this did not achieve statistical significance, possibly because early termination of the study limited the number of patients enrolled. Overall survival was similar in the two groups.",
"     </li>",
"     <li>",
"      A second randomized trial within the US Intergroup studied various combinations of remission induction (ATRA alone versus chemotherapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"       daunorubicin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      ) plus maintenance therapy (daily ATRA for one year versus observation), all in combination with a consolidation chemotherapy program in 350 patients with previously untreated APL [",
"      <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/11\">",
"       11",
"      </a>",
"      ]. CR rates were similar after initial induction (approximately 70 percent). At a median follow-up of 6.2 years, estimated rates of five-year disease-free survival for the various treatment combinations were [",
"      <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/16\">",
"       16",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Chemotherapy induction plus two cycles of consolidation chemotherapy followed by observation &mdash; 16 percent",
"     </li>",
"     <li>",
"      Chemotherapy induction plus two cycles of consolidation chemotherapy plus ATRA maintenance &mdash; 47 percent",
"     </li>",
"     <li>",
"      ATRA induction plus two cycles of consolidation chemotherapy followed by observation &mdash; 55 percent",
"     </li>",
"     <li>",
"      ATRA induction plus two cycles of consolidation chemotherapy followed by ATRA maintenance &mdash; 74 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The duration of coagulopathy appears shortened when ATRA is added to induction chemotherapy (eg, three days compared with six days with chemotherapy alone) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/10,17,18\">",
"     10,17,18",
"    </a>",
"    ]. The addition of chemotherapy to ATRA helps to control hyperleukocytosis that occurs in up to 50 percent of patients treated with ATRA alone. In this way, the combination of ATRA plus chemotherapy limits complications that may occur when either agent is used alone.",
"   </p>",
"   <p>",
"    For patients with newly diagnosed APL, we recommend induction therapy with ATRA plus anthracycline-based chemotherapy rather than treatment with either ATRA or chemotherapy alone. Multiple trials have investigated the optimal means of combining ATRA and chemotherapy during induction. These are described in the following sections.",
"   </p>",
"   <p>",
"    Of interest, a randomized study in 1075 patients &lt;60 years of age was unable to identify any subgroup of patients with",
"    <strong>",
"     non-APL",
"    </strong>",
"    acute myeloid leukemia likely to derive a significant survival benefit from the addition of ATRA to chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/19\">",
"     19",
"    </a>",
"    ]. Preliminary data suggest that among patients with non-APL AML, those with mutations in the nucleophosmin-1 (NPM-1) gene may benefit from ATRA when combined with induction chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Choice of chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anthracycline-based regimens typically used for the treatment of AML have been administered to patients with APL, initially alone and then as a base for regimens employing ATRA. There have been no direct comparisons between agents, but the best results have been obtained when ATRA was combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    or with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/43/40630?source=see_link\">",
"     idarubicin",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef51345 \" href=\"UTD.htm?19/44/20173\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/5,10,16,20-25\">",
"     5,10,16,20-25",
"    </a>",
"    ]. APL is especially susceptible to anthracycline therapy because of low expression of the drug efflux pump p-glycoprotein (MDR-1) on the cell membrane of the leukemic cells [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prospective randomized trials described in the previous sections using a combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"       daunorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      , and ATRA for induction therapy reported CR rates of 80 to 95 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/5,10,16,22\">",
"       5,10,16,22",
"      </a>",
"      ]. A prospective, randomized trial that investigated whether cytarabine could be eliminated from this regimen found that patients who received cytarabine had similar CR rates but fewer relapses and improved survival, when compared with patients who did not receive cytarabine [",
"      <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/23,27\">",
"       23,27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective analysis of patients treated with ATRA plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/43/40630?source=see_link\">",
"       idarubicin",
"      </a>",
"      induction reported a CR rate of 91 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/28\">",
"       28",
"      </a>",
"      ]. The most common causes of early mortality were hemorrhage (5 percent), infection (2.3 percent), and differentiation syndrome (1.4 percent). Lethal bleeding occurred most frequently in the first week of therapy while deaths due to infection or differentiation syndrome were spread throughout the course of induction treatment. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Differentiation syndrome'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In the prospective ATRA,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/43/40630?source=see_link\">",
"       idarubicin",
"      </a>",
"      , and IV",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/47/16119?source=see_link\">",
"       arsenic trioxide",
"      </a>",
"      (ATO) in APL trial (the Australian APML4 trial), of 124 patients with newly diagnosed de novo APL who underwent induction with ATRA, intravenous ATO, and four doses of age-adjusted idarubicin, 118 (95 percent) attained a hematologic CR [",
"      <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/29\">",
"       29",
"      </a>",
"      ]. The four deaths (3.2 percent) during induction were due to myocardial ischemia, intracerebral hemorrhage (two patients), and cerebral edema. Following two cycles of consolidation with ATRA and intravenous ATO, all patients achieved a molecular CR and received two years of maintenance therapy with ATRA, oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"       mercaptopurine",
"      </a>",
"      . Disease-free survival at two years was 98 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is less experience reported in the literature using other anthracyclines or anthracycline derivatives. However, one cooperative group has produced excellent outcomes with successive induction and consolidation cycles using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/43/40630?source=see_link\">",
"     idarubicin",
"    </a>",
"    and ATRA followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    plus ATRA without the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Timing of chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several trials have demonstrated better outcomes when chemotherapy is administered with ATRA during induction (simultaneous administration) rather than postponing chemotherapy until a CR is achieved with ATRA (sequential administration).",
"   </p>",
"   <p>",
"    The largest of these was a prospective randomized trial that compared sequential and simultaneous administration of ATRA and chemotherapy in 413 patients with newly diagnosed APL [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/5\">",
"     5",
"    </a>",
"    ]. In the simultaneous program, combination chemotherapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    was added on the third day of ATRA therapy while chemotherapy was postponed until after achievement of CR in the sequential arm. While the rates of CR were similar in the two treatment groups, patients who received simultaneous therapy had significantly lower rates of relapse at two years (6 versus 16 percent) and a trend towards lower rates of differentiation syndrome (11 versus 20 percent) when compared with those who received sequential therapy. After a median follow-up of 10 years, this lower relapse rate persisted, but lost its statistical significance (13 versus 22 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Length of ATRA treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is some evidence to suggest that ATRA should be continued during induction until CR is achieved. A prospective trial of 239 patients with APL receiving standard chemotherapy were randomly assigned to therapy with ATRA at a dose of 45",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day either for five days before the start of chemotherapy (short course) or starting with the first day of chemotherapy and continuing daily until attainment of CR, up to a maximum of 60 days (extended ATRA) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/22\">",
"     22",
"    </a>",
"    ]. For those patients with a presenting white blood cell count (WBC)",
"    <span class=\"nowrap\">",
"     &lt;10,000/microL,",
"    </span>",
"    extended ATRA resulted in improved CR rates (94 versus 76 percent), reduced relapse rates (13 versus 35 percent at 4 years), and superior overall survival (80 versus 57 percent at 4 years). There was no benefit of extended ATRA for those with a presenting WBC",
"    <span class=\"nowrap\">",
"     &gt;10,000/microL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Administration and side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;For",
"    induction, we prefer the combination used in the North American Intergroup study C9710: daily ATRA (45",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"    </span>",
"    orally divided into two doses), starting on day zero, followed by seven days of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    by continuous infusion (200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day) and four days of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    (50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day), both starting on day 3, although other combinations can be used. Children and adolescents should receive a reduced dose of ATRA (25",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day) in combination with chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/4\">",
"     4",
"    </a>",
"    ]. ATRA is continued throughout the period of pancytopenia until a CR is obtained. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=see_link\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This regimen results in severe pancytopenia in all patients and therefore requires transfusion support and antibiotics as needed. Daily laboratory testing generally includes a complete blood count and chemistries with renal function, glucose, and electrolytes. Calcium, phosphorus, and uric acid levels should be monitored until normal. Liver function tests should be assessed at least weekly. Coagulation parameters, including fibrinogen, D-dimer, PT, aPTT, and platelet counts, should be monitored closely. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Monitoring during therapy and supportive care'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Common non-hematologic side effects include stomatitis (mostly mild), reversible alopecia, nausea and vomiting (25 percent severe), and diarrhea (mostly mild).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"     Daunorubicin",
"    </a>",
"    can be associated with cardiac arrhythmias and heart failure; a flu-like syndrome and rash due to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    may be seen during induction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43930?source=see_link&amp;anchor=H42#H42\">",
"     \"Infusion reactions to systemic chemotherapy\", section on 'Anthracyclines and related agents'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43930?source=see_link&amp;anchor=H58#H58\">",
"     \"Infusion reactions to systemic chemotherapy\", section on 'Cytarabine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Drug toxicities due to ATRA are generally minor. Headache is common; pseudotumor cerebri has been described, but is rare. Nasal stuffiness, dry red skin, chapped lips, transient elevations in serum aminotransferases and bilirubin, and hypertriglyceridemia can occur, but rarely require an alteration in treatment. However, there are two serious and specific complications that can result from ATRA treatment of APL: differentiation syndrome and hyperleukocytosis. These are discussed in more detail below. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Differentiation syndrome'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H20\">",
"     'Hyperleukocytosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Arsenic trioxide plus ATRA",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/47/16119?source=see_link\">",
"     Arsenic trioxide",
"    </a>",
"    (ATO), alone or in combination with ATRA, is capable of producing complete molecular remissions (as defined by the absence of the PML-RARalpha fusion transcript using RT-PCR) in previously untreated APL [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/30-36\">",
"     30-36",
"    </a>",
"    ]. For most patients with newly diagnosed APL, we prefer ATRA plus chemotherapy principally because of the greater experience and longer follow-up of patients treated with this combination. However, ATO plus ATRA may be an excellent option for patients, such as older adults, who are not able to tolerate anthracycline-based therapy (",
"    <a class=\"graphic graphic_table graphicRef51345 \" href=\"UTD.htm?19/44/20173\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preliminary results are available from the Intergroup APL0406 randomized phase III trial comparing ATRA plus ATO with ATRA plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/43/40630?source=see_link\">",
"     idarubicin",
"    </a>",
"    (AIDA) in 154 adults with newly diagnosed APL with a total white blood cell count &le;10 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L",
"    </span>",
"    (ie, low- or intermediate-risk APL) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/37\">",
"     37",
"    </a>",
"    ]. In the experimental arm, ATRA (45",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    plus ATO (0.15",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    was administered daily until CR followed by consolidation with intermittent ATRA and ATO for seven and four courses, respectively. AIDA did not incorporate ATO into the post-remission therapy. At a median follow-up of 34 months, when compared with AIDA, ATRA plus ATO resulted in the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Similar rates of complete remission (100 versus 95 percent).",
"     </li>",
"     <li>",
"      Fewer deaths during induction therapy (0 versus 4 patients).",
"     </li>",
"     <li>",
"      Similar estimated rates of disease-free survival (97 versus 90 percent) and cumulative incidence of relapse (1.5 versus 5.6 percent) at two years.",
"     </li>",
"     <li>",
"      Superior estimated two-year event-free survival (97 versus 86 percent) and overall survival (99 versus 91 percent).",
"     </li>",
"     <li>",
"      Similar rates of differentiation syndrome, less thrombocytopenia and neutropenia, and more leukocytosis, hepatic toxicity, and QTc prolongation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following is a survey of nonrandomized prospective trials that have evaluated ATO plus ATRA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment with ATO (10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      IV in adults until complete remission or for a maximum of 60 days) was evaluated in 72 newly diagnosed patients with APL [",
"      <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/31\">",
"       31",
"      </a>",
"      ]. CR was attained in 86 percent. Following CR and a four-week interval, ATO was given in the above dose for four weeks as a consolidation course. After a second four-week interval, the agent was given 10",
"      <span class=\"nowrap\">",
"       days/month",
"      </span>",
"      for six months as maintenance treatment for those still in CR. At a median follow-up of 60 months, estimated rates of event-free, disease-free, and overall survival at five years were 69, 80, and 74 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/34\">",
"       34",
"      </a>",
"      ]. All patients with good-risk disease, defined here by a WBC &lt;5 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L",
"      </span>",
"      and platelets &gt;20 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L,",
"      </span>",
"      were alive at five years.",
"     </li>",
"     <li>",
"      The same approach was evaluated in a second prospective trial of 197 patients with newly diagnosed APL using ATO (0.15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV daily in adults until CR or for a maximum of 60 days) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/38\">",
"       38",
"      </a>",
"      ]. Morphologic CR was seen in 86 percent. Death due to APL differentiation syndrome was seen in 13 percent. Early mortality was more common among patients presenting with a WBC &gt;10 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L",
"      </span>",
"      (42 versus 6 percent). At a median follow-up of 38 months, rates of disease-free and overall survival at five years were 67 and 64 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/35\">",
"       35",
"      </a>",
"      ]. Disease-free survival improved with increasing number of consolidation cycles.",
"     </li>",
"     <li>",
"      A prospective trial evaluated ATRA and ATO, with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/3/1078?source=see_link\">",
"       gemtuzumab ozogamicin",
"      </a>",
"      (GO) in 82 patients with newly diagnosed APL [",
"      <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/39\">",
"       39",
"      </a>",
"      ]. Ninety percent of patients achieved a CR. At a median follow-up of 25 months, the three-year estimated rate of overall survival was 86 percent, and was 100 percent for the subset of 22 patients who had both a white blood cell count",
"      <span class=\"nowrap\">",
"       &lt;5000/microL",
"      </span>",
"      and a platelet count",
"      <span class=\"nowrap\">",
"       &gt;20,000/microL",
"      </span>",
"      at the time of diagnosis. Toxicity was mild and reversible, and, after remission induction, treatment could be given on an outpatient basis. Side effects of ATO include fluid retention, differentiation syndrome, peripheral sensory neuropathy, and electrocardiographic abnormalities. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/37/12888?source=see_link&amp;anchor=H4#H4\">",
"       \"Treatment of relapsed or refractory acute promyelocytic leukemia in adults\", section on 'Arsenic trioxide'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Another prospective trial of ATRA plus ATO in 85 patients with newly diagnosed APL followed for a median of 70 months reported a CR rate of 94 percent with five-year event-free and overall survival rates of 89 and 92 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While further studies are needed, emerging data would suggest that the combination of ATRA plus ATO without chemotherapy may be a good alternative for chemotherapy-based regimens in low-risk and intermediate-risk APL. Long term follow up data for patients treated with this regimen are not yet available. As an example, an initial single-arm prospective study (APML4) described above suggested that induction with ATO, ATRA, and four doses of age-adjusted",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/43/40630?source=see_link\">",
"     idarubicin",
"    </a>",
"    was well tolerated and resulted in high CR rates [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Choice of chemotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Evaluating response to induction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of remission induction treatment in APL is the attainment of a morphological CR with recovery of normal hematopoiesis, followed by a molecular remission. Sometimes molecular remission is attained only after completion of consolidation therapy. Premature evaluation of response may be misleading and is discouraged. A &ldquo;day 14&rdquo; bone marrow exam during induction is rarely informative and is not necessary. Blasts and promyelocytes may remain elevated in the marrow for many weeks and the RT-PCR signal of the fusion gene may remain detectable during a slow decline. Primary resistance, however, is very uncommon.",
"   </p>",
"   <p>",
"    An initial impression of response to induction therapy can be obtained with a bone marrow aspiration and biopsy performed after approximately 30 to 35 days when patients recover their absolute neutrophil count",
"    <span class=\"nowrap\">",
"     (&gt;1000/microL)",
"    </span>",
"    and platelet count",
"    <span class=\"nowrap\">",
"     (&gt;100,000/microL)",
"    </span>",
"    and become independent from red cell transfusions. An earlier evaluation, such as that generally done for other variants of AML (eg, on day 14), is not recommended since it may result in over treatment (ie, there may be delayed clearance of malignant promyelocytes from the marrow even after they have lost their proliferative potential) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/4\">",
"     4",
"    </a>",
"    ]. Of importance, information attained in such an early evaluation generally cannot be used to determine failure of a response to induction therapy. Response definitions are presented separately. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Evaluating response after consolidation'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12073?source=see_link\">",
"     \"Remission criteria in acute myeloid leukemia and monitoring for residual disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who achieve a hematological complete remission (CR) with induction therapy proceed directly to consolidation therapy. Patients who achieve a partial response after the initial course may achieve a CR after additional therapy. Primary induction failure is rare, but those who do not eventually achieve a hematological CR should be treated with regimens for resistant disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/37/12888?source=see_link\">",
"     \"Treatment of relapsed or refractory acute promyelocytic leukemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CONSOLIDATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 90 percent of patients with newly diagnosed APL will achieve a hematological complete remission (CR) with induction therapy. However, without additional cytotoxic therapy, virtually all of these patients will relapse. Consolidation therapy is directed at leukemia cells that survived induction therapy but are not detectable by conventional tests thereby converting patients with morphologic and cytogenetic CR into a more durable molecular remission and eventually a cure.",
"   </p>",
"   <p>",
"    Standard consolidation consists of two cycles of an anthracycline (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/43/40630?source=see_link\">",
"     idarubicin",
"    </a>",
"    ) plus ATRA. More recently, data suggest an important role for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/47/16119?source=see_link\">",
"     arsenic trioxide",
"    </a>",
"    (ATO). For patients who achieve a CR with ATRA plus chemotherapy induction, we recommend two cycles of consolidation chemotherapy with ATO followed by two cycles of daunorubicin plus ATRA rather than daunorubicin plus ATRA or daunorubicin therapy alone. Patients who underwent induction therapy with ATO plus ATRA may continue with ATO based consolidation, but the evidence supporting this approach is still very limited [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Arsenic trioxide plus ATRA'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Is there a role for ATRA in post-remission therapy?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The additional benefit attained from adding ATRA to consolidation therapy may vary according to the patient's risk of relapse as determined by white blood cell and platelet counts at presentation. The duration of ATRA therapy during induction and the specific chemotherapy used also have an impact on outcome. While there may be a low risk population that does not require ATRA as part of their consolidation therapy, this remains to be confirmed in prospective, randomized trials. For the time being, we recommend ATRA to be included in consolidation treatment. For all patients with APL who achieve a hematological CR with induction, we recommend two cycles of consolidation therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/47/16119?source=see_link\">",
"     arsenic trioxide",
"    </a>",
"    followed by two cycles of additional consolidation chemotherapy with three days of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    plus seven days of ATRA (",
"    <a class=\"graphic graphic_table graphicRef77537 \" href=\"UTD.htm?20/41/21148\">",
"     table 1",
"    </a>",
"    ). This regimen was shown to be superior to a standard post-remission regimen that did not contain arsenic trioxide in the randomized North American Intergroup study C9710. In Europe, where arsenic trioxide is not so readily available for APL patients in first CR, other consolidation regimens described below have provided similar excellent outcomes.",
"   </p>",
"   <p>",
"    A retrospective comparison of two prospective non-randomized Italian trials that included 732 patients investigated the need for ATRA in the consolidation phase [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    In both of these trials, patients underwent induction therapy with ATRA and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/43/40630?source=see_link\">",
"     idarubicin",
"    </a>",
"    followed by anthracycline-based consolidation and maintenance with ATRA. The main difference between the two protocols was the incorporation of ATRA into consolidation therapy in the second protocol as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 172 patients treated from 1996 to 1999 (LPA96 study) did not receive ATRA therapy as part of their consolidation.",
"     </li>",
"     <li>",
"      The 560 patients treated after November 1999 (LPA99 study) received ATRA in addition to the other scheduled consolidation unless they had low risk disease as defined by a WBC count less than",
"      <span class=\"nowrap\">",
"       10,000/microL",
"      </span>",
"      and platelets above",
"      <span class=\"nowrap\">",
"       40,000/microL.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both protocols achieved CR in 90 percent of patients. Patients who received ATRA as part of their consolidation therapy had significantly lower rates of clinical and molecular relapse:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low-risk patients who received consolidation that did not contain ATRA had 93 to 97 percent disease-free survival (DFS) at three years.",
"     </li>",
"     <li>",
"      Intermediate-risk patients (WBC count",
"      <span class=\"nowrap\">",
"       &lt;10,000/microL",
"      </span>",
"      but platelets",
"      <span class=\"nowrap\">",
"       &lt;40,000/microL)",
"      </span>",
"      had superior rates of DFS at three years (97 versus 82 percent) when ATRA was added to their consolidation.",
"     </li>",
"     <li>",
"      Of the high-risk patients (WBC count",
"      <span class=\"nowrap\">",
"       &gt;10,000/microL),",
"      </span>",
"      only 77 percent were alive and free of relapse at three years even when ATRA was incorporated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While these results suggest excellent outcomes for low-risk patients treated without ATRA in consolidation, it does not rule out the possibility that ATRA may provide additional benefit to these patients. In addition, this study illuminates the poor outcomes for high-risk patients even when ATRA is incorporated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Is there a role for arsenic trioxide in post-remission therapy?",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/47/16119?source=see_link\">",
"     Arsenic trioxide",
"    </a>",
"    (ATO) provides an important contribution for consolidation. A randomized trial in North America investigated the safety and utility of two courses of ATO (0.15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for five days each week for five weeks) followed by consolidation with ATRA plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    versus consolidation with ATRA and daunorubicin alone in 518 adults with newly diagnosed APL achieving CR or PR following a standard ATRA-containing induction program. At a median follow-up of 29 months, the following results were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/42\">",
"     42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The CR rate for adults was 89 percent, using the identical induction regimen in each treatment arm.",
"     </li>",
"     <li>",
"      Three-year event-free (81 versus 66 percent) and overall (86 versus 79 percent) survival rates were both significantly higher for those receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/47/16119?source=see_link\">",
"       arsenic trioxide",
"      </a>",
"      consolidation.",
"     </li>",
"     <li>",
"      Among the 452 patients achieving CR, there were only 71 post-CR events (16 percent), an insufficient number at present to comment on disease-free survival by treatment arm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This study provides evidence from a large randomized controlled trial regarding the place of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/47/16119?source=see_link\">",
"     arsenic trioxide",
"    </a>",
"    in the current management of APL. While the results are consistent with an additive value of arsenic trioxide, the outcome in the control group (ie, those treated with ATRA plus chemotherapy but no ATO for consolidation) was not as good as that reported in other studies with different entry criteria and chemotherapy regimens, making conclusions less convincing. Importantly, however, treatment outcomes in high-risk patients (eg, WBC",
"    <span class=\"nowrap\">",
"     &gt;10,000/microL)",
"    </span>",
"    were markedly improved on the ATO-containing treatment arm of this randomized study. ATO may eliminate pre-existing subclones of APL that have acquired mutations in the ligand binding domain of",
"    <span class=\"nowrap\">",
"     PML/RARa,",
"    </span>",
"    making them relatively resistant to ATRA and responsible for relapse.",
"   </p>",
"   <p>",
"    For patients with APL who achieve a CR with induction, the most widely prescribed post-remission therapy in North America uses two cycles of consolidation chemotherapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/47/16119?source=see_link\">",
"     arsenic trioxide",
"    </a>",
"    followed by two cycles of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    plus ATRA rather than daunorubicin plus ATRA alone [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H542221881\">",
"    <span class=\"h2\">",
"     Can post-remission therapy be risk-adapted?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with APL can be risk-stratified for relapse into three groups based upon WBC and platelet counts at diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/43\">",
"     43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low-risk disease (WBC count &lt;10,000 and platelets &gt;40,000)",
"     </li>",
"     <li>",
"      Intermediate-risk disease (WBC count &lt;10,000 but platelets &lt;40,000)",
"     </li>",
"     <li>",
"      High-risk disease (WBC count &gt;10,000 and platelets &lt;40,000)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Using current regimens, there is little difference in outcomes between the low-risk and intermediate-risk groups. Induction therapy followed by consolidation with ATRA plus an anthracycline and standard maintenance results in three-year disease-free survival rates of approximately 97, 97, and 77 percent for those with low-, intermediate-, or high-risk disease, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Prospective studies have begun to investigate whether therapy can be altered based upon risk as determined by these criteria. The goal of such studies is to decrease the treatment toxicity for those with low-risk disease while preserving their excellent outcomes and to improve outcomes among those with high-risk disease.",
"   </p>",
"   <p>",
"    As an example, a prospective trial examined the use of risk-adapted therapy in 372 adults with APL in first complete remission after induction with ATRA plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/43/40630?source=see_link\">",
"     idarubicin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/44\">",
"     44",
"    </a>",
"    ]. Consolidation was adjusted according to risk. Patients with low- or intermediate-risk disease were assigned fewer doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    during consolidation, while patients with high-risk disease had",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    added to consolidation. When compared with historical matched controls, patients with low- and intermediate-risk disease had shorter durations of neutropenia and thrombocytopenia. Disease-free and overall survival rates at three years were not significantly different. Alternatively, patients with high-risk disease demonstrated a significantly lower rate of relapse at three years (11 versus 26 percent).",
"   </p>",
"   <p>",
"    Another single-arm prospective trial of risk-adapted therapy included 453 adults with APL in first complete remission after induction with ATRA plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/43/40630?source=see_link\">",
"     idarubicin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/24\">",
"     24",
"    </a>",
"    ]. Patients with low- or intermediate-risk disease (WBC count &lt;10,000) were assigned to consolidation with three anthracycline-based courses, while patients with high-risk disease (WBC count &gt;10,000) had",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    -based consolidation. When compared with historical matched controls, patients with low- and intermediate-risk disease had significantly improved disease-free survival rates at six years (86 versus 77 percent) and a lower cumulative incidence of relapse (11 versus 20 percent), but similar rates of overall survival (89 versus 85 percent). Patients with high-risk disease had superior overall survival at six years (83 versus 61 percent), disease-free survival (85 versus 50 percent), and a lower cumulative incidence of relapse (9 versus 50 percent).",
"   </p>",
"   <p>",
"    Longer follow-up and studies of these approaches that incorporate newer agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/47/16119?source=see_link\">",
"     arsenic trioxide",
"    </a>",
"    ) are needed before risk-adapted therapy can be widely implemented.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Evaluating response after consolidation",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the completion of consolidation, the response to treatment is again evaluated with a bone marrow aspirate and biopsy. This sample should be tested for the PML-RARalpha fusion transcript using reverse transcription polymerase chain reaction (RT-PCR). The goal of APL treatment is the achievement of a",
"    <strong>",
"     molecular",
"    </strong>",
"    complete remission (CRm), as defined by the absence of the PML-RARalpha fusion transcript using RT-PCR methods with a sensitivity threshold of at least 10",
"    <sup>",
"     -3",
"    </sup>",
"    or 10",
"    <sup>",
"     -4",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12073?source=see_link\">",
"     \"Remission criteria in acute myeloid leukemia and monitoring for residual disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A CRm takes time to achieve. It is usually attained only after completion of consolidation therapy, although it may occur more promptly if",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/47/16119?source=see_link\">",
"     arsenic trioxide",
"    </a>",
"    is used for consolidation. Therefore, RT-PCR need not be attempted immediately after completion of induction treatment, as this premature evaluation may give a misleading interpretation of response failure. Patients who achieve CRm should proceed directly to maintenance therapy. Patients who have a positive RT-PCR test at the conclusion of the planned consolidation sequence should have a second bone marrow aspirate and biopsy with RT-PCR testing repeated in four weeks. If this second test is negative, the patient may proceed to maintenance therapy. If the second RT-PCR is still positive, the patient should proceed to treatment for resistant disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/37/12888?source=see_link\">",
"     \"Treatment of relapsed or refractory acute promyelocytic leukemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MAINTENANCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7385800\">",
"    <span class=\"h2\">",
"     Is maintenance necessary?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial randomized trials demonstrated that maintenance therapy decreases the incidence of relapse and improves disease-free survival among patients who have undergone induction with ATRA plus chemotherapy followed by consolidation therapy. As described above, induction and consolidation therapy have since evolved to include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/47/16119?source=see_link\">",
"     arsenic trioxide",
"    </a>",
"    (ATO) in addition to ATRA and chemotherapy based upon studies that suggest improved event-free and overall survival with this approach. As such, the role of maintenance therapy among patients who achieve a molecular complete remission (CRm) after initial therapy that incorporates ATO and ATRA is controversial. Recognizing that the benefit from maintenance therapy likely depends to a considerable extent upon the precise induction and consolidation treatment, we suggest the use of maintenance therapy rather than observation alone until additional data become available. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Is there a role for arsenic trioxide in post-remission therapy?'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Initial randomized trials of ATRA plus chemotherapy demonstrated that, when compared with observation, patients assigned to ATRA maintenance demonstrated superior rates of disease-free survival at five years (74 versus 55 percent, respectively) and a lower 10-year cumulative incidence of relapse (33 versus 43 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit observed in these early trials has led to the frequent use of maintenance therapy in all patients with APL. However, maintenance therapy may not be necessary for all patients (eg, those in CRm following consolidation or those who receive other",
"    <span class=\"nowrap\">",
"     induction/consolidation",
"    </span>",
"    therapies). Additional randomized trials are needed to answer the question regarding the need for maintenance therapy in APL and, if necessary, the best maintenance regimen.",
"   </p>",
"   <p>",
"    The complexity of this issue was illustrated in three randomized trials of maintenance therapy after the achievement of a CRm:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial involving 175 patients in CRm following induction and three cycles of consolidation chemotherapy, the addition of six courses of intensive maintenance chemotherapy, as compared with observation only, unexpectedly conferred significantly poorer six-year disease-free survival (63 versus 80 percent) and overall survival (86 versus 99 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/46\">",
"       46",
"      </a>",
"      ]. Of note, two patients on the intensive maintenance arm developed therapy-related",
"      <span class=\"nowrap\">",
"       MDS/AML",
"      </span>",
"      compared with none on the observation arm.",
"     </li>",
"     <li>",
"      In another randomized trial including 586 patients with newly diagnosed APL in CRm after induction with ATRA and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/43/40630?source=see_link\">",
"       idarubicin",
"      </a>",
"      followed by three cycles of intensive consolidation therapy, maintenance did not appear to improve disease-free survival [",
"      <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/47\">",
"       47",
"      </a>",
"      ]. However, in this particular study, relatively high dose levels of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      used in induction treatment may have obviated the need for maintenance therapy.",
"     </li>",
"     <li>",
"      Preliminary results from another randomized trial (North American Leukemia Intergroup Trial C9710) of 518 patients with newly diagnosed APL demonstrated very few relapses among patients who had received ATO for consolidation therapy followed by one year of maintenance with either ATRA alone or a combination of ATRA, 6-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"       mercaptopurine",
"      </a>",
"      (6-MP), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/48\">",
"       48",
"      </a>",
"      ]. When compared with those who received the three-drug combination maintenance therapy, patients treated with single agent ATRA maintenance demonstrated similar rates of disease-free and overall survival and lower rates of hematologic and non-hematologic adverse events.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Until further data are available, we suggest the use of maintenance therapy rather than observation. This preference is largely based upon the apparent low toxicity of maintenance therapy in combination with the potential, yet unproven, disease-free survival benefit. Most prospective studies have investigated various combinations of ATRA, 6-MP, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    for maintenance therapy. ATO has not been routinely incorporated into maintenance and remains investigational in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/49\">",
"     49",
"    </a>",
"    ]. When maintenance is administered, either single agent ATRA or combination maintenance therapy is reasonable [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/42,48\">",
"     42,48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Single agent ATRA &mdash; ATRA 45",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      PO for seven days repeated every other week for one year.",
"     </li>",
"     <li>",
"      Combination maintenance therapy &mdash; ATRA 45",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      PO daily on an intermittent schedule (eg, 15 days every three months or seven days every two weeks) plus 6-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"       mercaptopurine",
"      </a>",
"      60",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      PO every evening plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      20",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      PO per week as tolerated. All three medications are taken for one year, with doses adjusted according to the presence or absence of myelosuppression",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      liver function abnormalities. If there is unexpectedly severe or prolonged myelosuppression in patients taking 6-mercaptopurine, the medication should be stopped and an analysis obtained for thiopurine methyltransferase activity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/32/22026?source=see_link&amp;anchor=H6#H6\">",
"       \"Overview of pharmacogenomics\", section on 'Thiopurine methyltransferase'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of these, we suggest single agent ATRA based upon preliminary data that adding 6-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"     mercaptopurine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    does not improve outcomes but does increase toxicity and complexity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/48\">",
"     48",
"    </a>",
"    ]. Other clinicians prefer combination maintenance therapy due to greater experience with this regimen and the longer follow-up of patients treated with this regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Monitoring response during maintenance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a molecular complete remission (CRm) is achieved, patients are followed periodically with reverse transcription polymerase chain reaction (RT-PCR) for the PML-RARalpha fusion transcript in order to monitor for relapse. Monitoring for residual disease is most sensitive using bone marrow aspirate samples. Peripheral blood samples have not yet demonstrated equivalence to bone marrow samples, but they may allow monitoring for MRD at more frequent intervals. This may be especially important when fluctuating levels have been noted.",
"   </p>",
"   <p>",
"    We perform RT-PCR on the peripheral blood or marrow every three months for the first three years of complete remission, since most relapses will occur in the first three years (",
"    <a class=\"graphic graphic_table graphicRef77537 \" href=\"UTD.htm?20/41/21148\">",
"     table 1",
"    </a>",
"    ). If CRm is lost, the patient undergoes bone marrow evaluation for confirmation within two weeks and proceeds to therapy for relapsed disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/37/12888?source=see_link\">",
"     \"Treatment of relapsed or refractory acute promyelocytic leukemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MONITORING DURING THERAPY AND SUPPORTIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of cytopenias, infections, tumor lysis, menorrhagia, and other complications common to all patients with AML are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=see_link&amp;anchor=H14#H14\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\", section on 'Supportive care'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/26/37285?source=see_link\">",
"     \"Heavy or irregular uterine bleeding during chemotherapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14168?source=see_link\">",
"     \"Overview of the complications of acute myeloid leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3402?source=see_link&amp;anchor=H21712037#H21712037\">",
"     \"Tumor lysis syndrome: Prevention and treatment\", section on 'Clinical impact of TLS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following sections review complications that are specific to patients with APL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Control of coagulopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;APL is characterized by frequent and severe hemorrhage that can result from disseminated intravascular coagulation (DIC)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    primary fibrinolysis. Treatment of the coagulopathy (DIC) associated with APL may be difficult and should be managed expectantly. Coagulation parameters, including fibrinogen, D-dimer, PT, aPTT, and platelet counts, should be monitored closely. Transfusions of platelets and cryoprecipitate or fresh frozen plasma are used to maintain the platelet count above 20,000 to",
"    <span class=\"nowrap\">",
"     30,000/microL",
"    </span>",
"    and the plasma fibrinogen concentration above 150",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/8,50\">",
"     8,50",
"    </a>",
"    ]. Higher platelet counts of 30,000 to",
"    <span class=\"nowrap\">",
"     50,000/microL",
"    </span>",
"    may be beneficial to control overt bleeding. In addition, anecdotal evidence supports attempting to maintain the platelet count above",
"    <span class=\"nowrap\">",
"     50,000/microL",
"    </span>",
"    during periods of DIC, as reflected by falling fibrinogen or high D-dimer levels [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/51\">",
"     51",
"    </a>",
"    ]. Our approach to the control of coagulopathy is mainly based upon our own clinical experience and observations. There have been case reports using recombinant factor VIIa for the treatment of severe life-threatening hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Invasive procedures such as central venous catheterization, lumbar puncture, and bronchoscopy should be avoided before and during induction remission.",
"   </p>",
"   <p>",
"    The role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is controversial, and we suggest that it not be used for prophylaxis in this setting. Inhibitors of fibrinolysis should be considered only for those patients with life-threatening bleeding. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/12/200?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults\", section on 'Disseminated intravascular coagulation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=see_link&amp;anchor=H28#H28\">",
"     \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\", section on 'Heparin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Differentiation syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differentiation syndrome (previously \"retinoid acid syndrome\" or cytokine storm), occurs in approximately 25 percent of APL patients within 2 to 21 days after initiation of treatment and is seen more frequently in patients with a high white blood cell count at diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. It can occur in the absence of ATRA and is characterized by fever, peripheral edema, pulmonary infiltrates, hypoxemia, respiratory distress, hypotension, renal and hepatic dysfunction, and serositis resulting in pleural and pericardial effusions. The symptoms of fever, hypotension, dyspnea, and pulmonary infiltrates can mimic sepsis. Sometimes, but not always, the cytokine syndrome is accompanied by hyperleukocytosis.",
"   </p>",
"   <p>",
"    Early recognition and aggressive management with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    therapy (10 mg IV every 12 hours for three or more days) has been effective in most patients. This is largely based upon our clinical experience and observations of a lower rate of mortality associated with differentiation syndrome when prompt dexamethasone treatment is added in prospective trials or if dexamethasone is given prophylactically in patients with high WBC counts at diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/55\">",
"     55",
"    </a>",
"    ]. Other therapeutic interventions such as temporary cessation of ATRA or ATO, leukapheresis, or prompt institution of cytotoxic chemotherapy have not been effective after respiratory distress is established. ATRA or ATO can be restarted in most cases once the syndrome has resolved. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/32/37384?source=see_link\">",
"     \"Differentiation (retinoic acid) syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Hyperleukocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperleukocytosis, likely due to the rapid maturation of a large mass of leukemic cells, occurs in up to 50 percent of patients treated with ATRA alone at induction. The marked increase in WBC count may result in leukostasis, but complications are uncertain and management is controversial. The frequency of hyperleukocytosis has decreased since most current remission induction regimens now combine ATRA with cytotoxic chemotherapy. Leukapheresis may exacerbate the underlying coagulopathy in APL and is therefore not used [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19576?source=see_link\">",
"     \"Hyperleukocytosis and leukostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most investigators have advocated the prompt institution of full doses of induction chemotherapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    in all patients showing a rapid rise in the leukocyte count after starting ATRA therapy; this may include as many as 70 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/10\">",
"     10",
"    </a>",
"    ]. When compared with those with a normal or decreased white blood cell (WBC) count, patients with an elevated WBC count have a similar rate of complete remission, but have a higher rate of relapse and are more likely to develop the differentiation syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. Some studies also report a higher induction death rate in patients with WBC count",
"    <span class=\"nowrap\">",
"     &gt;10,000/microL.",
"    </span>",
"   </p>",
"   <p>",
"    Although formal proof is lacking, some investigators add corticosteroids for prevention of the differentiation syndrome when WBC counts are or rise above",
"    <span class=\"nowrap\">",
"     10,000/microL.",
"    </span>",
"    (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Differentiation syndrome'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     High intracranial pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic intracranial hypertension (IIH), commonly called pseudotumor cerebri, can complicate the treatment of APL with ATRA. IIH is more common in children and adolescents treated with ATRA and the incidence in this population decreased with the use of lower dose ATRA (eg, 25",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of IIH is suspected in patients with headache, papilledema,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vision loss. Evaluation includes a physical examination including evaluation of the optic nerve, lumbar puncture, and cerebral imaging studies. The diagnosis is confirmed in patients with increased intracranial pressure, normal cerebrospinal fluid, and negative cerebral imaging studies (eg, computed tomography or magnetic resonance imaging scan). Papilledema is common, but not necessary for the diagnosis. Some patients may require serial lumbar puncture or intracranial pressure monitoring to document sustained elevated pressures.",
"   </p>",
"   <p>",
"    On occasion, the symptoms resolve after the initial diagnostic lumbar puncture. If this occurs, no further medical treatment is necessary. If symptoms persist, therapeutic options include the temporary discontinuation or dose reduction of ATRA, analgesics,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the administration of steroids and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17417?source=see_link\">",
"     \"Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/54/41833?source=see_link&amp;anchor=H7#H7\">",
"     \"Idiopathic intracranial hypertension (pseudotumor cerebri): Prognosis and treatment\", section on 'Carbonic anhydrase inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SPECIAL SCENARIOS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general treatment principles for APL apply to most disease presentations and patient populations. However, certain populations, particularly pregnant women, patients with therapy-related APL, and those with genetic variations of APL, require special consideration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Pregnant women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients diagnosed with APL during pregnancy pose a distinct challenge requiring a team approach with a hematologist, obstetrician, and neonatologist. The treatment approach depends largely upon the trimester of pregnancy during which APL is diagnosed [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     First trimester",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both ATRA and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/47/16119?source=see_link\">",
"     arsenic trioxide",
"    </a>",
"    (ATO) are considered to be highly teratogenic and are contraindicated during the first trimester of pregnancy. The critical factor in determining the treatment of women with APL in the first trimester of pregnancy is whether the pregnancy will be electively terminated once the patient is hemodynamically stable:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the patient plans to terminate the pregnancy, then conventional therapy with ATRA plus chemotherapy can be started.",
"     </li>",
"     <li>",
"      If elective termination of the pregnancy is unacceptable to the patient, the only available treatment option is the administration of chemotherapy alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As described in more detail above, when compared with patients who receive ATRA plus chemotherapy, patients treated with chemotherapy alone have inferior response rates and progression-free survival and higher relapse rates. Perhaps most importantly, the risk of hemorrhage due to coagulopathy is much higher in patients treated with chemotherapy alone. If treatment with chemotherapy alone is chosen,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    may be the preferred anthracycline for pregnant women. There is greater experience with daunorubicin administration during pregnancy and concerns over the lipophilic nature of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/43/40630?source=see_link\">",
"     idarubicin",
"    </a>",
"    , which may increase placental transfer and fetal toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/4,57\">",
"     4,57",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'ATRA plus chemotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If a remission is achieved with chemotherapy alone and the pregnancy continues normally, ATRA may be added during the second or third trimester. After delivery, breastfeeding is contraindicated during treatment with chemotherapy or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/47/16119?source=see_link\">",
"     arsenic trioxide",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Second or third trimester",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two main options are available for women who are diagnosed with APL in the second or third trimester of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Remission induction with ATRA alone with chemotherapy administration postponed until after delivery.",
"     </li>",
"     <li>",
"      Simultaneous administration of ATRA plus chemotherapy as given for patients who are not pregnant at the time of diagnosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The immediate institution of simultaneous administration of ATRA plus chemotherapy offers the best chance of cure but is accompanied by the risk of an increased rate of spontaneous abortion, prematurity, low birth weight, neonatal neutropenia, and sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17207?source=see_link\">",
"     \"Breast cancer during pregnancy and lactation: Epidemiology and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When compared with patients who undergo induction with ATRA plus chemotherapy, patients treated with ATRA alone have similar rates of remission, but higher rates of hyperleukocytosis during induction and higher rates of relapse. This treatment approach requires frequent monitoring with RT-PCR after induction to monitor for relapse while awaiting delivery. Vaginal delivery is generally preferred since it is associated with a reduced risk of bleeding. After delivery, breastfeeding is contraindicated during treatment with chemotherapy or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/47/16119?source=see_link\">",
"     arsenic trioxide",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H4\">",
"     'ATRA plus chemotherapy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H20\">",
"     'Hyperleukocytosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Therapy-related APL",
"    </span>",
"    &nbsp;&mdash;&nbsp;An unknown percentage of patients treated with chemotherapy (especially",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    , anthracyclines, and other topoisomerase II inhibitors)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy for malignant or non-malignant conditions will develop therapy-related APL (t-APL) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/11/28858/abstract/4,58\">",
"     4,58",
"    </a>",
"    ]. Patients with t-APL appear to have a similar prognosis as de novo APL and benefit from standard APL therapy. As such, most patients with t-APL can be treated with standard APL therapy.",
"   </p>",
"   <p>",
"    A percentage of patients with t-APL will have a history of anthracycline exposure or cardiac impairment that limits their ability to receive further treatment with anthracyclines. In such patients, alternative regimens, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/47/16119?source=see_link\">",
"     arsenic trioxide",
"    </a>",
"    plus ATRA may be used. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Arsenic trioxide plus ATRA'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=see_link\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Genetic variations of APL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of patients with APL demonstrate the t(15;17)(q22;q12) translocation resulting in the",
"    <span class=\"nowrap\">",
"     PML/RARA",
"    </span>",
"    fusion gene. Alternative fusion genes have been described that result in leukemias that would now be classified as \"AML with a variant RARA translocation.\" The study of the treatment of patients with genetic variations of APL is complicated by the rarity of these conditions. Some appear to be sensitive to ATRA therapy while others are not.",
"   </p>",
"   <p>",
"    In general, patients with variations identified as ATRA-sensitive are treated with standard ATRA-based therapy, as described above. Patients with variants known to be resistant to ATRA are treated with standard AML induction therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=see_link\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following variants have been identified as ATRA-sensitive:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       NuMA/RARa",
"      </span>",
"      and t(11;17)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       NPM1/RARa",
"      </span>",
"      and t(5;17)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       FIP1L1/RARa",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following variants are ATRA-resistant or unknown:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       STAT5b/RARa",
"      </span>",
"      and interstitial chromosome 17 deletion &mdash; resistant",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       PLZF/RARa",
"      </span>",
"      and t(11;17) &mdash; relatively resistant",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       PRKAR1A/RARa",
"      </span>",
"      &mdash; unknown",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with APL and additional cytogenetic abnormalities (eg, trisomy 8) or particular molecular abnormalities (eg, gene mutations in FLT3) are considered to have the same prognosis as standard APL. These molecular variants of APL are described in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17976?source=see_link&amp;anchor=H7#H7\">",
"     \"Molecular biology of acute promyelocytic leukemia\", section on 'Variant translocations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/4/14402?source=see_link\">",
"       \"Patient information: Acute myeloid leukemia (AML) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/13/38098?source=see_link\">",
"       \"Patient information: Leukemia in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/30/34275?source=see_link\">",
"       \"Patient information: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute promyelocytic leukemia (APL) represents a medical emergency with a high rate of early mortality. It is necessary to start treatment without delay as soon as the diagnosis is suspected based upon cytologic criteria, and before definitive (cyto)genetic confirmation of the diagnosis has been made. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Emergent pretreatment evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of APL is comprised of several stages that, in total, span one to two years of treatment (",
"      <a class=\"graphic graphic_table graphicRef77537 \" href=\"UTD.htm?20/41/21148\">",
"       table 1",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Remission induction",
"     </li>",
"     <li>",
"      Consolidation",
"     </li>",
"     <li>",
"      Maintenance",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with newly diagnosed APL, we recommend induction therapy with all-trans retinoic acid (ATRA) plus chemotherapy, rather than treatment with ATRA or chemotherapy alone (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We suggest ATRA plus anthracycline-based chemotherapy rather than treatment with ATRA plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/47/16119?source=see_link\">",
"       arsenic trioxide",
"      </a>",
"      (ATO) (",
"      <a class=\"graphic graphic_table graphicRef51345 \" href=\"UTD.htm?19/44/20173\">",
"       table 2",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The combination of ATO plus ATRA should be considered for patients who are not candidates for anthracycline-based therapy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Induction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Administration and side effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with APL who achieve a complete remission (CR) with ATRA plus chemotherapy induction, we recommend two cycles of consolidation chemotherapy with ATO followed by two cycles of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"       daunorubicin",
"      </a>",
"      plus ATRA rather than daunorubicin plus ATRA or daunorubicin therapy alone (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Other post-remission regimens using anthracyclines may be equally effective. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Consolidation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For all patients with APL who achieve a molecular complete remission (CRm), we suggest the use of maintenance therapy rather than observation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For maintenance, we suggest the use of intermittent single agent ATRA rather than the combination of intermittent ATRA, 6-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"       mercaptopurine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Maintenance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are two important treatment issues that require careful attention in order to maximize survival:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Disseminated intravascular coagulation &mdash; If this complication is present, we recommend the use of transfusions of platelets and cryoprecipitate to maintain the platelet count above 30,000 to",
"      <span class=\"nowrap\">",
"       50,000/microL",
"      </span>",
"      or higher and the plasma fibrinogen concentration above 150",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). As the benefit of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      use in this setting is not clear, we suggest that it not be used (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, the best treatment approach is the immediate initiation of treatment with ATRA followed quickly by chemotherapy. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Control of coagulopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Differentiation syndrome &mdash; Early recognition and aggressive management of this syndrome is paramount. If present, we recommend immediate treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (10 mg IV every 12 hours for three or more days), along with temporary cessation of ATRA if severe symptoms were present (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). ATRA can be restarted once the syndrome has resolved. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Differentiation syndrome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/2\">",
"      HILLESTAD LK. Acute promyelocytic leukemia. Acta Med Scand 1957; 159:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/3\">",
"      Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002; 99:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/4\">",
"      Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009; 113:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/5\">",
"      Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999; 94:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/6\">",
"      Zhang X, Zhou H, Wang J, et al. Arsenic trioxide, retinoic acid and Ara-c regulated the expression of annexin II on the surface of APL cells, a novel co-receptor for plasminogen/tissue plasminogen activator. Thromb Res 2002; 106:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/7\">",
"      Park JH, Qiao B, Panageas KS, et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood 2011; 118:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/8\">",
"      Tallman MS, Altman JK. How I treat acute promyelocytic leukemia. Blood 2009; 114:5126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/9\">",
"      Wang ZY, Chen Z. Differentiation and apoptosis induction therapy in acute promyelocytic leukaemia. Lancet Oncol 2000; 1:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/10\">",
"      Fenaux P, Le Deley MC, Castaigne S, et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood 1993; 82:3241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/11\">",
"      Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997; 337:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/12\">",
"      Asou N, Adachi K, Tamura J, et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol 1998; 16:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/13\">",
"      Sanz MA, Vellenga E, Ray&oacute;n C, et al. All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia. Blood 2004; 104:3490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/14\">",
"      Di Bona E, Avvisati G, Castaman G, et al. Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia. Br J Haematol 2000; 108:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/15\">",
"      Ad&egrave;s L, Guerci A, Raffoux E, et al. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Blood 2010; 115:1690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/16\">",
"      Tallman MS, Andersen JW, Schiffer CA, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 2002; 100:4298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/17\">",
"      Barbui T, Finazzi G, Falanga A. The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood 1998; 91:3093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/18\">",
"      Falanga A, Iacoviello L, Evangelista V, et al. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid. Blood 1995; 86:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/19\">",
"      Burnett AK, Hills RK, Green C, et al. The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. Blood 2010; 115:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/20\">",
"      Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 1997; 90:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/21\">",
"      Sanz MA, Mart&iacute;n G, Ray&oacute;n C, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood 1999; 94:3015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/22\">",
"      Burnett AK, Grimwade D, Solomon E, et al. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. Blood 1999; 93:4131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/23\">",
"      Ad&egrave;s L, Chevret S, Raffoux E, et al. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol 2006; 24:5703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/24\">",
"      Lo-Coco F, Avvisati G, Vignetti M, et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood 2010; 116:3171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/25\">",
"      Iland H, Bradstock K, Seymour J, et al. Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia. Haematologica 2012; 97:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/26\">",
"      Candoni A, Damiani D, Michelutti A, et al. Clinical characteristics, prognostic factors and multidrug-resistance related protein expression in 36 adult patients with acute promyelocytic leukemia. Eur J Haematol 2003; 71:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/27\">",
"      Ad&egrave;s L, Sanz MA, Chevret S, et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood 2008; 111:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/28\">",
"      de la Serna J, Montesinos P, Vellenga E, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 2008; 111:3395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/29\">",
"      Iland HJ, Bradstock K, Supple SG, et al. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood 2012; 120:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/30\">",
"      Niu C, Yan H, Yu T, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999; 94:3315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/31\">",
"      Mathews V, George B, Lakshmi KM, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 2006; 107:2627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/32\">",
"      Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 2006; 107:3469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/33\">",
"      Hu J, Liu YF, Wu CF, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 2009; 106:3342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/34\">",
"      Mathews V, George B, Chendamarai E, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol 2010; 28:3866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/35\">",
"      Ghavamzadeh A, Alimoghaddam K, Rostami S, et al. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol 2011; 29:2753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/36\">",
"      Zhang Y, Zhang Z, Li J, et al. Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia. Cancer 2013; 119:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/37\">",
"      Lo-Coco F, Avvisati G, Orlando SM, et al. ATRA and arsenic trioxide (ATO) versus ATRA and idarubicin (AIDA) for newly diagnosed, non high-risk acute promyelocytic leukemia (APL): Results of the phase III, prospective, randomized, intergroup APL0406 study by the Italian-German coperative groups Gimema-SAL-AMLSG (abstract 6). Blood 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/38\">",
"      Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol 2006; 17:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/39\">",
"      Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 2009; 27:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/40\">",
"      Sanz MA, Mart&iacute;n G, Gonz&aacute;lez M, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 2004; 103:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/41\">",
"      Sanz MA, Montesinos P, Vellenga E, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. Blood 2008; 112:3130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/42\">",
"      Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 2010; 116:3751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/43\">",
"      Sanz MA, Lo Coco F, Mart&iacute;n G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000; 96:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/44\">",
"      Sanz MA, Montesinos P, Ray&oacute;n C, et al. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood 2010; 115:5137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/45\">",
"      Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21:4642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/46\">",
"      Asou N, Kishimoto Y, Kiyoi H, et al. A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood 2007; 110:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/47\">",
"      Avvisati G, Lo-Coco F, Paoloni FP, et al. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood 2011; 117:4716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/48\">",
"      Powell BL, Moser BK, Stock W, et al. Adding Mercaptopurine and Methotrexate to Alternate Week ATRA Maintenance Therapy Does Not Improve the Outcome for Adults with Acute Promyelocytic Leukemia (APL) in First Remission: Results From North American Leukemia Intergroup Trial C9710 (abstract 258). Blood 2011; 118:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/49\">",
"      Au WY, Kumana CR, Lee HK, et al. Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study. Blood 2011; 118:6535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/50\">",
"      Sanz MA, Tallman MS, Lo-Coco F. Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia. Blood 2005; 105:3019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/51\">",
"      Tallman MS, Brenner B, Serna Jde L, et al. Meeting report. Acute promyelocytic leukemia-associated coagulopathy, 21 January 2004, London, United Kingdom. Leuk Res 2005; 29:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/52\">",
"      Zver S, Andoljsek D, Cernelc P. Effective treatment of life-threatening bleeding with recombinant activated factor VII in a patient with acute promyelocytic leukaemia. Eur J Haematol 2004; 72:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/53\">",
"      Takitani K, Koh M, Inoue A, et al. Pharmacokinetics of all-trans retinoic acid in adults and children with acute promyelocytic leukemia. Am J Hematol 2006; 81:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/54\">",
"      Vahdat L, Maslak P, Miller WH Jr, et al. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 1994; 84:3843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/55\">",
"      Montesinos P, Bergua JM, Vellenga E, et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood 2009; 113:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/56\">",
"      Kelaidi C, Chevret S, De Botton S, et al. Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. J Clin Oncol 2009; 27:2668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/57\">",
"      Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol 2004; 5:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/11/28858/abstract/58\">",
"      Beaumont M, Sanz M, Carli PM, et al. Therapy-related acute promyelocytic leukemia. J Clin Oncol 2003; 21:2123.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4498 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-FBD0C7583D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_11_28858=[""].join("\n");
var outline_f28_11_28858=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EMERGENT PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INDUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ATRA plus chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Choice of chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Timing of chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Length of ATRA treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Administration and side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Arsenic trioxide plus ATRA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Evaluating response to induction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CONSOLIDATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Is there a role for ATRA in post-remission therapy?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Is there a role for arsenic trioxide in post-remission therapy?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H542221881\">",
"      Can post-remission therapy be risk-adapted?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Evaluating response after consolidation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MAINTENANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7385800\">",
"      Is maintenance necessary?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Monitoring response during maintenance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MONITORING DURING THERAPY AND SUPPORTIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Control of coagulopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Differentiation syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Hyperleukocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      High intracranial pressure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SPECIAL SCENARIOS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Pregnant women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - First trimester",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Second or third trimester",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Therapy-related APL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Genetic variations of APL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4498\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4498|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/31/26097\" title=\"picture 1\">",
"      Tretinoin APL differentiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4498|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/41/21148\" title=\"table 1\">",
"      Treatment of APL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/44/20173\" title=\"table 2\">",
"      APL induction regimens",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17207?source=related_link\">",
"      Breast cancer during pregnancy and lactation: Epidemiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=related_link\">",
"      Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/12/200?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/32/37384?source=related_link\">",
"      Differentiation (retinoic acid) syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/26/37285?source=related_link\">",
"      Heavy or irregular uterine bleeding during chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19576?source=related_link\">",
"      Hyperleukocytosis and leukostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17417?source=related_link\">",
"      Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/54/41833?source=related_link\">",
"      Idiopathic intracranial hypertension (pseudotumor cerebri): Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=related_link\">",
"      Induction therapy for acute myeloid leukemia in younger adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43930?source=related_link\">",
"      Infusion reactions to systemic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17976?source=related_link\">",
"      Molecular biology of acute promyelocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/32/22026?source=related_link\">",
"      Overview of pharmacogenomics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14168?source=related_link\">",
"      Overview of the complications of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/4/14402?source=related_link\">",
"      Patient information: Acute myeloid leukemia (AML) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/30/34275?source=related_link\">",
"      Patient information: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/13/38098?source=related_link\">",
"      Patient information: Leukemia in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12073?source=related_link\">",
"      Remission criteria in acute myeloid leukemia and monitoring for residual disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29146?source=related_link\">",
"      Treatment of acute myeloid leukemia in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/37/12888?source=related_link\">",
"      Treatment of relapsed or refractory acute promyelocytic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3402?source=related_link\">",
"      Tumor lysis syndrome: Prevention and treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_11_28859="Strength exam elbow";
var content_f28_11_28859=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54423&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54423&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Strength examination of the elbow",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Joint action",
"       </td>",
"       <td class=\"subtitle1\">",
"        Position and action for examination",
"       </td>",
"       <td class=\"subtitle1\">",
"        Muscles tested",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extension",
"       </td>",
"       <td>",
"        Resisted extension",
"       </td>",
"       <td>",
"        Triceps",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Flexion",
"       </td>",
"       <td>",
"        Forearm supinated - resisted flexion",
"       </td>",
"       <td>",
"        Biceps brachii",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Forearm&nbsp;neutral- resisted flexion",
"       </td>",
"       <td>",
"        Brachioradialis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Forearm &nbsp;pronated- resisted flexion",
"       </td>",
"       <td>",
"        Brachialis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Supination",
"       </td>",
"       <td>",
"        Hand in neutral, perpendicular to ground",
"       </td>",
"       <td rowspan=\"2\">",
"        Biceps, supinator",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Resisted rotation of \"palm up\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Pronation",
"       </td>",
"       <td>",
"        Hand in neutral, perpendicular to ground",
"       </td>",
"       <td rowspan=\"2\">",
"        Pronator teres, quadratus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Resisted rotation of \"palm down\"",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The shoulder is in the neutral position with the elbow flexed at 90&deg; and touching the iliac crest.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_11_28859=[""].join("\n");
var outline_f28_11_28859=null;
var title_f28_11_28860="Unusual pathogens for pneumonia";
var content_f28_11_28860=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F78779&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F78779&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Unusual pathogens causing nonresolving or progressive pneumonia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Pathogen (related disease)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Populations at risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mycobacterium tuberculosis (tuberculosis)",
"       </td>",
"       <td>",
"        Elderly, immigrants, HIV-positive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atypical mycobacteria (bronchiectasis)",
"       </td>",
"       <td>",
"        COPD, HIV-positive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nocardia (nocardiosis)",
"       </td>",
"       <td>",
"        Immunocompromised host",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Actinomyces israelii (actinomycosis)",
"       </td>",
"       <td>",
"        Aspiration risk, chest wall involvement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aspergillus (aspergillosis)",
"       </td>",
"       <td>",
"        Immunocompromised host, Evidence of vascular invasion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        Endemic fungi:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Histoplasma capsulatum (histoplasmosis)",
"       </td>",
"       <td class=\"sublist_other\">",
"        Mississippi River Valley",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Coccidioides immitis (coccidioidomycosis)",
"       </td>",
"       <td class=\"sublist_other\">",
"        Southwestern United States",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Blastomyces dermatitidis (blastomycosis)",
"       </td>",
"       <td class=\"sublist_other\">",
"        Southeast and midwest United States",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coxiella burnetii (Q fever)",
"       </td>",
"       <td>",
"        Exposure to cats, cattle, or sheep",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Francisella tularensis (tularemia)",
"       </td>",
"       <td>",
"        Exposure to rabbits or ticks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chlamydia psittaci (psittacosis)",
"       </td>",
"       <td>",
"        Avian sources",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yersinia pestis (plague)",
"       </td>",
"       <td>",
"        Exposure to rats",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leptospira interrogans (leptospirosis)",
"       </td>",
"       <td>",
"        Exposure to rats",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pseudomonas pseudomallei (melioidosis)",
"       </td>",
"       <td>",
"        Southeast Asia (rodent exposure), mimics tuberculosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paragonimus westermani (paragonimiasis)",
"       </td>",
"       <td>",
"        Asia/Africa/Central and South America",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hantavirus",
"       </td>",
"       <td>",
"        Southwestern United States with exposure to mice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anthrax",
"       </td>",
"       <td>",
"        More common in Asia Minor, Iran, Turkey, Greece, South Africa; contact with infected animal carcasses or hides",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_11_28860=[""].join("\n");
var outline_f28_11_28860=null;
var title_f28_11_28861="Anticoagulants in children with cancer";
var content_f28_11_28861=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57476&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57476&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Advantages and disadvantages of various anticoagulant agents in children with cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Anticoagulant",
"       </td>",
"       <td class=\"subtitle1\">",
"        Monitoring",
"       </td>",
"       <td class=\"subtitle1\">",
"        Advantages",
"       </td>",
"       <td class=\"subtitle1\">",
"        Disadvantages/complications",
"       </td>",
"       <td class=\"subtitle1\">",
"        Special considerations for children with cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Unfractionated heparin (UFH)",
"       </td>",
"       <td rowspan=\"4\">",
"        <p>",
"         aPTT",
"        </p>",
"        <p>",
"         Anti-Xa",
"        </p>",
"       </td>",
"       <td rowspan=\"4\">",
"        Easy reversal",
"       </td>",
"       <td>",
"        Bleeding",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td>",
"        Bleeding may be exaggerated due to thrombocytopenia and coagulopathy",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Difficult to monitor aPTT",
"       </td>",
"       <td rowspan=\"3\">",
"        Osteoporosis may be exaggerated in children treated with glucocorticoids (eg, ALL, NHL)",
"        <sup>",
"         [6-8]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"        <p>",
"         Osteoporosis",
"         <sup>",
"          [3-5]",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <sup>",
"         </sup>",
"         Heparin-induced thrombocytopenia",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Low molecular weight heparin (LMWH)",
"       </td>",
"       <td rowspan=\"3\">",
"        Anti-Xa levels",
"       </td>",
"       <td>",
"        Compared&nbsp;with UFH more efficacious and safe",
"       </td>",
"       <td>",
"        Subcutaneous administration",
"       </td>",
"       <td>",
"        Target anti-Xa levels in children are unknown",
"        <sup>",
"         [9]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cost effective",
"       </td>",
"       <td rowspan=\"2\">",
"        Therapeutic range is not established so that bleeding may occur (0 to 5.6 percent)",
"       </td>",
"       <td rowspan=\"2\">",
"        Difficult to reverse anticoagulation in emergency situation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Easy to monitor",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Oral anticoagulants",
"       </td>",
"       <td>",
"        INR",
"       </td>",
"       <td>",
"        Oral administration",
"       </td>",
"       <td>",
"        Dose requirements strongly influenced by age",
"        <sup>",
"         [10]",
"        </sup>",
"       </td>",
"       <td>",
"        Dietary alterations (due to mucositis, TPN) and antibacterial therapy (PCP prophylaxis or treatment for fever and neutropenia) leads to unpredictable exogenous and endogenous vitamin K levels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Difficult monitoring",
"       </td>",
"       <td rowspan=\"3\">",
"        Low cost",
"       </td>",
"       <td>",
"        Efficacy affected by diet",
"        <sup>",
"         [11]",
"        </sup>",
"        *",
"       </td>",
"       <td rowspan=\"3\">",
"        Warfarin metabolism by cytochrome P450 system leading to numerous drug interactions with anticancer agents (eg, corticosteroids)",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Difficult to adjust dose around time of invasive procedures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         No stability data on solution or suspension making dosing in young children and in children unable to swallow tablets difficult",
"         <sup>",
"          [12]",
"         </sup>",
"        </p>",
"        <p>",
"         &nbsp;",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ALL: acute lymphoblastic leukemia; aPTT: activated partial thromboplastin time; INR: international normalization ratio; LMWH: low molecular weight heparin; PCP: pneumocystis carinii; NHL: non-Hodgkin lymphoma; TPN: total parenteral nutrition; UFH: unfractionated heparin.",
"     <br>",
"      * Infants may have resistance to warfarin if formula fed (vitamin K enriched), whereas breastfed infants may be oversensitive due to poor vitamin K content in breast milk.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Monagle P, Chan A, Massicotte P, et al. Antithrombotic therapy in children: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:645S.",
"       </li>",
"       <li>",
"        Athale UH, Wiernikowaski J. Thromboembolic complications in children with cancer. Thromb Res 2006; 118:137.",
"       </li>",
"       <li>",
"        Murphy MS, John PR, Mayer AD, et al. Heparin therapy and bone fractures. Lancet 1992; 340:1098.",
"       </li>",
"       <li>",
"        Avioli LV. Heparin-induced osteopenia: an appraisal. Adv Exp Med Biol 1975; 52:375.",
"       </li>",
"       <li>",
"        Sackler JP, Liu L. Heparin-induced osteoporosis. Br J Radio 1973; 46:548.",
"       </li>",
"       <li>",
"        Roebuck DJ. Skeletal complications in pediatric oncology patients. Radiographics 1999; 19:873.",
"       </li>",
"       <li>",
"        Halton JM, Atkinson SA, Fraher L, et al. Altered mineral metabolism and bone mass in children during treatment for acute lymphoblastic leukemia. J Bone Miner Res 1996; 11:1774.",
"       </li>",
"       <li>",
"        Arikoski P, Komulainen J, Riikonen P, et al. Impaired development of bone mineral density during chemotherapy: a prospective analysis of 46 children newly diagnosed with cancer. J Bone Miner Res 1999; 14:2002.",
"       </li>",
"       <li>",
"        Revel-Vilk S, Chan AKC. Anticoagulation therapy in children. Semin Thromb Hemost 2003; 29:425.",
"       </li>",
"       <li>",
"        Streif W, Andrew M, Marzinotto V, et al. Analysis of warfarin therapy in pediatric patients: A prospective cohort study of 319 patients. Blood 1999; 94:3007.&nbsp;",
"       </li>",
"       <li>",
"        Andrew M, Monagle P, Brooker L. Oral anticoagulant therapy in pediatric patients. Thromboembolic Complications During Infancy and Childhood, BC Decker Inc, Hamilton 2000. p.321.",
"       </li>",
"       <li>",
"        Buck ML. Anticoagulation with warfarin in infants and children. Ann Pharmacother 1996; 30:1316.",
"       </li>",
"      </ol>",
"      <br>",
"       Reproduced with permission from: Athale, UH, Chan, AKC. Thromboembolic complications in pediatric hematologic malignancies. Semin Thromb Hemost 2007; 33:416. Copyright &copy; 2007 Thieme Publishers.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_11_28861=[""].join("\n");
var outline_f28_11_28861=null;
var title_f28_11_28862="Interstitial granulomatous dermatitis";
var content_f28_11_28862=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F52974&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F52974&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Interstitial granulomatous dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 284px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous, annular plaques are present on the trunk.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_11_28862=[""].join("\n");
var outline_f28_11_28862=null;
var title_f28_11_28863="Displaced oblique metatarsal shaft fracture";
var content_f28_11_28863=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F82536&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F82536&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Displaced oblique metatarsal shaft fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 301px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    On this view, there is minimal displacement of the fracture in the fourth metatarsal shaft (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Eiff, MP, Hatch, RL, Calmbach, W (Eds). Fracture Management for Primary Care, 2nd Edition, W.B. Saunders Company, Philadelphia 2002. Copyright &copy; 2002 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_11_28863=[""].join("\n");
var outline_f28_11_28863=null;
